

SATURDAY, APRIL 14**

EDUCATIONAL SESSION • 8:00 a.m.–10:00 a.m.

Room S402, McCormick Place South (Level 4)

Cancer Genomics to Targeted Therapies in Thyroid Cancer**Chair:** Manisha H. Shah, Columbus, OH

- 8:00 a.m. Overview of thyroid cancer: Epidemiology to state-of-art standard of care.** Steven I. Sherman, Houston, TX
- 8:20 a.m. Cancer genomics: Well to poorly differentiated thyroid carcinoma.** James A. Fagin, New York, NY
- 8:45 a.m. Discovering targeted therapies of thyroid cancer using *Drosophila* models.** Ross L. Cagan, New York, NY
- 9:05 a.m. BRAF-targeted therapy and mechanisms of resistance in thyroid cancer clinical trials.** Manisha H. Shah, Columbus, OH

Room S406 (Vista Ballroom), McCormick Place South (Level 4)

Emerging Methods for Quantitative Functional Genomic Analysis**Chair:** Martin Hirst, Vancouver, BC, Canada

- 8:00 a.m. Sequence-based DNA methylation analysis.** Martin Hirst, Vancouver, BC, Canada
- 8:30 a.m. High-resolution profiling of protein-DNA interaction dynamics.** Steven Henikoff, Seattle, WA
- 9:00 a.m. How and why look for clusters of cis-regulatory elements (COREs, aka super-enhancers) in cancer.** Mathieu Lupien, Toronto, ON, Canada
- 9:30 a.m. 3D genome organization in cancer.** Feng Yue, Hershey, PA

Room S100 (Grand Ballroom), McCormick Place South (Level 1)

Metabolic Landscapes and Reprogramming for Cancer Therapy**Chair:** Peter Carmeliet, Leuven, Belgium

- 8:00 a.m. Angiogenesis revisited: Role and (therapeutic) implications of endothelial metabolism.** Peter Carmeliet, Leuven, Belgium
- 8:30 a.m. Reprogram the tumor microenvironment by interrupting glutamine metabolism.** Ping-Chih Ho, Epalinges, Switzerland
- 9:00 a.m. Autophagy and cellular metabolism in cancer progression and treatment.** Eileen P. White, New Brunswick, NJ
- 9:30 a.m. Title to be announced.** Navdeep S. Chandel, Chicago, IL

**Program as of March 20, 2018

Room S504, McCormick Place South (Level 5)

Methods for Translational Research to Address Cancer Health Disparities

Chair: Chanita Hughes-Halbert, Charleston, SC

- 8:00 a.m.** **Defining populations at risk for disparities based on social determinants and genetic ancestry.** Rick A. Kittles, Duarte, CA
- 8:40 a.m.** **A sociobiologic framework for precision medicine and minority men's health.** Chanita Hughes-Halbert, Charleston, SC
- 9:20 a.m.** **Population and tumor heterogeneity in cancer genome science and precision oncology.** John D. Carpten, Los Angeles, CA

Room S103, McCormick Place South (Level 1)

Recent Advances and Opportunities in Small Cell Lung Cancer (SCLC) Research

Chair: Lauren Averett Byers, Houston, TX

- 8:00 a.m.** **Genomics of small cell lung cancer.** Julie George, Cologne, Germany
- 8:30 a.m.** **Modeling genetically defined subsets of small cell lung cancer using mice.** David Macpherson, Seattle, WA
- 9:00 a.m.** **Opportunities for targeted and immune therapies in SCLC.** Christine L. Hann, Baltimore, MD
- 9:30 a.m.** **Translational research in SCLC: Emerging biomarkers and potential of liquid biopsies.** Lauren Averett Byers, Houston, TX

Room S501, McCormick Place South (Level 5)

Response and Resistance to CDK4/6 Inhibitors in Breast Cancer

Chair: Nikhil Wagle, Boston, MA

- 8:00 a.m.** **Targeting CDKs in the treatment of breast cancer.** Nicholas C. Turner, London, United Kingdom
- 8:30 a.m.** **Identifying clinical biomarkers for CDK4/6 inhibitors.** Fabrice Andre, Villejuif, France
- 9:00 a.m.** **Biologic mechanisms underlying the sensitivity of ER+ cancers to CDK4/6i.** Sarat Chandarlapaty, New York, NY
- 9:30 a.m.** **Mechanisms of intrinsic and acquired resistance to CDK4/6 inhibitors.** Nikhil Wagle, Boston, MA

SATURDAY, APRIL 14**

Educational Sessions (cont'd)

Room S404, McCormick Place South (Level 4)

Rethinking Immunotherapeutic Approaches to Pediatric Solid Malignancies**Chair:** John M. Maris, Philadelphia, PA

- 8:00 a.m.** **Probing the surface proteome for immunotherapy targets in high-risk pediatric cancers.** Poul H. B. Sorensen, Vancouver, BC, Canada
- 8:30 a.m.** **Activating innate and adaptive immune responses via in situ vaccination.** Paul Sondel, Madison, WI
- 9:00 a.m.** **Targeting children's solid cancer through cellular engineering.** John Anderson, London, United Kingdom
- 9:30 a.m.** **Slowly but surely: HER2-specific CAR T cells for pediatric cancers.** Nabil Ahmed, Houston, TX

Room S106, McCormick Place South (Level 1)

RNA Metabolism in Cancer**Chair:** Omar Abdel-Wahab, New York, NY

- 8:00 a.m.** **Understanding and targeting RNA splicing factor mutations in cancer.** Omar Abdel-Wahab, New York, NY
- 8:30 a.m.** **The functional impact of alternative splicing in cancer.** Eduardo Eyras, Barcelona, Spain
- 9:00 a.m.** **Targeting RNA post-transcriptional processing by inhibition of protein arginine methyltransferases.** Ernesto Guccione, New York, NY
- 9:30 a.m.** **From genetics to cancer therapeutics: New frontiers in the RNA world.** Thomas F. Westbrook, Houston, TX

Room S105, McCormick Place South (Level 1)

Theoretical Approaches to Fundamental Issues in Cancer**Cochairs:** Krastan B. Blagoev, Alexandria, VA; Herbert Levine, Houston, TX

- 8:00 a.m.** **Quantifying mutational signatures in cancer.** Ludmil B. Alexandrov, La Jolla, CA
- 8:30 a.m.** **Quantitative analysis of tumor growth in advanced human cancers and cancer (stem) cells.** Krastan B. Blagoev, Alexandria, VA
- 9:00 a.m.** **Quantitative approach to immune system diversity.** Aleksandra Walczak, Paris, France
- 9:30 a.m.** **The role of epithelial plasticity in the transition to metastatic disease.** Mohit Kumar Jolly, Houston, TX

**Program as of March 20, 2018

N Hall C, McCormick Place North (Level 1)

Tumor Immunology and Immunotherapy for Nonimmunologists: Understanding and Intervening in the Immune Response from Premalignancy to Metastatic Disease

Chair: Steven M. Dubinett, Los Angeles, CA

8:00 a.m. **The potential for cancer immunoprevention.** Mary L. Disis, Seattle, WA

8:30 a.m. **The immune landscape in premalignancy.** Steven M. Dubinett, Los Angeles, CA

9:00 a.m. **Opportunities beyond checkpoint.** Robert H. Vonderheide, Philadelphia, PA

9:30 a.m. **Neutralizing immune-suppressive myeloid cells.** Dmitry I. Gabrilovich, Philadelphia, PA

Room N228, McCormick Place North (Level 2)

The Use and Abuse of Chemical Probes: Ensuring Best Practice for Interrogating Biology and Target Validation

Chair: Paul Workman, London, United Kingdom

8:00 a.m. **The good, the bad and the ugly: Choose your chemical probes wisely to explore cancer biology.** Paul Workman, London, United Kingdom

8:30 a.m. **Harnessing large-scale public data for the objective assessment of chemical probes.** Albert A. Antolin, London, United Kingdom

9:00 a.m. **Chemical probe standards: From bench to journal pages.** Milka Kostic, Boston, MA

9:30 a.m. **Oncology target validation with chemical probes: Exploring polycomb repressive complex 1 function in cancer.** Stephen V. Frye, Chapel Hill, NC

SATURDAY, APRIL 14**

METHODS WORKSHOP • 8:00 a.m.–10:00 a.m.

Room N227, McCormick Place North (Level 2)

Advances in Patient-Derived Xenograft Modeling in Cancer**Chair:** Leonard D. Shultz, Bar Harbor, ME

- 8:00 a.m.** **Next-generation humanized mice in cancer research.** Leonard D. Shultz, Bar Harbor, ME
- 8:30 a.m.** **Targeting the innate immune response in models of leukemia and lymphoma.** David M. Weinstock, Boston, MA
- 9:00 a.m.** **Understanding clonal complexity of human hematologic malignancies by single-cell genomics and PDX modeling.** Fumihiko Ishikawa, Kanagawa, Japan
- 9:30 a.m.** **Integrated genomics for PDX.** Carol J. Bult, Bar Harbor, ME

Room S102, McCormick Place South (Level 1)

Clinical Trial Design Part 1: Clinical Trial Design for Targeted Therapies**Chair:** Tatiana Prowell, Silver Spring, MD

- 8:00 a.m.** **Trial designs for targeted cancer therapies: The case for being inclusive.** Tatiana Prowell, Silver Spring, MD
- 8:30 a.m.** **Trial designs for targeted cancer therapies: Tackling primary and secondary resistance.** Keith T. Flaherty, Boston, MA
- 9:00 a.m.** **Incorporation of circulating biomarkers in targeted cancer therapy trials.** Lecia V. Sequist, Boston, MA

Room N427, McCormick Place North (Level 4)

Knowledgebases for Precision Medicine: Variant Interpretation and Clinical Trial Matching**Chair:** Obi Lee Griffith, St. Louis, MO

- 8:00 a.m.** **Using the Cancer Genome Interpreter for gene panel design and variant interpretation.** David Tamborero, Barcelona, Spain
- 8:30 a.m.** **Using cBioPortal and oncoKB to interpret cancer driver and clinically actionable variants.** Debyani Chakravarty, New York, NY
- 9:00 a.m.** **MatchMiner: Matching variants to precision medicine clinical trials.** Catherine A. Del Vecchio Fitz, Boston, MA
- 9:30 a.m.** **CIViC: Best practices for curating germline and somatic cancer variants.** Obi Lee Griffith, St. Louis, MO

**Program as of March 20, 2018

Room S405, McCormick Place South (Level 4)

Oncology Biomarker Detection, Characterization, and Quantification by Mass Spectrometry

Chair: Ahmed M. Aman, Toronto, ON, Canada

- 8:00 a.m.** **Intraoperative tumor grading through rapid lipidomic profiling with picosecond infrared laser mass spectrometry (PIRL-MS).** Arash Zarrine-Afsar, Toronto, ON, Canada
- 8:30 a.m.** **Application of mass spectrometry in CANscript: A patient-derived ex-vivo platform for biomarker discovery in cancer.** Aaron J. Goldman, Cambridge, MA
- 9:00 a.m.** **Urinary prostaglandin E2 metabolites as biomarkers in cancer.** Ginger L. Milne, Nashville, TN
- 9:30 a.m.** **Recent advances in mass spectrometry-based oncology biomarker discovery.** Ahmed M. Aman, Toronto, ON, Canada

PROFESSIONAL ADVANCEMENT SESSION • 9:00 a.m.–4:00 p.m.

Great Lakes A-D, Marriott Marquis Chicago Hotel

Thirteenth Annual AACR Undergraduate Student Caucus and Poster Competition

(not eligible for CME credit)

Chair: Kathleen W. Scotto, New Brunswick, NJ

Moderators: Beverly D. Lyn-Cook, Jefferson, AR
Jose G. Trevino, Gainesville, FL

- 9:40 a.m.** **Special remarks from the AACR President.** Michael A. Caligiuri, Duarte, CA
- 9:50 a.m.** **Understanding cancer.** Ernest T. Hawk, Houston, TX
- 10:10 a.m.** **Message from a cancer survivor.** Desiree Walker, New York, NY
- 10:25 a.m.** **Navigating the Annual Meeting.** Elaine R. Mardis, Columbus, OH
- Prize distribution.** Margaret Foti, AACR CEO, Philadelphia, PA

SATURDAY, APRIL 14**

EDUCATIONAL SESSION • 10:15 a.m.–12:15 p.m.

Room S106, McCormick Place South (Level 1)

Autophagy in Cancer Therapy**Chair:** Andrew M. Thorburn, Aurora, CO

- 10:15 a.m.** **Autophagy overview and roles in tumor cell death.** Andrew M. Thorburn, Aurora, CO
- 10:45 a.m.** **Autophagy in tumor progression to metastasis.** Kay F. Macleod, Chicago, IL
- 11:15 a.m.** **Autophagy in the tumor immune response.** Lorenzo Galluzzi, New York, NY
- 11:45 a.m.** **Targeting autophagy in the clinic and next-generation autophagy drugs.** Ravi K. Amaravadi, Philadelphia, PA

Room N427, McCormick Place North (Level 4)

Basket Trials for Precision Oncology**Chair:** David B. Solit, New York, NY

- 10:15 a.m.** **Introduction.** David B. Solit, New York, NY
- 10:30 a.m.** **Prospective tumor genomic profiling to guide targeted therapy treatment.** Gopa Iyer, New York, NY
- 11:05 a.m.** **Basket trials for patients with rare oncogenic drivers.** Stephen M. Rothenberg, Stamford, CT
- 11:40 a.m.** **Using molecular features of tumors to discover signals of activity for targeted treatments in cancer: Lessons learned from NCI precision oncology trials.** Barbara A. Conley, Rockville, MD

Room S100 (Grand Ballroom), McCormick Place South (Level 1)

Big Data, Deep Learning, and AI Methods for Cancer Analysis**Chair:** Anna Goldenberg, Toronto, ON, Canada

- 10:15 a.m.** **Deep learning approaches to predict and interpret noncoding regulatory elements and disease-associated genetic variants.** Anshul Kundaje, Stanford, CA
- 10:45 a.m.** **Biomarker discovery from big pharmacogenomic data.** Benjamin Haibe-Kains, Toronto, ON, Canada
- 11:15 a.m.** **Modeling drug response using deep learning.** Anna Goldenberg, Toronto, ON, Canada
- 11:45 a.m.** **Deep learning for pathology.** Aditya Khosla, Cambridge, MA

**Program as of March 20, 2018

Room S105, McCormick Place South (Level 1)

Cancer Evolution: Biologic and Clinical Significance of Intratumoral Heterogeneity

Chair: A. Sorana Morrissy, Calgary, AB, Canada

- 10:15 a.m.** **Measuring intratumoral heterogeneity: From genomic data to clinical implications.** A. Sorana Morrissy, Calgary, AB, Canada
- 10:45 a.m.** **The power of selection: Learning how evolutionary dependencies shape cancer.** Giovanni Ciriello, Lausanne, Switzerland
- 11:15 a.m.** **Integrative approaches to understanding the interplay of molecular mechanisms influencing tumor evolution.** Nicholas McGranahan, London, United Kingdom
- 11:45 a.m.** **Experimental approaches for distinguishing genomic and functional tumor cell heterogeneity.** Peter B. Dirks, Toronto, ON, Canada

Room W190, McCormick Place West (Level 1)

Computational Methods for Cancer Genomics Research

Chair: X. Shirley Liu, Boston, MA

- 10:15 a.m.** **ITCR program overview.** Juli Klemm, Rockville, MD
- 10:26 a.m.** **Analyze your functional genomics data in the context of public data on Xena.** Jingchun Zhu, Santa Cruz, CA
- 10:37 a.m.** **Visualize and analyze cancer genomics data through cBioPortal.** Tali Mazor, Boston, MA
- 10:48 a.m.** **Integrative genomics viewer.** Michael M. Reich, La Jolla, CA
- 10:59 a.m.** **Interactive next-generation clustered heat maps for TCGA.** John N. Weinstein, Houston, TX
- 11:10 a.m.** **Analysis of cancer variants through CRAVAT.** Rachel Karchin, Baltimore, MD
- 11:21 a.m.** **Cancer transcriptome analysis through Trinity.** Brian Haas, Cambridge, MA
- 11:32 a.m.** **Model cancer gene regulation through Cistrome.** X. Shirley Liu, Boston, MA
- 11:43 a.m.** **The Cancer Proteome Atlas (TCPA).** Han Liang, Houston, TX
- 11:54 a.m.** **Build, share, and publish biologic networks using NDEX, the Network Data Exchange.** Dexter R. Pratt, La Jolla, CA
- 12:05 p.m.** **Discussion**

SATURDAY, APRIL 14**

Educational Session (cont'd)

Room N227, McCormick Place North (Level 2)

Development of Brain Penetrant Inhibitors: From Genomics to the Clinic**Chair:** Priscilla K. Brastianos, Brookline, MA

- 10:15 a.m.** **Therapeutic targets in primary and metastatic brain tumors.** Priscilla K. Brastianos, Brookline, MA
- 10:45 a.m.** **Use and limitations of patient derived xenograft models for drug discovery in brain tumors.** Jann N. Sarkaria, Rochester, MN
- 11:15 a.m.** **Brain penetrant kinase chemotherapeutics: Learnings from CNS discovery.** Mary M. Mader, Indianapolis, IN
(not eligible for CME credit)
- 11:45 a.m.** **Development of CNS targeted therapies: Case studies.** Pratik S. Multani, San Diego, CA

Room S103, McCormick Place South (Level 1)

From Chemistry to the Clinic: Part 1—Chemical Probes for Identifying and Validating Drug Targets**Chair:** Angela N. Koehler, Cambridge, MA

- 10:15 a.m.** **Why do we need chemical probes for cancer research?** Angela N. Koehler, Cambridge, MA
- 10:45 a.m.** **Strategies for discovery, characterization and use of covalent inhibitors as chemical probes.** Sara J. Buhrlage, Boston, MA
- 11:15 a.m.** **Redefining druggability using chemoproteomic platforms.** Daniel Nomura, Berkeley, CA
- 11:45 a.m.** **Chemical genetics updated: Unanticipated insights from chemical probes.** John Tallarico, Cambridge, MA

Room S402, McCormick Place South (Level 4)

Harnessing the Power of Mouse Models to Deconstruct Cancer Pathways and Understand Therapeutic Responses**Chair:** Laura D. Attardi, Stanford, CA

- 10:15 a.m.** **Deciphering p53 transcriptional programs in tumor suppression.** Laura D. Attardi, Stanford, CA
- 10:45 a.m.** **Altered nucleolar trafficking of the Bln helicase in the mouse reduces size, increases DNA damage and tumor susceptibility, and facilitates premature aging.** Joanna L. Groden, Columbus, OH
- 11:15 a.m.** **Mouse models of lung cancer to decipher molecular and therapeutically relevant subtypes.** Trudy G. Oliver, Salt Lake City, UT
- 11:45 a.m.** **Leveraging mouse models to study therapeutic resistance in lung cancer.** Katerina A. Politi, New Haven, CT

**Program as of March 20, 2018

Room S406 (Vista Ballroom), McCormick Place South (Level 4)

Impact of the Microbiome in Cancer Immunity

Chair: Jennifer A. Wargo, Houston, TX

- 10:15 a.m.** **Title to be announced.** Nadim Jose Ajami, Houston, TX
- 10:45 a.m.** **The influence of the microbiome on chemotherapy and immunotherapy response.** Laurence Zitvogel, Villejuif, France
- 11:15 a.m.** **Modulating the microbiome to enhance responses to therapy.** Jennifer A. Wargo, Houston, TX
- 11:45 a.m.** **The role of the intestinal microbiota in hematopoietic cell transplantation.** Marcel Van Den Brink, New York, NY

Room N228, McCormick Place North (Level 2)

Old and New Puzzles in the Genetic Epidemiology of Cancer

Chair: Peter Kraft, Boston, MA

- 10:15 a.m.** **Assessing the shared genetic basis of different cancers.** John S. Witte, San Francisco, CA
- 10:45 a.m.** **Integrating functional data in post-GWAS studies.** Bogdan Pasaniuc, Los Angeles, CA
- 11:15 a.m.** **Gene-environment interplay and cancer: Epidemiologic evidence.** Peter Kraft, Boston, MA
- 11:45 a.m.** **Clinical utility of cancer risk models: What to expect from polygenic risk scores.** Ruth Pfeiffer, Bethesda, MD

Room W196, McCormick Place West (Level 1)

Tumor Immunology and Immunotherapy for Nonimmunologists: Roundtable Discussions

Chair: Olivera J. Finn, Pittsburgh, PA

Roundtable Faculty and Topics:

Changing the tumor microenvironment to boost the anticancer immune response.

Emmanuel T. Akporiaye, Portland, OR

Epitope identification. Karen S. Anderson, Tempe, AZ

Cancer immunotherapy: Clinical and translational research opportunities. Michael B.

Atkins, Washington, DC

SATURDAY, APRIL 14**

Educational Session (cont'd)

Not all tumor neoantigens are born equal. Luigi Buonaguro, Naples, Italy

Human immune monitoring and biomarkers. Lisa H. Butterfield, Pittsburgh, PA

Cancer immunotherapy trials. Martin A. Cheever, Seattle, WA

Topic to be announced. Raphael Clynes, Monrovia, CA

Topic to be announced. Brian J. Czerniecki, Tampa, FL

Autoimmune adverse events following checkpoint blockade therapy. Kavita Dhodapkar, New Haven, CT

The roles of cancer vaccines as part of combination immunotherapy. Mary L. Disis, Seattle, WA

In situ vaccination with intratumoral dendritic cells. Steven M. Dubinett, Los Angeles, CA

Topic to be announced. Marc S. Ernstoff, Buffalo, NY

The role of the CXCR4 pathway of T-cell exclusion in immune escape by cancer. Douglas T. Fearon, Cold Spring Harbor, NY

Topic to be announced. Olivera J. Finn, Pittsburgh, PA

Myeloid-derived suppressor cells and other myeloid cells in cancer. Dmitry I. Gabrilovich, Philadelphia, PA

Topic to be announced. Jerome Galon, Paris, France

Immunity and immune evasion in hematologic malignancies. Justin P. Kline, Chicago, IL

Cancer vaccines. Keith L. Knutson, Jacksonville, FL

Role of bone marrow myeloid-derived suppressor cells in hematologic malignancies. Yulia Nefedova, Philadelphia, PA

Myeloid-derived suppressor cells in cancer immunotherapy: Novel therapeutic approaches. Augusto C. Ochoa, New Orleans, LA

Engineering T cells with lentiviral vector: A practical approach to CAR-T. Rimas J. Orentas, Gaithersburg, MD

Topic to be announced. Laszlo G. Radvanyi, Billerica, MA

Unique tumor-specific antigens: Mutant neoantigens. Hans Schreiber, Chicago, IL

Contribution of dendritic cells to the antitumor immune response. Stefani Spranger, Cambridge, MA

Clinical studies with myeloid-derived suppressor cells. James E. Talmadge, Omaha, NE

Topic to be announced. Robert H. Vonderheide, Philadelphia, PA

Topic to be announced. Theresa L. Whiteside, Pittsburgh, PA

**Program as of March 20, 2018

METHODS WORKSHOP • 10:15 a.m.–12:15 p.m.

Room S102, McCormick Place South (Level 1)

Clinical Trial Design Part 2: Dose-Finding

Chair: Steven Piantadosi, Los Angeles, CA

- 10:15 a.m.** **Introduction: Historical and methodologic perspective.** Steven Piantadosi, Los Angeles, CA
- 10:45 a.m.** **Overview of dose-finding designs and strategies.** Mark Conaway, Charlottesville, VA
- 11:15 a.m.** **Practical issues conducting dose-finding trials.** Xiaobu Ye, Baltimore, MD
- 11:45 a.m.** **Extending the CRM for general dose-finding.** Steven Piantadosi, Los Angeles, CA

N Hall C, McCormick Place North (Level 1)

Liquid Biopsy Meets Cancer Epigenomics

Chair: Daniel Diniz De Carvalho, Toronto, ON, Canada

- 10:15 a.m.** **Highly sensitive tumor detection and classification using methylome analysis of plasma cfDNA.** Daniel Diniz De Carvalho, Toronto, ON, Canada
- 10:45 a.m.** **Noninvasive detection of cancers in plasma with DNA methylation haplotypes.** Kun Zhang, La Jolla, CA
- 11:15 a.m.** **CancerLocator: Harnessing the diagnostic potential of cell-free DNA methylation.** Jasmine Xianghong Zhou, Los Angeles, CA
- 11:45 a.m.** **Epigenetic traces in plasma DNA.** Michael R. Speicher, Graz, Austria
- Title to be announced.** Yuval Dor, Jerusalem, Israel

SATURDAY, APRIL 14**

Room S404, McCormick Place South (Level 4)

Multiplex Imaging of Tumor Tissues: Techniques and Data Analysis

Chair: Janis Marie Taube, Baltimore, MD

- 10:15 a.m.** **Multiplexed IHC consecutive staining on a single slide and image analysis.**
Sacha Gnjjatic, New York, NY
- 10:45 a.m.** **Developing and validating a multispectral, multiplexed IF assay.** Janis Marie Taube, Baltimore, MD
- 11:15 a.m.** **Application of multiplexed immunofluorescence and digital image analysis to define the immune microenvironment of classical Hodgkin lymphoma.** Scott Rodig, Boston, MA
- 11:45 a.m.** **Multiplexed measurement of protein targets using imaging mass cytometry and digital spatial profiling.** David L. Rimm, New Haven, CT

REGULATORY SCIENCE

AND POLICY SESSION • 10:15 a.m.–12:15 p.m.

Room S401bcd, McCormick Place South (Level 4)

NGS Oncopanel: Regulatory Considerations

(not eligible for CME credit)

Chair: Reena Philip, Silver Spring, MD

You Li, Silver Spring, MD

Yali Li, Cambridge, MA

Katherine B. Szarama, Baltimore, MD

Ahmet Zehir, New York, NY

**Program as of March 20, 2018

EDUCATIONAL SESSION • 1:00 p.m.–3:00 p.m.

Room N227, McCormick Place North (Level 2)

Autoimmunity Meets Tumor Immunity on the Road to Nucleic Acids Sensing

Chair: Sandra Demaria, New York, NY

- 1:00 p.m.** **The role of nucleic acids in type I interferon-mediated inflammation and autoimmunity.** Keith Elkon, Seattle, WA
- 1:30 p.m.** **Cytosolic DNA links genome instability with innate immunity.** Andrew Jackson, Edinburgh, United Kingdom
- 2:00 p.m.** **Clinical implications of disrupting the DNA damage response in cancer therapy.** Kevin J. Harrington, London, United Kingdom
- 2:30 p.m.** **Genotoxic treatment-induced DNA sensing in the context of immunotherapy.** Sandra Demaria, New York, NY

Room S105, McCormick Place South (Level 1)

Biosimilars: Biologic Science, Regulatory Science, and Clinical Practice

Chair: Sara A. Hurvitz, Santa Monica, CA

- 1:00 p.m.** **Biosimilar biologic products: The US FDA perspective.** Joseph Franklin, Silver Spring, MD
- 1:30 p.m.** **Biologic complexity: Implications for biosimilar development.** Simon Hotchin, Thousand Oaks, CA
- 2:00 p.m.** **Biosimilar development: Clinical implications and applications.** Sara A. Hurvitz, Santa Monica, CA
- 2:30 p.m.** **Biosimilar regulatory policy: Understanding the landscape and relevance to medical practice presentation.** Sue Lim, Rockville, MD

Room S106, McCormick Place South (Level 1)

Cancer Prevention and Early Diagnosis in Low- and Middle-Income Countries (LMICs)

Chair: Benjamin O. Anderson, Seattle, WA

- 1:00 p.m.** **Introduction.** Benjamin O. Anderson, Seattle, WA
- 1:10 p.m.** **Cancer prevention and early diagnosis: Regional issues facing Latin America and the Caribbean.** Silvana Luciani, Washington, DC
- 1:30 p.m.** **Cervical cancer prevention strategies for LMICs: How in the world do we do it?** Ophira Ginsburg, New York, NY

SATURDAY, APRIL 14**

Educational Session (cont'd)

- 1:50 p.m.** **Colorectal cancer early diagnosis in low- and middle-income countries.**
Katherine Van Loon, San Francisco, CA
- 2:20 p.m.** **Resource-stratified guidelines and phased implementation: Where the rubber hits the road in LMICs.** Benjamin O. Anderson, Seattle, WA

Room S404, McCormick Place South (Level 4)

Computational Methods for Characterizing Tumor Evolution**Chair:** Christina Curtis, Stanford, CA

- 1:00 p.m.** **Phylogenetic inference of migration patterns in metastatic cancers.**
Benjamin J. Raphael, Princeton, NJ
- 1:30 p.m.** **Cancer evolution measured at single-cell resolution.** Sohrab Shah,
Vancouver, BC, Canada
- 2:00 p.m.** **Quantifying patient-specific evolutionary dynamics.** Christina Curtis,
Stanford, CA
- 2:30 p.m.** **Timing landmark events in cancer evolution using molecular clocks.**
Peter J. Campbell, Cambridge, United Kingdom

Room S103, McCormick Place South (Level 1)

From Chemistry to the Clinic: Part 2—Lead Optimization in Cancer Drug Discovery and Development, Multifactorial Optimization from Early Hits to Drug Candidates**Cochairs:** Philip Jones, Houston, TX; John Yuan Wang, Andover, MA

- 1:00 p.m.** **Introduction: Lead optimization, getting all the right characteristics into a single molecule.** Philip Jones, Houston, TX
- 1:03 p.m.** **Discovery and evolution of orally bioavailable selective estrogen receptor degraders for ER+ breast cancer: From GDC-0810 to GDC-0927.**
Xiaojing Wang, San Francisco, CA
- 1:30 p.m.** **Discovery of BLU-554: A potent and highly selective covalent FGFR4 inhibitor for targeted treatment of advanced hepatocellular carcinoma.**
Chandra V. Miduturu, Cambridge, MA
- 2:00 p.m.** **Discovery of H3B-8800: A novel, orally bioavailable, small-molecule SF3b modulator.** Dominic J. Reynolds, Cambridge, MA
- 2:30 p.m.** **Indoleamine-2,3-dioxygenase: The journey from a surprising mechanism of inhibition to an exciting clinical candidate.** Aaron Balog, Princeton, NJ

**Program as of March 20, 2018

Room S402, McCormick Place South (Level 4)

Genetic, Epigenetic, and Cellular Context Driving Pediatric Brain Tumor Development

Chair: Annie A. Huang, Toronto, ON, Canada

- 1:00 p.m.** **Reinforcing vulnerable epigenetic states in rare embryonal pediatric brain tumors.** Annie A. Huang, Toronto, ON, Canada
- 1:30 p.m.** **Uncovering context-dependent drivers in embryonal brain tumors using transposon modeling.** David A. Largaespada, Minneapolis, MN
- 2:00 p.m.** **Cell context and consequence of oncogenic histone mutations in pediatric gliomas.** Suzanne J. Baker, Memphis, TN
- 2:30 p.m.** **Leveraging chromatin states to pinpoint therapeutic targets in pediatric ependymoma.** Stephen C. Mack, Houston, TX

Room N427, McCormick Place North (Level 4)

Hijacking the Epigenome in Cancer: Challenges and Opportunities

Chair: Nada Jabado, Montreal, QC, Canada

- 1:00 p.m.** **Introduction: Epigenetic-driven cancers: Challenges and opportunities.** Nada Jabado, Montreal, QC, Canada
- 1:02 p.m.** **Histone H3 variants and human cancer.** Peter W. Lewis, Madison, WI
- 1:30 p.m.** **Subgroup-specific enhancer hijacking in medulloblastoma.** Paul A. Northcott, Memphis, TN
- 2:00 p.m.** **Deregulation of H3K36 methylation pathways in cancer.** Chao Lu, New York, NY
- 2:30 p.m.** **Epigenetic dysregulation and mutational partnerships in pediatric glioma.** Jacek Majewski, Montreal, QC, Canada

Room W196, McCormick Place West (Level 1)

New Insights into the Biology and Treatment of Virus-Associated Malignancies

Chair: Catherine Bollard, Washington, DC

- 1:00 p.m.** **Targeting HPV antigens by vaccination.** Cornelia L. Trimble, Baltimore, MD
- 1:30 p.m.** **Recent advances in the biology and management of EBV-associated lymphomas.** Kieron Dunleavy, Washington, DC
- 2:00 p.m.** **Immunotherapy for KSHV-associated and HIV-associated malignancies.** Thomas S. Uldrick, Seattle, WA
- 2:30 p.m.** **Virus-directed T-cell therapies for virus-associated cancers.** Catherine Bollard, Washington, DC

SATURDAY, APRIL 14**

Educational Session (cont'd)

Room W190, McCormick Place West (Level 1)

NGS Methods for Tumor Detection and Response Prediction**Chair:** Aadel A. Chaudhuri, Stanford, CA

- 1:00 p.m.** **Solid tumor MRD detection using C+DNA.** Aadel A. Chaudhuri, Stanford, CA
- 1:30 p.m.** **Early detection and characterization of cancer using noninvasive liquid biopsies.** Victor E. Velculescu, Baltimore, MD
- 2:00 p.m.** **Tracking minimal residual disease and cancer evolution in early-stage NSCLC.** Charles Swanton, London, United Kingdom
- 2:30 p.m.** **The cancer genome's influence on immunotherapy.** Nadeem Riaz, New York, NY

Room N228, McCormick Place North (Level 2)

Opportunities in Drugging Protein-Protein Interactions Using Inhibitors and Degraders**Chair:** Rima S. Al-Awar, Toronto, ON, Canada

- 1:00 p.m.** **Chemically induced degradation of the oncogenic transcription factor BCL6.** Manfred Koegl, Vienna, Austria
- 1:30 p.m.** **From PPI inhibition to targeted protein degradation: A journey with VHL ligands.** Alessio Ciulli, Dundee, United Kingdom
- 2:00 p.m.** **Discovery and optimization of novel, potent and orally bioavailable BCL6-BTB inhibitors.** Methvin Isaac, Toronto, ON, Canada
- 2:30 p.m.** **The challenge of drugging protein-protein interactions: Lessons learned from the discovery of PRC2 complex inhibitor A-395.** William N. Pappano, North Chicago, IL

N Hall C, McCormick Place North (Level 1)

Predictors and Mechanisms of Success or Failure of Immunotherapy**Chair:** Charles G. Drake, New York, NY

- 1:00 p.m.** **PD-L1 expression and its uncertain future as a predictor of immunotherapy response.** Charles G. Drake, New York, NY
- 1:40 p.m.** **The quantification of T-cell responses to mutation associated neoantigens (MANA).** Drew M. Pardoll, Baltimore, MD
- 2:20 p.m.** **Molecular approaches to predicting the efficacy of immune-based therapy.** Jason J. Luke, Chicago, IL

**Program as of March 20, 2018

Room S504, McCormick Place South (Level 5)

Translational Control of Cancer

Chair: Nahum Sonenberg, Montreal, QC, Canada

- 1:00 p.m.** **Translational control of cancer via the mRNA 5'-cap binding complex, eIF4F.** Nahum Sonenberg, Montreal, QC, Canada
- 1:30 p.m.** **Targeted profiling of RNA translation for studying mTOR-dependent and -independent translational regulation.** Jean J. Zhao, Boston, MA
- 2:00 p.m.** **Translating the cancer genome one codon at a time and its therapeutic implications.** Davide Ruggero, San Francisco, CA
- 2:30 p.m.** **Translating translational control to the clinic in breast and ovarian cancer.** Robert J. Schneider, New York, NY

METHODS WORKSHOP • 1:00 p.m.–3:00 p.m.

Room S100 (Grand Ballroom), McCormick Place South (Level 1)

Cancer Modeling in the CRISPR Age

Chair: Andrea Ventura, New York, NY

- 1:00 p.m.** **CRISPR-based liver cancer modeling and gene therapy.** Wen Xue, Worcester, MA
- 1:30 p.m.** **CRISPR-based modeling of colorectal cancer in vivo and ex vivo.** Lukas E. Dow, New York, NY
- 2:00 p.m.** **Engineering complex chromosomal rearrangements by in vivo and ex vivo somatic genome editing.** Andrea Ventura, New York, NY
- 2:30 p.m.** **CRISPR/Cas9-based precision medicine approaches in lung cancer research.** Thales Papagiannakopoulos, New York, NY

SATURDAY, APRIL 14**

Methods Workshop (cont'd)

Room S102, McCormick Place South (Level 1)

Clinical Trial Design Part 3: Trials Utilizing Combination Therapies**Chair:** Gina Petroni, Charlottesville, VA

- 1:00 p.m.** **Introduction.** Gina Petroni, Charlottesville, VA
- 1:30 p.m.** **A Bayesian adaptive phase I/II design of cisplatin and cabazitaxel in prostate cancer with visceral metastasis.** Mourad Tighiouart, Los Angeles, CA
- 2:00 p.m.** **From the statistical bench to bedside: implementing proper designs in the ESMART pediatric combination phase I/II trials.** Xavier Paoletti, Paris, France
- 2:30 p.m.** **Successful implementation of novel early-phase designs for combination therapies.** Gina Petroni, Charlottesville, VA

Room S406 (Vista Ballroom), McCormick Place South (Level 4)

Methods to Evaluate the Immunologic Landscape of Tumors**Chair:** Jerome Galon, Paris, France

- 1:00 p.m.** **Immune contexture of tumor: Novel methods and novel paradigm.** Jerome Galon, Paris, France
- 1:40 p.m.** **Measuring effector and suppressor cellular responses and circulating proteins.** Lisa H. Butterfield, Pittsburgh, PA
- 2:50 p.m.** Speaker to be announced

Room S501, McCormick Place South (Level 5)

NCI's UH2/UH3 Novel Assay Development Program**Chair:** Sameek Roychowdhury, Columbus, OH

- 1:00 p.m.** **Title to be announced.** Sameek Roychowdhury, Columbus, OH
- 1:40 p.m.** **Title to be announced.** David Polsky, New York, NY
- 2:20 p.m.** **Title to be announced.** Joseph A. Califano, La Jolla, CA

**Program as of March 20, 2018

PROFESSIONAL ADVANCEMENT SESSION • 1:00 p.m.–3:00 p.m.

Regency CD, Hyatt Regency McCormick Place

**Women in Cancer Research Professional Advancement Session:
Challenges and Solutions for Wonder Women in Science
(not eligible for CME credit)**

Cochairs: Lori S. Friedman, South San Francisco, CA; Kornelia Polyak, Boston, MA

Panelists: Edith P. Mitchell, Philadelphia, PA
Ashani T. Weeraratna, Philadelphia, PA

Speaker to be announced

**REGULATORY SCIENCE
AND POLICY SESSION • 1:00 p.m.–3:00 p.m.**

Room S401bcd, McCormick Place South (Level 4)

**Cancer Genomic Reference Samples—Sequencing Consortium
Results and Beyond**

Chair: Zivana Tezak, Silver Springs, MD

Wenming Xiao, Jefferson, AR

Li Tai Fang, Belmont, CA

Howard Jacob, North Chicago, IL

Maryellen de Mars, Manassas, VA

Panelists: Michael F. Berger, New York, NY
Rasika Kalamegham, Washington, DC
Jeffrey M. Trent, Phoenix, AZ

SATURDAY, APRIL 14**

EDUCATIONAL SESSION • 3:15 p.m.–5:15 p.m.

Room N427, McCormick Place North (Level 4)

Advances in Cancer Vaccines**Chair:** Pedro J. Romero, Epalinges, Switzerland

- 3:15 p.m.** **Personalized neoepitope-based cancer vaccines.** Özlem Türeci, Mainz, Germany
- 3:45 p.m.** **Dendritic cell targeted vaccines.** Nina Bhardwaj, New York, NY
- 4:35 p.m.** **Inducing tumor-specific CD8T cell memory responses.** Pedro J. Romero, Epalinges, Switzerland

N Hall C, McCormick Place North (Level 1)

Co-stimulation and Co-inhibition in T Cell-Mediated Immunity**Chair:** Ana C. Anderson, Boston, MA

- 3:15 p.m.** **CTLA-4: Discovery, role in self-tolerance, and autoimmunity.** James P. Allison, Houston, TX
- 3:45 p.m.** **PD-L1/PD-1: Mechanism of action and rational combinations.** Ira Mellman, South San Francisco, CA
- 4:15 p.m.** **The next generation of immune checkpoints.** Ana C. Anderson, Boston, MA
- 4:45 p.m.** **T-cell co-stimulation via TNFR family members in immunotherapy.** Ignacio Melero, Pamplona, Spain

Room S501, McCormick Place South (Level 5)

Common Statistical Errors and Mistakes in Cancer Research: How to Avoid Them**Chair:** Yu Shyr, Nashville, TN

- 3:15 p.m.** **Common statistical errors and mistakes in cancer research: How to avoid them—Omics research.** Yu Shyr, Nashville, TN
- 3:45 p.m.** **Interpreting regression models: What do all those betas mean?** Thomas Braun, Ann Arbor, MI
- 4:15 p.m.** **Common statistical errors and mistakes in cancer research: How to avoid them—Manuscript and grant writing.** Heidi L. Weiss, Lexington, KY
- 4:45 p.m.** **So what? Statistical significance vs. clinical significance.** Alex A. Adjei, Rochester, MN

**Program as of March 20, 2018

Room S406 (Vista Ballroom), McCormick Place South (Level 4)

Computational Methods and Resources for Immunogenomics and Immune Therapy

Chair: Malachi Griffith, St. Louis, MO

- 3:15 p.m.** **Online resources and bioinformatics tools for immunogenomics.** Malachi Griffith, St. Louis, MO
- 3:45 p.m.** **Title to be announced.** Maxim Artyomov, St. Louis, MO
- 4:15 p.m.** **Designing and validating personalized cancer vaccines.** Jeffrey E. Hammerbacher, New York, NY
- 4:45 p.m.** **Approaches for T-cell receptor repertoire sequencing.** Trevor J. Pugh, Toronto, ON, Canada

Room S103, McCormick Place South (Level 1)

From Chemistry to the Clinic: Part 3—Approaches to Drug Design for Neuro-oncology

Chair: Timothy Heffron, South San Francisco, CA

- 1:00 p.m.** **Challenges and principles of drug design in neuro-oncology.** Zoran Rankovic, Memphis, TN
- 1:30 p.m.** **Strategies in the discovery of GDC-0084: A BBB penetrating PI3K/mTOR inhibitor.** Timothy Heffron, South San Francisco, CA
- 2:00 p.m.** **Discovery of the clinical candidate AZD1390: A high-quality, potent and selective inhibitor of ATM kinase with the ability to cross the blood-brain barrier.** Kurt G. Pike, Cambridge, United Kingdom
- 2:30 p.m.** **Structural data in the discovery of lorlatinib and insights into mechanisms of ALK acquired resistance.** Ted W. Johnson, San Diego, CA

Room S404, McCormick Place South (Level 4)

Frontiers in Personalized Immunotherapy of Hematologic Malignancies

Chair: Larry W. Kwak, Duarte, CA

- 3:15 p.m.** **Novel targeting of familiar immune targets in B-cell malignancies.** Larry W. Kwak, Duarte, CA
- 3:45 p.m.** **Immune targeting of the microenvironment in classical Hodgkin lymphoma.** Margaret A. Shipp, Boston, MA
- 4:15 p.m.** **CAR T cell strategies for lymphomas.** Sattva S. Neelapu, Houston, TX
- 4:45 p.m.** **Personalized neoantigen vaccine strategies in hematologic malignancies.** Catherine J. Wu, Boston, MA

SATURDAY, APRIL 14**

Educational Session (cont'd)

Room S105, McCormick Place South (Level 1)

New Developments in the Treatment of Metastatic Colorectal Cancer**Chair:** Edward Chu, Pittsburgh, PA

- 3:15 p.m.** **Overview on the treatment of metastatic colorectal cancer.** Edward Chu, Pittsburgh, PA
- 3:45 p.m.** **Novel targeted therapy approaches for metastatic colorectal cancer.** Scott Kopetz, Houston, TX
- 4:15 p.m.** **Update and new strategies for the immunotherapy of MSI-high metastatic colorectal cancer.** Dung T. Le, Baltimore, MD
- 4:45 p.m.** **Title to be announced.** James J. Lee, Pittsburgh, PA

Room W196, McCormick Place West (Level 1)

No More “Triple-Negative Breast Cancer”: Molecular Classification and Personalized Therapy**Chair:** Charles M. Perou, Chapel Hill, NC

- 3:15 p.m.** **Introduction.** Charles M. Perou, Chapel Hill, NC
- 3:20 p.m.** **Precision medicine for TNBC patients using a systems biology approach.** Charles M. Perou, Chapel Hill, NC
- 3:45 p.m.** **Triple-negative breast cancer: Targeting a genetically diverse disease.** Brian D. Lehmann, Hendersonville, TN
- 4:10 p.m.** **Targeting the androgen receptor in TNBC.** Ayca Gucalp, New York, NY
- 4:45 p.m.** **Targeted therapy for TNBC: Signs of progress after a decade of hope.** Stacy L. Moulder, Houston, TX

Room N227, McCormick Place North (Level 2)

Pancreatic Cancer Prevention**Chair:** Anirban Maitra, Houston, TX

- 3:15 p.m.** **Early detection and prevention of pancreas cancer.** Anirban Maitra, Houston, TX
- 3:45 p.m.** **Pancreatic cancer immunoprevention: Novel strategies.** Florencia McAllister, Houston, TX
- 4:15 p.m.** **Generating immunity to pancreatic cancer.** Stephanie K. Dougan, Boston, MA
- 4:45 p.m.** **Chemoprevention of pancreas cancer.** Chinthalapally V. Rao, Oklahoma City, OK

**Program as of March 20, 2018

Room S102, McCormick Place South (Level 1)

The Paradox Toolbox: Developing a Better Understanding of Associations between Obesity and Cancer—and What to Do about It?

Chair: Wendy Demark-Wahnefried, Birmingham, AL

- 3:15 p.m.** **Introduction.** Wendy Demark-Wahnefried, Birmingham, AL
- 3:20 p.m.** **Overview of BMI, cancer survival, and overall survival.** Pamela J. Goodwin, Toronto, ON, Canada
- 3:50 p.m.** **A causal link between excess weight and poor prognosis after cancer can be questioned.** Andrew Renehan, Manchester, United Kingdom
- 4:20 p.m.** **Do weight loss interventions have a role in cancer survivorship: A need to proceed, but doing so with caution.** Wendy Demark-Wahnefried, Birmingham, AL
- 4:50 p.m.** **Panel discussion.** Bette J. Caan, Oakland, CA

Room N228, McCormick Place North (Level 2)

Revisiting Vitamin C as an Epigenetic Therapeutic

Chair: Benjamin G. Neel, New York, NY

- 3:15 p.m.** **Restoration of TET function as a therapeutic strategy in leukemia.** Luisa Cimmino, New York, NY
- 3:45 p.m.** **Epigenetic regulation of stem cell function and leukemia suppression by vitamin C.** Sean J. Morrison, Dallas, TX
- 4:15 p.m.** **TET proteins and vitamin C control the stability of Foxp3 expression in T regulatory cells.** Anjana Rao, La Jolla, CA
- 4:45 p.m.** **Vitamin C as an epigenetic drug in cancer.** Kirsten Gronbaek, København, Denmark

Room S106, McCormick Place South (Level 1)

Single-Cell Analysis of the Cancer Epigenome and Transcriptome

Chair: Mario L. Suvà, Charlestown, MA

- 3:15 p.m.** **Dissecting adult and pediatric gliomas by single-cell genomics.** Mario L. Suvà, Charlestown, MA
- 3:45 p.m.** **Computational analysis of single-cell cancer transcriptomes: Progress and challenges.** Claudia Kleinman, Montreal, QC, Canada
- 4:15 p.m.** **Functional single-cell genomics for targeting genetically complex acute myeloid leukemia.** Fumihiko Ishikawa, Kanagawa, Japan
- 4:45 p.m.** **Dissecting normal and clonal hematopoietic differentiation topologies with single-cell genomics.** Daniel Landau, New York, NY

SATURDAY, APRIL 14**

Educational Session (cont'd)

Room W190, McCormick Place West (Level 1)

What Can We Learn about Cancer by Combining Germline and Somatic Data?**Chair:** Jan Korbel, Heidelberg, Germany

- 3:15 p.m.** **Germline determinants of the somatic mutation landscape in 2,642 cancer genomes.** Jan Korbel, Heidelberg, Germany
- 3:45 p.m.** **Interaction of inherited polymorphisms and somatic events in cancer.**
Hannah K. Carter, La Jolla, CA
- 4:15 p.m.** **Germline and somatic alterations and impact on clinical decision making.**
Michael F. Berger, New York, NY
- 4:45 p.m.** **Integrating germline and somatic data to provide insights into epidemiology studies.** Ulrike Peters, Seattle, WA

METHODS WORKSHOP • 3:15 p.m.–5:15 p.m.

Room S100 (Grand Ballroom), McCormick Place South (Level 1)

Assessing the T-cell Repertoire in Clinical Trials**Chair:** Jennifer S. Sims, New York, NY

- 3:15 p.m.** **The next generation of TCR repertoire profiling.** Jennifer S. Sims, New York, NY
- 3:45 p.m.** **TCR response from immune repertoire sequencing data.** Aleksandra Walczak, Paris, France
- 4:15 p.m.** **Single-cell TCR profiling.** Gurinder Atwal, Cold Spring Harbor, NY
- 4:45 p.m.** **Molecular tools to study T-cell repertoire, specificity, and function.**
Arnold Han, New York, NY

Room S504, McCormick Place South (Level 5)

Characterizing the Pre-cancer Genome: Identification of Early Drivers**Chair:** Eduardo Vilar-Sanchez, Houston, TX

- 3:15 p.m.** **The making of the pre-cancer atlas: Opportunities and challenges.** Sudhir Srivastava, Rockville, MD
- 3:45 p.m.** **Single-cell genomics for the analysis of premalignancy.** Nicholas E. Navin, Bellaire, TX

**Program as of March 20, 2018

- 4:15 p.m.** **Genomic analysis of precancers in the GI tract.** Eduardo Vilar-Sanchez, Houston, TX
- 4:45 p.m.** **Pre-cancer genomic analysis in hematologic disorders.** Benjamin L. Ebert, Boston, MA

Room S405, McCormick Place South (Level 4)

Tracking Tumor Metabolism in Action

Chair: Joshua D. Rabinowitz, Princeton, NJ

- 3:15 p.m.** **Tracing tissue and tumor metabolism with mass spectrometry.** Joshua D. Rabinowitz, Princeton, NJ
- 3:45 p.m.** **Probing tumor metabolic heterogeneity with imaging mass spectrometry.** Shawn Davidson, Cambridge, MA
- 4:15 p.m.** **Bridging MR imaging and mass spectrometry analysis of human tumor metabolism.** Elizabeth Maher, Dallas, TX
- 4:45 p.m.** **Utilizing hyperpolarized MRI to study metabolism noninvasively.** Kayvan R. Keshari, New York, NY

PROFESSIONAL ADVANCEMENT SESSION • 3:30 p.m.–5:30 p.m.

Jackson Park ABC, Hyatt Regency

Personalized Career Conversations

Sponsored by the Associate Member Council, Minorities in Cancer Research, and Women in Cancer Research
(not eligible for CME credit)

MEET AND GREET • 5:00 p.m.–6:30 p.m.

Dusable, Hyatt Regency

AACR Undergraduate Scholars

(not eligible for CME credit)

Chair: Kathleen W. Scotto, New Brunswick, NJ

SATURDAY, APRIL 14**

PROFESSIONAL ADVANCEMENT SESSION • 5:30 p.m.–7:30 p.m.

Great Lakes E-G, Marriott Marquis Chicago Hotel

Careers in Clinical Cancer Research Roundtable

(not eligible for CME credit)

Chair: Carlos L. Arteaga, Dallas, TX

MEET AND GREET • 6:30 p.m.–8:30 p.m.

Regency AB, Hyatt Regency

New Member Networking Mixer

(not eligible for CME credit)

Elizabeth M. Jaffee, 2018-2019 AACR President, Baltimore, MD

**Program as of March 20, 2018

SUNDAY, APRIL 15**

MEET-THE-EXPERT SESSION • 7:00 a.m.–8:00 a.m.

Room S103, McCormick Place South (Level 1)

Accelerating the Pace of Change by Incorporating Early End Point into Care and Trials

Laura J. Esserman, San Francisco, CA

Room N228, McCormick Place North (Level 2)

Chimeric Antigen Receptor (CAR)-Engineered T and NK Cells and HSV1-Based Oncolytic Virotherapy for Cancer Treatment

Jianhua Yu, Columbus, OH

Room S402, McCormick Place South (Level 4)

Communicating with the e-Patient in the Era of Digital Health

Michael A. Thompson, Delafield, WI

Room S100 (Grand Ballroom), McCormick Place South (Level 1)

CRISPR-Cas9: A Bacterial Immune System Becomes a Star in Gene Editing

Emmanuelle Charpentier, Berlin, Germany

Room N227, McCormick Place North (Level 2)

CTC Characterization and Applications

Evi S. Lianidou, Athens, Greece

Room S105, McCormick Place South (Level 1)

Developing Software for Immunotherapy: Lessons Learned from Silicon Valley

Jeffrey E. Hammerbacher, New York, NY

Room S404, McCormick Place South (Level 4)

Impact of Molecular Tumor Characterization on Clinical Decision Making in Malignant Glioma

Roger Stupp, Chicago, IL

Room S106, McCormick Place South (Level 1)

Linking Biologic Heterogeneity and Genetic Complexity of Human Malignancies Using the “Humanized Mouse”

Fumihiko Ishikawa, Kanagawa, Japan

**Program as of March 20, 2018

Room S406 (Vista Ballroom), McCormick Place South (Level 4)

Myeloid-Derived Suppressor Cells in Regulation of Tumor Immunity and Response to Therapy

Dmitry I. Gabrilovich, Philadelphia, PA

Room W190, McCormick Place West (Level 1)

Precision Medicine and K-RAS-Driven Cancers: What Are We Doing Wrong?

Mariano Barbacid, Madrid, Spain

Room W196, McCormick Place West (Level 1)

The Tumor Microenvironment Promotes and Sustains Pancreatic Cancer

David A. Tuveson, Cold Spring Harbor, NY

SUNDAY

NCI/NIH-SPONSORED SESSION • 7:00 a.m.–8:00 a.m.

Room W192, McCormick Place West (Level 1)

NIH Grants Session: Changes in Review, Funding, and Funding Opportunities at the NCI

(not eligible for CME credit)

Chair: Daniel L. Gallahan, Bethesda, MD

7:05 a.m. Amy L. Rubinstein, Bethesda, MD

7:25 a.m. Daniel L. Gallahan, Bethesda, MD

7:45 a.m. **Discussion**

**Program as of March 20, 2018

OPENING CEREMONY • 8:00 a.m.–9:45 a.m.

N Hall B (Plenary Hall), McCormick Place North (Level 3)

(not eligible for CME credit)

Join us on Sunday for the Annual Meeting Opening Ceremony, a yearly tradition marking the start of four days filled with outstanding and innovative science.

Highlights of the Opening Ceremony include:

- Remarks from AACR CEO Margaret Foti and AACR President Michael A. Caligiuri
- Twelfth Annual AACR Team Science Award
- Recognition of the newly inducted Fellows of the AACR Academy
- The Third Annual AACR June L. Biedler Prize for Cancer Journalism
- The 2018 Distinguished Public Service Awards
- The Fifteenth Annual AACR Award for Lifetime Achievement in Cancer Research
- The Twelfth Annual AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research

**Don't miss this exciting event,
which leads directly into the Opening Plenary Session!**

See you there!

SUNDAY, APRIL 15**

OPENING PLENARY SESSION • 9:45 a.m.–12:15 p.m.

N Hall B (Plenary Hall), McCormick Place North (Level 3)

Opening Plenary: Advancing Cancer Medicine: From Discovery to Patient Care

Chair: Elaine R. Mardis, Columbus, OH

9:45 a.m. Introduction. Elaine R. Mardis, Columbus, OH

9:50 a.m. Liquid biopsy: Novel technologies and clinical applications. Klaus Pantel, Hamburg, Germany

10:15 a.m. Immune checkpoint therapy: From CTLA-4 to PD-1/PD-L1 and beyond. Padmanee Sharma, Houston, TX

10:40 a.m. CT001 Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Efficacy and safety results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial. Alexander M. M. Eggermont, Villejuif, France

11:05 a.m. Discussant. Antoni Ribas, Los Angeles, CA

11:15 a.m. Mobilizing immunity against ovarian cancer. George Coukos, Lausanne, Switzerland

11:40 a.m. Cancer chromosome evolution in metastases, immune evasion, adaptation and clinical outcome: Insights from the TRACERx studies. Charles Swanton, London, United Kingdom

12:05 p.m. Opportunities/challenges for the future. Elaine R. Mardis, Columbus, OH

AWARDS AND LECTURES • 12:15 p.m.–1:00 p.m.

Room S100 (Grand Ballroom), McCormick Place South (Level 1)

Twenty-First Annual Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research

12:15 p.m. Protein phosphorylation: Pancreatic cancer and new frontiers in histidine phosphorylation. Tony Hunter, La Jolla, CA

Dr. Hunter is recognized for his work in discovering tyrosine kinases, enzymes controlling cell signaling to regulate cell proliferation, metabolism, and other processes. His original discovery of tyrosine phosphorylation established how many oncoproteins transform cells and how growth factor receptors transduce signals.

**Program as of March 20, 2018

NCI/NIH-SPONSORED SESSION • 12:15 p.m.–1:45 p.m.

Room W192, McCormick Place West (Level 1)

NCI-Sponsored Training Awards and Opportunities

(not eligible for CME credit)

Jonathan S. Wiest, Bethesda, MD

Ming Lei, Rockville, MD

Mark Damico, Bethesda, MD

Michael K. Schmidt, Rockville, MD

CLINICAL TRIALS PLENARY SESSION 1 • 12:45 p.m.–2:45 p.m.

N Hall C, McCormick Place North (Level 1)

Multimodality Immuno-oncology Approaches

Chair: Louis M. Weiner, Washington, DC

- 12:45 p.m.** **CT003 Preoperative pembrolizumab (pembro) before radical cystectomy (RC) for muscle-invasive urothelial bladder carcinoma (MIUC): Interim clinical and biomarker findings from the phase II PURE-01 study.**
Andrea Necchi, Milan, Italy
- 1:05 p.m.** **Discussant to be announced**
- 1:15 p.m.** **CT004 Front-line therapy of DIPG using the IDO pathway inhibitor indoximod in combination with radiation and chemotherapy.** Theodore S. Johnson, Augusta, GA
- 1:35 p.m.** **Discussant to be announced**
- 1:45 p.m.** **CT005 FLT3 ligand (CDX-301) and stereotactic radiotherapy for advanced non-small cell lung cancer.** Nitin Ohri, Bronx, NY
- 2:05 p.m.** **Discussant.** Silvia C. Formenti, New York, NY
- 2:15 p.m.** **CT006 Intraperitoneal radioimmunotherapy for desmoplastic small round cell tumor: Results of a phase I study (clinicaltrials.gov identifier NTC01099644).** Shakeel Modak, New York, NY
- 2:35 p.m.** **Discussant.** Kunle Odunsi, Buffalo, NY

SUNDAY, APRIL 15**

MEET AND GREET • 1:00 p.m.–2:00 p.m.

Booth 1431, Exhibit Hall A, McCormick Place South (Level 3)

Meet the Editor-in-Chief of *Clinical Cancer Research*: Keith T. Flaherty, MD
(not eligible for CME credit)

Keith T. Flaherty, Boston, MA

MAJOR SYMPOSIA • 1:00 p.m.–2:45 p.m.

Room S105, McCormick Place South (Level 1)

Beyond microRNAs: Emerging Roles of Other Noncoding RNAs in Cancer

Chair: Howard Y. Chang, Stanford, CA

1:00 p.m. Introduction

1:05 p.m. Genome regulation by long noncoding RNAs. Howard Y. Chang, Stanford, CA [SY25-01*]

1:35 p.m. Functional long noncoding RNAs in cancer pathways. Maite Huarte, Pamplona, Spain

2:05 p.m. Surprising roles for tRNAs in regulation of cancer progression. Sohail Tavazoie, New York, NY

Room N228, McCormick Place North (Level 2)

Defining and Addressing the Heterogeneity of Hepatocellular Carcinoma (HCC)

Chair: Richard S. Finn, Los Angeles, CA

1:00 p.m. Introduction

1:05 p.m. Bridging the gap between science and treatment in HCC. Richard S. Finn, Los Angeles, CA

1:35 p.m. Heterogeneity in molecular subtype of hepatocellular carcinoma. Yujin Hoshida, New York, NY [SY36-02*]

2:05 p.m. Immunotherapy takes off in HCC. Ignacio Melero, Pamplona, Spain

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings* (the abstract number is listed in brackets above).

**Program as of March 20, 2018

Room S100 (Grand Ballroom), McCormick Place South (Level 1)

Metastatic Microenvironment Dictates Progression and Therapy Responses

Chair: Mikala Egeblad, Cold Spring Harbor, NY

- 1:00 p.m. Introduction**
- 1:05 p.m. Inflammation-induced neutrophil extracellular traps (NETs) awaken dormant cancer in the lung microenvironment.** Mikala Egeblad, Cold Spring Harbor, NY [SY38-01*]
- 1:35 p.m. Postpartum tissue remodeling drives breast cancer metastasis.** Pepper Jo Schedin, Portland, OR [SY38-02*]
- 2:05 p.m. Microenvironment dictates differential response of primary tumor versus metastases.** Rakesh K. Jain, Boston, MA [SY38-03*]

N Hall B (Plenary Hall), McCormick Place North (Level 3)

Personalized Neoantigen Vaccines

Chair: Catherine J. Wu, Boston, MA

- 1:00 p.m. Introduction**
- 1:05 p.m. Determinants of neoantigen immunogenicity.** Lelia Delamarre, San Francisco, CA [SY14-01*]
- 1:35 p.m. Personalized therapies: Neoantigen discovery and vaccination.** Nina Bhardwaj, New York, NY [SY14-02*]
- 2:05 p.m. Designing and improving personal neoantigen-targeting vaccines.** Catherine J. Wu, Boston, MA

Room S406 (Vista Ballroom), McCormick Place South (Level 4)

Translational Applications of Systems Biology

Chair: Andrea Califano, New York, NY

- 1:00 p.m. Introduction**
- 1:05 p.m. Systematic approaches to identify cancer dependencies.** William C. Hahn, Boston, MA [SY35-01*]
- 1:30 p.m. Cancer systems biology: From bench to bedside.** Andrea Califano, New York, NY
- 1:55 p.m. Systems approach to targeting adaptive responses to PARP inhibitors in cancer.** Gordon B. Mills, Houston, TX
- 2:20 p.m. Effects of altering receptor structure in CAR T cells: Predictions from an experimentally validated systems biology model.** Stacey D. Finley, Los Angeles, CA [NG01*]

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings* (the abstract number is listed in brackets above).

SUNDAY, APRIL 15**

**RECENT ADVANCES IN CANCER
HEALTH DISPARITIES RESEARCH • 1:00 p.m.–2:45 p.m.**

Room S102, McCormick Place South (Level 1)

**Can Cervical Cancer Screening and Prevention Be Implemented
in Developing Countries and the Evolution of Treatment in
Under-Resourced Countries**

Chair: Linus T. Chuang, Danbury, CT

- 1:00 p.m.** **Cervical cancer screening in low- and middle-income countries: New approaches leading to success.** Silvia De Sanjose, Hospitalet, Spain
- 1:30 p.m.** **Preventing cervical cancer in the first mile of the care continuum.** Nimmi Ramanujam, Durham, NC
- 2:00 p.m.** **Evolution of clinical trials in cervical cancer treatments in resource-constrained settings.** Linus T. Chuang, Danbury, CT

Room N427, McCormick Place North (Level 4)

Genetic Ancestry and Breast Cancer Risk

Chair: Lisa A. Newman, Detroit, MI

- 1:00 p.m.** **“Ethnicity,” nationality, genetic ancestry, and breast cancer in women of Latin American origins.** Laura Fejerman, San Francisco, CA
- 1:30 p.m.** **African ancestry and breast cancer risk.** Julie R. Palmer, Boston, MA
- 2:00 p.m.** **African ancestry and markers of inflammation related to breast cancer risk.** Melissa B. Davis, Detroit, MI

Room S404, McCormick Place South (Level 4)

Multiple Myeloma

Chair: Robert Z. Orlowski, Houston, TX

- 1:00 p.m.** **Immunotherapy for AL amyloidosis.** Suzanne Lentzsch, New York, NY
- 1:30 p.m.** **CAR T-cells in myeloma.** James N. Kochenderfer, Houston, TX
- 2:00 p.m.** **Novel small-molecule therapeutics.** Robert Z. Orlowski, Houston, TX

**Program as of March 20, 2018

RECENT ADVANCES IN ORGAN SITE RESEARCH • 1:00 p.m.–2:45 p.m.

Room W190, McCormick Place West (Level 1)

Dharma Master Jiantai Recent Advances in Lung Cancer Research Session: Latest Advances in Small Cell Lung Cancer

Chair: Julien Sage, Stanford, CA

- 1:00 p.m.** **Mechanisms of acquired therapeutic resistance in SCLC.** Charles M. Rudin, New York, NY
- 1:30 p.m.** **Targeting DNA damage response and immune checkpoints in SCLC.** Lauren Averett Byers, Houston, TX
- 2:00 p.m.** **Tumor heterogeneity and therapy response in SCLC.** Julien Sage, Stanford, CA

Room N227, McCormick Place North (Level 2)

Ovarian Cancer Metastasis

Chair: Dineo Khabele, Kansas City, KS

- 1:00 p.m.** **Ovarian cancer metastasis and the role of tumor-associated macrophages.** Dineo Khabele, Kansas City, KS
- 1:30 p.m.** **New tools to study ovarian cancer micrometastasis.** Ahmed A. Ahmed, Oxford, United Kingdom
- 2:00 p.m.** **Targeting the tumor microenvironment in ovarian cancer metastasis.** Anil K. Sood, Houston, TX

Room W196, McCormick Place West (Level 1)

Targeting Pancreatic Cancer

Chair: Ben Z. Stanger, Philadelphia, PA

- 1:00 p.m.** **Targeting the drug- and immune-privileged sanctuary of pancreas cancer.** Sunil R. Hingorani, Seattle, WA
- 1:30 p.m.** **Understanding immune heterogeneity in pancreas cancer.** Ben Z. Stanger, Philadelphia, PA
- 2:00 p.m.** **Exploring tumor suppressor gene mutations in pancreas cancer.** Scott W. Lowe, New York, NY

SUNDAY, APRIL 15**

**RECENT ADVANCES IN PREVENTION
AND INTERCEPTION RESEARCH • 1:00 p.m.–2:45 p.m.**

Room S106, McCormick Place South (Level 1)

Pediatric Cancer Survivorship

Chair: Lisa R. Diller, Boston, MA

- 1:00 p.m.** **Prevention in the context of pediatric cancer: Improving outcomes in survivors.** Lisa R. Diller, Boston, MA
- 1:05 p.m.** **Prevention of late effects: Can we learn from laboratory models?** Jason N. Berman, Halifax, NS, Canada
- 1:35 p.m.** **Prevention of late toxicity using clinical trials: Chemoprevention of late congestive heart failure.** Saro Armenian, Duarte, CA
- 2:05 p.m.** **Risk of second malignancy cancer after childhood and adolescent cancer: Does epidemiology inform risk reduction strategy?** Flora E. van Leeuwen, Amsterdam, Netherlands

**REGULATORY SCIENCE AND
POLICY SESSION • 1:00 p.m.–2:45 p.m.**

Room S401bcd, McCormick Place South (Level 4)

**Has Pandora's Box Been Opened? The Site-Agnostic Approval
of Pembrolizumab**

Chair: Steven J. Lemery, Silver Spring, MD

Speakers: Janaki Veeraraghavan, Silver Spring, MD
Russell R. Broaddus, Houston, TX
Heather L. Hampel, Columbus, OH
Michael J. Overman, Houston, TX
Zsofia K. Stadler, New York, NY

**Program as of March 20, 2018

DRUG DEVELOPMENT TRACK— SPECIAL SESSION • 1:00 p.m.–3:00 p.m.

Room S103, McCormick Place South (Level 1)

New Drugs on the Horizon 1

Cochairs: Julian Blagg, Sutton, Surrey, United Kingdom; Andrew J. Phillips, Cambridge, MA

- 1:00 p.m.** **AZD4573: A potent and selective CDK9 inhibitor for the treatment of hematologic malignancies.** Lisa Drew, Waltham, MA
(not eligible for CME credit)
- 1:24 p.m.** **The discovery of BT1718: A novel bicyclic peptide drug conjugate for the treatment of solid tumors expressing MT1-MMP.** Nicholas J. Keen, Lexington, MA
(not eligible for CME credit)
- 1:48 p.m.** **FPA150: A recombinant, afucosylated, fully human IgG1 monoclonal antibody for the treatment of malignancies that express high levels of B7-H4 anti-B7H4 talk.** Charles D. Kaplan, South San Francisco, CA
- 2:12 p.m.** **Pharmacologic profile and antitumor properties of LXH254, a highly selective RAF kinase inhibitor.** Darrin D. Stuart, Cambridge, MA
[DDT01-04*]
- 2:36 p.m.** **ABBV-744: A first-in-class highly BDII-selective BET bromodomain inhibitor.** Warren Kati, North Chicago, IL [DDT01-05*]
(not eligible for CME credit)

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings* (the abstract number is listed in brackets above).

SUNDAY, APRIL 15**

POSTER SESSION • 1:00 p.m.-5:00 p.m.

Exhibit Hall A, McCormick Place South (Level 3)

(not eligible for CME credit)

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner, the Annual Meeting App (available at www.AACR.org/AACR2018), and in the print Poster Sessions and Exhibits Guide. A limited number of copies of the print guide are available in the Exhibit Hall.

SUNDAY

Tumor Biology

- Section 1 Angiogenesis Inhibitors and Stimulators
- Section 2 Breast Cancer Metastasis
- Section 3 Dormancy and Aging: The Influential Microenvironment
- Section 4 Mechanisms Underlying Metastasis 1
- Section 5 Role of the Innate Immune System in Tumorigenesis
- Section 6 Targeting Cancer Stemness
- Section 7 The Mechanical Microenvironment in Tumorigenesis
- Section 8 Tumor Heterogeneity 1
- Section 45 Late-Breaking Research: Tumor Biology 1

Epidemiology

- Section 9 Genetic Contributions to Cancer Epidemiology 1: GWAS and Pathway and Candidate Gene Studies

Prevention Research

- Section 10 Chemoprevention of Cancer

Bioinformatics and Systems Biology

- Section 12 Integrative Cancer Biology 1
- Section 44 Late-Breaking Research: Bioinformatics and Systems Biology

Molecular and Cellular Biology / Genetics

- Section 14 BCL-2 Family and Mitochondrial Apoptosis
- Section 15 Cancer Predisposition and Synthetic Lethality
- Section 16 Chromatin Structure and Function
- Section 17 Emerging Concepts

**Program as of March 20, 2018

- Section 18 Functional Genomics
- Section 19 High-Throughput Sequencing 1
- Section 20 Metabolism and Cellular Functions 1
- Section 21 MicroRNA Regulation in Cancer Biology
- Section 22 Noncoding RNAs as Oncogenes and Tumor Suppressors
- Section 23 Oncogenes and Tumor Suppressor Genes

Clinical Research

- Section 25 Biomarker Discovery 1
- Section 26 Clinical Risk Factors and Outcomes in Solid Tumors / Survivorship Research
- Section 27 Immune Response to Therapies 1
- Section 28 Modifiers of the Tumor Microenvironment 1
- Section 29 Molecular Diagnostics 1: Cytogenetics, Clinical Molecular Genetics, and Clinical Imaging
- Section 30 Radiation Oncology

Cancer Chemistry

- Section 31 Chemical and Structural Biology

Immunology

- Section 32 Inflammation, Immunity, and Cancer
- Section 33 Response and Resistance to Immune Checkpoint Blockade
- Section 34 Vaccines 1

Experimental and Molecular Therapeutics

- Section 35 Antibody-Drug Conjugates: Agents and Technology
- Section 36 Biomarker Identification and Novel Methods
- Section 37 Experimental Agents and Combinations for Hematologic Malignancies 1
- Section 38 Growth Factors and Protein Kinases as Targets
- Section 39 Modulators of Ionizing Radiation and Other Radiotherapeutics
- Section 40 New Therapy with New Mechanism of Action
- Section 41 Strategies to Reversing Drug Resistance
- Section 43 Late-Breaking Research: Experimental and Molecular Therapies 1

Clinical Trials

- Section 42 Phase I Clinical Trials 1

SUNDAY, APRIL 15**

SPECIAL SESSION • 1:15 p.m.–2:00 p.m.

AACRcentral Amphitheater, Hall A, McCormick Place South (Level 3)

**Molecular Epidemiology Working Group (MEG)
Networking Session with Early-Career Researchers**
(not eligible for CME credit)

Opening remarks: MEG Chair. Melissa L. Bondy, Houston, TX

AACR funding/grants information and process. Yixian Zhang, Philadelphia, PA

American Cancer Society funding/grants information and process.
William C. Phelps, Atlanta, GA

View from the NCI. Deborah Marie Winn, Rockville, MD

NCI/NIH-SPONSORED SESSION • 1:45 p.m.–3:15 p.m.

Room W192, McCormick Place West (Level 1)

**Helping Extramural Innovators Advance New Therapies into the Clinic:
NCI Developmental Therapeutics Program**
(not eligible for CME credit)

Jerry M. Collins, Rockville, MD

Rosemarie Aurigemma, Rockville, MD

Paul Grothaus, Rockville, MD

Suzanne Forry, Bethesda, MD

Connie L. Sommers, Bethesda, MD

MEET AND GREET • 2:00 p.m.–4:00 p.m.

AACRcentral-MICR Resource Center, Hall A

Minorities in Cancer Research Council Meet and Greet
(not eligible for CME credit)

Council Chair: John M. Carethers, Ann Arbor, MI

**Program as of March 20, 2018

Council Chair-Elect: Brian M. Rivers, Atlanta, GA

Council Chair-Elect Designate: Laura Fejerman, San Francisco, CA

Past Chair: Rick A. Kittles, Duarte, CA

Council Members: Kimlin T. Ashing, Duarte, CA
 Lisa L. Baumbach-Reardon, Phoenix, AZ
 John D. Carpten, Los Angeles, CA
 Gerardo Colón-Otero, Jacksonville, FL
 Beverly D. Lyn-Cook, Jefferson, AR
 Coleman K. Obasaju, Indianapolis, IN
 Mary Jackson Scroggins, Washington, DC
 Sanya A. Springfield, Bethesda, MD
 Robert A. Winn, Chicago, IL

AACRcentral-WICR Resource Center, Hall A

Women in Cancer Research Council Meet and Greet
(not eligible for CME credit)

Council Chair: Judith S. Sebolt-Leopold, Ann Arbor, MI

Council Chair-Elect: Lucile L. Adams-Campbell, Washington, DC

Past Chair: Patricia M. LoRusso, New Haven, CT

Council Members: Cathrin Brisken, Lausanne, Switzerland
 Sara A. Courtneidge, Portland, OR
 Marcia R. Cruz-Correa, San Juan, PR
 Caroline Dive, Manchester, United Kingdom
 Lori S. Friedman, South San Francisco, CA
 Brigitte B. Ma, Hong Kong, Hong Kong
 Morag Park, Montréal, QC, Canada
 Kornelia Polyak, Boston, MA

SPECIAL SESSION • 2:30 p.m.-3:30 p.m.

AACRcentral Amphitheater, Hall A, McCormick Place South (Level 3)

Rally: Celebrating 30 Years of Associate Membership
(not eligible for CME credit)

Michael A. Caligiuri, AACR President; Margaret Foti, AACR CEO; Kathleen W. Scotto, AACR Science Education and Career Advancement Committee Chair; Kenneth Dutton-Regester, AACR Associate Member Council (AMC) Chair

SUNDAY, APRIL 15**

POSTER DISCUSSION SESSION • 3:00 p.m.–4:00 p.m.

Room S402, McCormick Place South (Level 4)

Pediatric Cancer

(not eligible for CME credit)

Chair: David Malkin, Toronto, ON, Canada

The abstracts presented in this Poster Discussion Session will also be presented in the following Poster Session:

Pediatric Cancer

Monday, April 16, 2018, 8:00 a.m.–12:00 p.m.

Section 28, Hall A, McCormick Place South (Level 3)

- 3:00 p.m. Introduction**
- 3:10 p.m. 1629 Targeting resistance mechanisms to CDK4/6 inhibitors in Ewing sarcoma with an IGF1R inhibitor drug combination strategy.** Lillian M. Guenther, Boston, MA
- 3:15 p.m. 1630 FLT3 chimeric antigen receptor T-cell therapy induces B to T cell lineage switch in infant acute lymphoblastic leukemia.** Christopher D. Chien, Bethesda, MD
- 3:20 p.m. 1631 T-cell dysfunction in pediatric cancer patients at diagnosis and after chemotherapy can limit chimeric antigen receptor potential.** David M. Barrett, Philadelphia, PA
- 3:25 p.m. 1632 Suppression of EWS-FLI1 transcription using a combination therapy of mithramycin and cyclin-dependent kinase 9 inhibition.** Guillermo Flores, Grand Rapids, MI
- 3:30 p.m. 1633 Chemical proteomics identifies druggable proteins in ALK-driven neuroblastomas.** Smita Matkar, Philadelphia, PA
- 3:35 p.m. 1634 BRCA-like phenotype constitutes hallmark of osteosarcoma.** Michal Kovac, Basel, Switzerland

SCIENCE POLICY SESSION • 3:00 p.m.–4:30 p.m.

Room S401bcd, McCormick Place South (Level 4)

How the AACR Is Working for You in Washington: A Town Hall Meeting on Cancer Research Funding and Science Policy Initiatives

Chair: George D. Demetri, Boston, MA

**Program as of March 20, 2018

Panelists: Kristin Anderson, Seattle, WA
Beth Anne Baber, San Diego, CA
M. K. Holohan Quattrocchi, Bethesda, MD
Mary Lee Watts, Washington, DC

CLINICAL TRIALS MINISYMPOSIUM 1 • 3:00 p.m.-5:00 p.m.

Room N427, McCormick Place North (Level 4)

New Treatment Approaches for Breast and Ovarian Cancer

Chair: Leisha A. Emens, Baltimore, MD

3:00 p.m. Introduction

3:05 p.m. **CT035** A phase Ib study of miransertib (ARQ 092) in combination with anastrozole in patients with PIK3CA or AKT1-mutant ER+ endometrial or ovarian cancer. David Hyman, New York, NY

3:20 p.m. **CT036** Targeting MUC16 with the THIOMABTM-drug conjugate DMUC4064A in patients with platinum-resistant ovarian cancer: A phase I expansion study. Kathleen Moore, Oklahoma City, OK

3:35 p.m. **CT037** Phase I safety, pharmacokinetic and pharmacodynamic study of CYC065, a cyclin-dependent kinase inhibitor, in patients with advanced cancers (NCT02552953). Geoffrey I. Shapiro, Boston, MA

3:50 p.m. **CT038** OlympiAD final overall survival: Olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Mark E. Robson, New York, NY

4:05 p.m. **CT039** Cyclin E1 (CCNE1) expression associates with benefit from palbociclib in metastatic breast cancer (MBC) in the PALOMA3 trial. Nicholas C. Turner, London, United Kingdom

4:20 p.m. **CT040** MONARCH 3: Abemaciclib as initial therapy for patients with HR+, HER2- advanced breast cancer—Results from the preplanned final PFS analysis. Matthew P. Goetz, Rochester, MN

4:35 p.m. **CT041** Primary results from FAIRLANE (NCT02301988), a double-blind placebo (PBO)-led randomized phase II trial of neoadjuvant ipatasertib (IPAT) + paclitaxel (PAC) for early triple-negative breast cancer (eTNBC). Mafalda Oliveira, Barcelona, Spain

4:50 p.m. Discussion

SUNDAY, APRIL 15**

CLINICAL TRIALS PLENARY SESSION 2 • 3:00 p.m.-5:00 p.m.

N Hall C, McCormick Place North (Level 1)

Advances in Precision Cancer Medicine

Chair: Razelle Kurzrock, San Diego, CA

- 3:00 p.m.** **CT043** Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in a phase I study of advanced, RET-altered solid tumors. Vivek Subbiah, Houston, TX
- 3:20 p.m.** **Discussant to be announced**
- 3:30 p.m.** **CT044** Efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC) and ALK kinase domain mutations. Alice T. Shaw, Boston, MA
- 3:50 p.m.** **Discussant to be announced**
- 4:00 p.m.** **CT045** Prospective precision medicine trial of crizotinib (C) in patients (pts) with advanced, inoperable inflammatory myofibroblastic tumor (IMFT) with and without ALK alterations: EORTC phase II study 90101 "CREATE". Patrick Schöffski, Leuven, Belgium
- 4:20 p.m.** **Discussant.** Benjamin J. Solomon, Melbourne, VIC, Australia
- 4:30 p.m.** **CT046** A phase I basket study of the PI3K inhibitor taselisib (GDC-0032) in PIK3CA-mutated locally advanced or metastatic solid tumors. Komal Jhaveri, New York, NY
- 4:50 p.m.** **Discussant.** Timothy A. Yap, Houston, TX

**DRUG DEVELOPMENT TRACK—
SPECIAL SESSION • 3:00 p.m.-5:00 p.m.**

Room S103, McCormick Place South (Level 1)

New Drugs on the Horizon 2

Cochairs: Melissa M. Vasbinder, Lexington, MA; Alan G. Olivero, South San Francisco, CA

- 3:00 p.m.** **FAP-4-1BBL: A next-generation, targeted costimulatory agonist for cancer immunotherapy.** Pablo Umana, Schlieren, Switzerland [DDT02-01*]

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings* (the abstract number is listed in brackets above).

**Program as of March 20, 2018

- 3:24 p.m.** **Targeting DLL3 with BiTE® antibody constructs and cell-based therapies for the treatment of SCLC.** Michael Giffin, Thousand Oaks, CA
(not eligible for CME credit)
- 3:48 p.m.** **Induction of detrimental aneuploidy in breast cancer cells and xenografts treated by the MPS1 inhibitor BOS172722.** Spyridon Linardopoulos, London, United Kingdom
- 4:12 p.m.** **BAY 2402234: A novel, selective dihydroorotate dehydrogenase (DHODH) inhibitor for the treatment of myeloid malignancies.** Andreas Janzer, Berlin, Germany [DDT02-04*]
- 4:36 p.m.** **eFT226: A selective and highly potent inhibitor of eukaryotic initiation factor 4A (eIF4A), a novel approach for the treatment of cancer.** Siegfried H. Reich, La Jolla, CA [DDT02-05*]

MINISYMPOSIA • 3:00 p.m.–5:00 p.m.

Room N228, McCormick Place North (Level 2)

Bioinformatics and Systems Biology

Computational Methods and Resources for Cancer Research

Cochairs: Steven G. Rozen, Singapore, Singapore; Roel Verhaak, Farmington, CT

- 3:00 p.m.** **Introduction**
- 3:05 p.m.** **922 Access, visualize, and analyze 5,000 whole-genomes from pediatric cancer patients on St. Jude Cloud.** Scott Newman, Memphis, TN
- 3:20 p.m.** **923 The cBioPortal for Cancer Genomics: An intuitive open-source platform for exploration, analysis, and visualization of cancer genomics data.** Jianjiong Gao, New York City, NY
- 3:35 p.m.** **924 A mathematical-experimental approach for predicting host responses in a preclinical model for trastuzumab-treated HER2+ breast cancer.** Angela M. Jarrett, Austin, TX
- 3:50 p.m.** **925 In silico models accurately predict in vivo response for IL-6 blockade in head and neck cancer.** Fereshteh Nazari, Ann Arbor, MI
- 4:05 p.m.** **926 Multi-Center Mutation Calling in Multiple Cancers: The MC3 Project.** Kyle Ellrott, Portland, OR
- 4:20 p.m.** **927 TCPA: An open-access resource for cancer functional proteomics data.** Jun Li, Houston, TX
- 4:35 p.m.** **928 Regulatory heterogeneity in glioblastoma multiforme informs novel drug target discovery.** Yunpeng Liu, Cambridge, MA

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings* (the abstract number is listed in brackets above).

Room S101, McCormick Place South (Level 1)

Cancer Chemistry

Molecules Addressing Challenges in Drug Discovery

Cochairs: Vinod F. Patel, Acton, MA; Jim Bischoff, Basel, Switzerland

- 3:00 p.m. Introduction**
- 3:05 p.m. 929 Discovery of novel covalent KRAS^{G12C} inhibitors that display high potency and selectivity in vitro and in vivo.** Liansheng Li, San Diego, CA (not eligible for CME credit)
- 3:20 p.m. 930 Targeted delivery of cytotoxic NAMPT inhibitors using antibody-drug conjugates.** Christopher S. Neumann, Bothell, WA
- 3:35 p.m. 931 Discovery of ABBV-744, a first-in-class highly BDII-selective BET bromodomain inhibitor.** George S. Sheppard, North Chicago, IL (not eligible for CME credit)
- 3:50 p.m. 932 Structure-based design of selective inhibitors for the β -catenin/T-cell factor protein-protein interaction.** Haitao (Mark) Ji, Tampa, FL
- 4:05 p.m. 933 Discovery of a potent dual ALK and EGFR T790M inhibitor.** Seock Yong Kang, Daegu, Republic of Korea
- 4:20 p.m. 934 Discovery of IACS-6274, a potent and selective GLS1 inhibitor advancing to the clinic with excellent pharmacokinetic properties and high oral exposures in preclinical species.** Michael Soth, Houston, TX
- 4:35 p.m. 935 Generation and preclinical characterization of CD123-CPI antibody-drug conjugate (ADC).** Yoon-Chi Han, Pearl River, NY

Room S105, McCormick Place South (Level 1)

Clinical Research

Liquid Biopsy 1

Cochairs: Peter Kuhn, Los Angeles, CA; Caroline Dive, Manchester, United Kingdom

- 3:00 p.m. Introduction**
- 3:05 p.m. 936 Analysis of cell-free DNA from 32,991 advanced cancers reveals novel co-occurring activating *RET* alterations and oncogenic signaling pathway aberrations.** Karen L. Reckamp, Duarte, CA
- 3:20 p.m. 937 Longitudinal circulating-tumor DNA profiling of *EGFR*-mutated non-small cell lung cancer patients treated with *EGFR*-tyrosine kinase inhibitors.** Sandra Ortiz-Cuaran, Lyon, France
- 3:35 p.m. 938 Detection of actionable mutations in plasma cfDNA samples from patients with non-small cell lung carcinoma using a novel amplicon-based Firefly NGS assay.** Grace Q. Zhao, Menlo Park, CA

**Program as of March 20, 2018

- 3:50 p.m.** **939 Analytical validation of InVisionFirst™, a liquid biopsy assay for high-sensitivity broad molecular profiling of circulating tumor DNA using plasma samples of cancer patients.** Samuel Woodhouse, Cambridge, United Kingdom
- 4:05 p.m.** **940 Analytical and clinical validation of the Idylla™ ctKRAS and ctNRAS-BRAF liquid biopsy tests identifies mCRC patient groups with high and low ctDNA shedding.** Bart Jacobs, Mechelen, Belgium
(not eligible for CME credit)
- 4:20 p.m.** **941 Method for sensitive detection of tumor fingerprints in plasma.** Fangyan Yu, Boston, MA
- 4:35 p.m.** **942 Sensitive detection of microsatellite instability (MSI) in tumors and liquid biopsies using nuclease-based enrichment.** Mike G. Makrigiorgos, Boston, MA

Room S504, McCormick Place South (Level 5)

Endocrinology

Novel Roles of Steroid Hormone Receptors

Cochairs: Suzanne A.W. Fuqua, Houston, TX; Jennifer K. Richer, Aurora, CO

- 3:00 p.m.** **Introduction**
- 3:05 p.m.** **943 SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust antitumor efficacy and limited cross-resistance in ER+ breast cancer.** Monsif Bouaboula, Cambridge, MA
- 3:20 p.m.** **944 Glucocorticoid receptor (GR)-mediated activation of cyclic-adenosine monophosphate (cAMP) pathway gene expression following androgen receptor (AR) antagonism of prostate cancer.** Tiha M. Long, Chicago, IL
- 3:35 p.m.** **945 Novel role for SIRT1 in noncanonical activation of AR signaling.** Shih-Bo Huang, San Antonio, TX
- 3:50 p.m.** **946 Suppression of breast cancer metastasis and extension of host animal survival by a new adamantyl antiestrogen, K-07, in a preclinical breast cancer metastasis model driven by constitutively active mutant estrogen receptors.** Mary J. Laws, Urbana, IL
- 4:05 p.m.** **947 Influence of abiraterone therapy on antitumor immunity in genetically engineered mouse prostate cancer models.** Eri Banno, Osaka-Sayama, Japan
- 4:20 p.m.** **948 Preventing estrogen receptor alpha-positive breast cancer outgrowth with the use of hormone replacement therapy.** Anna G. Dembo, Chicago, IL

4:35 p.m. **949 Progesterone receptor/IRS-1 cooperation promotes stem cell outgrowth and endocrine resistance in estrogen receptor-positive luminal breast cancer.** Amy R. Dwyer, Minneapolis, MN

Room S102, McCormick Place South (Level 1)

Experimental and Molecular Therapeutics

Novel Therapeutic Agents and Combinations

Cochairs: Vincent L. Giranda, North Wales, PA; Saul H. Rosenberg, North Chicago, IL

3:00 p.m. **Introduction**

3:05 p.m. **950 New strategy to sensitize pancreatic and bladder cancer to gemcitabine.** Francesca Vena, Jupiter, FL

3:20 p.m. **951 Direct small-molecule BAX activation in acute myeloid leukemia.** Evripidis Gavathiotis, Bronx, NY

3:35 p.m. **952 MORAb-202, a folate receptor-alpha (FRA)-targeting antibody-eribulin drug conjugate (ADC), exhibits durable antitumor activity and payload-mediated bystander effects on the tumor microenvironment in triple-negative breast cancer.** Keiji Furuuchi, Exton, PA
(not eligible for CME credit)

3:50 p.m. **953 LRRC15 is a novel antigen in sarcoma and the therapeutic target of the antibody-drug conjugate (ADC) ABBV-085.** Eytan Ben-Ami, Boston, MA

4:05 p.m. **954 Predicting synergistic drug combinations and resistance mechanisms from genomic features and single-agent response profiles.** Matthew G. Rees, Cambridge, MA

4:20 p.m. **955 Combined inhibition of MEK and mTOR pathways is effective in NRAS Q61K mutant small cell lung cancer.** Atsuko Ogino, Boston, MA

4:35 p.m. **956 Systematic identification of the actionable kinase dependencies of chemotherapy-resistant triple-negative breast cancer.** Jean-Philippe F. Coppé, San Francisco, CA

Room S406 (Vista Ballroom), McCormick Place South (Level 4)

Immunology

Engineering Immunotherapies for Anticancer Activity

Cochairs: Antoni Ribas, Los Angeles, CA; Daniel S. Chen, South San Francisco, CA

3:00 p.m. **Introduction**

**Program as of March 20, 2018

- 3:05 p.m.** **957 Design of CD19-4-1BBL, a novel CD19-targeted 4-1BB ligand for combination therapy with CD20 T-cell bispecific antibodies and CD20 antibodies.** Wei Xu, Schlieren, Switzerland
(not eligible for CME credit)
- 3:20 p.m.** **958 Anti-GD2 chimeric antigen receptor T cells as a potent immunotherapy regimen in xenograft models of histone 3 K27M mutant diffuse midline glioma.** Christopher W. Mount, Stanford, CA
- 3:35 p.m.** **959 Extracellular matrix-binding immunotherapies show enhanced antitumor efficacy and reduced adverse events.** Jun Ishihara, Chicago, IL
- 3:50 p.m.** **960 Defined cell composition and precise control over JCAR017 dose enables identification of relationships between chimeric antigen receptor T cell product attributes, pharmacokinetics, and clinical endpoints in NHL.** Ryan P. Larson, Seattle, WA
(not eligible for CME credit)
- 4:05 p.m.** **961 Intralesional injection of anti-PD-L1 (pembrolizumab) results in increased T-cell infiltrate in high-risk DCIS.** Michael J. Campbell, San Francisco, CA
- 4:20 p.m.** **962 Testing T-cell co-potential as an antitumor therapeutic strategy in humanized mouse models.** Alfreda D. Nelson, Columbia, MO
- 4:35 p.m.** **963 Screening of neoantigen-specific T cells in head and neck cancer and establishment of T-cell receptor-engineered T cells with cytotoxic reactivity.** Lili Ren, Chicago, IL

Room N226, McCormick Place North (Level 2)

Molecular and Cellular Biology / Genetics

Cell Signaling Pathways

Cochairs: Dianne Cox, Bronx, NY; Lucio Miele, New Orleans, LA

- 3:00 p.m.** **Introduction**
- 3:05 p.m.** **964 Genome-wide CRISPR screen identifies potential therapeutic combination of EGFR and FGFR inhibitors in oral cancer.** Megan Ludwig, Ann Arbor, MI
- 3:20 p.m.** **965 Deleterious effects of MAPK pathway hyperactivation in BRAF-mutant melanoma.** Grace P. Leung, Cambridge, MA
- 3:35 p.m.** **966 Oncogenic signaling pathways differentially regulate clathrin-mediated endocytosis in cancer cells.** Guan-Yu Xiao, Dallas, TX
- 3:50 p.m.** **967 Targeting notch one notch above.** Deniz A. Ucar-Bilyeu, New Orleans, LA

- 4:05 p.m.** **968 Targeting FAK inhibits YAP-dependent tumor growth in uveal melanoma.** Xiaodong Feng, La Jolla, CA
- 4:20 p.m.** **969 Tunneling nanotubes, a novel mode of tumor cell-macrophage communication in tumor cell invasion.** Samer Hanna, Bronx, NY
- 4:35 p.m.** **970 Transforming NTRK2 and NTRK3 mutations as potential drivers of leukemia.** Sunil K. Joshi, Portland, OR

Room N227, McCormick Place North (Level 2)

Molecular and Cellular Biology / Genetics

Epigenetic Mechanisms of Tumor Progression

Cochairs: Carol A. Lange, Minneapolis, MN; Jonna M. Frasor, Chicago, IL

- 3:00 p.m.** **Introduction**
- 3:05 p.m.** **971 Three-dimensional gene regulatory landscapes in normal and cancer cells.** Brian J. Abraham, Cambridge, MA
- 3:20 p.m.** **972 Defining the molecular context of MYC and WDR5 at chromatin.** Alissa D. Guarnaccia, Nashville, TN
- 3:35 p.m.** **973 MEKK3 sustains EMT and stemness in pancreatic cancer by regulating YAP and TAZ transcriptional activity.** Geny Piro, Verona, Italy
- 3:50 p.m.** **974 Alternative polyadenylation of androgen receptor variants in castration-resistant prostate cancer.** Jamie L. Van Etten, Minneapolis, MN
- 4:05 p.m.** **975 Functional CRISPR screen towards identifying novel epigenetic cofactors of oncogenic AR-activity.** Abhijit Parolia, Ann Arbor, MI
- 4:20 p.m.** **976 FOXA1 promotes a luminal growth program in prostate cancer.** Elizabeth J. Adams, New York, NY
- 4:35 p.m.** **977 Glycosylation of estrogen receptor alpha by N-acetylgalactosaminyltransferase 6 in breast cancer.** Boya Deng, Chicago, IL

Room S501, McCormick Place South (Level 5)

Clinical Research

Radiation Science

Chair: Bruce F. Kimler, Kansas City, KS

- 3:00 p.m.** **Introduction**
- 3:05 p.m.** **978 In vivo shRNA screening identifies synthetic cytotoxicity in CREBBP/EP300 mutant head and neck cancer.** Heath D. Skinner, Houston, TX

**Program as of March 20, 2018

- 3:20 p.m.** **979 EGLN inhibition reduces gastrointestinal radiation toxicity and improves survival in a murine model of locally advanced pancreatic cancer.** Cullen M. Taniguchi, Houston, TX
- 3:35 p.m.** **980 Molecular basis of adipose-derived stem cell (ASCs) therapy for management of radiation-induced fibrosis (RIF).** Asim Ejaz, Pittsburgh, PA
- 3:50 p.m.** **981 Wee-1 kinase inhibitor AZD-1775 radiosensitizes esophageal cancer through targeting G2 checkpoint activation.** Linlin Yang, Columbus, OH
- 4:05 p.m.** **982 Pharmacologic DNA-PK inhibition induces ATM/p53 dependent premature senescence with immunomodulatory phenotype in irradiated cancer cells.** Lyubomir T. Vassilev, Billerica, MA
- 4:20 p.m.** **983 Metabolic radiosensitization: Overcoming the radioresistance of hypoxic tumors by targeting OXPHOS.** Martin Benej, Columbus, OH
- 4:35 p.m.** **984 Systematic annotation of genetic variants that determine sensitivity to radiation: A pan-cancer encyclopedia.** Brian D. Yard, Cleveland, OH

Room S106 - McCormick Place South (Level 1)

Tumor Biology

Building the Microenvironment through Crosstalk

Cochairs: Sheila A. Stewart, St. Louis, MO; Sandra S. McAllister, Boston, MA

- 3:00 p.m.** **Introduction**
- 3:05 p.m.** **992 Pancreatic tuft cells resolve injury and restrain tumorigenesis.** Kathleen E. DelGiorno, La Jolla, CA
- 3:20 p.m.** **993 Wnt-er is coming: WNT5A promotes a slow cycling phenotype via p53 in conditions of stress.** Marie R. Webster, Philadelphia, PA
- 3:35 p.m.** **994 Cancer cells induce a protumorigenic senescent phenotype in fibroblasts through MMP1 but not autophagy in large cell carcinoma of the lung.** Jordi Alcaraz, Barcelona, Spain
- 3:50 p.m.** **995 Tumor-stroma IL-1 β -IRAK4 feedforward circuitry drives tumor fibrosis, chemo-resistance and is associated with poor prognosis in pancreatic cancer.** Daoxiang Zhang, St. Louis, MO
- 4:05 p.m.** **996 Host-derived MCP-1 dictates prostate cancer skeletal metastasis in vivo.** Yi Lu, Shenzhen, China
- 4:20 p.m.** **997 The cholesterol metabolite 27-hydroxycholesterol promotes breast cancer progression by affecting immune responses.** Amy E. Baek, Urbana, IL
- 4:35 p.m.** **998 Radiation-induced immunosuppressive macrophages limit CD8 T-cell mediated tumor killing.** Keaton I. Jones, Oxford, United Kingdom

Room S405, McCormick Place South (Level 4)

Tumor Biology

Patient-Derived Models of Cancer: Present and Future

Cochairs: Elisa De Stanchina, New York, NY; Katerina A. Politi, New Haven, CT

- 3:00 p.m. Introduction**
- 3:05 p.m. 985 The EurOPDX EDIReX project: Towards a European research infrastructure on patient-derived cancer models.** Enzo Medico, Candiolo, Italy
- 3:20 p.m. 986 The National Cancer Institute's patient-derived models repository (PDMR).** Yvonne A. Evrard, Frederick, MD
- 3:35 p.m. 987 Organoid-based characterization of patient tumors and microenvironments at single-cell resolution.** Ameen A. Salahudeen, Stanford, CA
- 3:50 p.m. 988 Short-term culture of organotypic tumor spheroids derived from patient xenografts in a novel 3D microfluidic chip predicts in vivo response of targeted therapies.** Russell Jenkins, Boston, MA
- 4:05 p.m. 989 Organoid cultures from normal and cancer-prone human breast tissues preserve complex epithelial lineages and can form chimeric mammary glands in vivo.** Jennifer M. Rosenbluth, Boston, MA
- 4:20 p.m. 990 Single-cell profiling of small cell lung cancer circulating tumor cell-derived xenograft models reveals intratumoral heterogeneity among mediators of chemoresistance.** C. Allison Stewart, Houston, TX
- 4:35 p.m. 991 Development and characterization of patient-derived xenografts from central nervous system metastasis reveal minor clone expansion linked with aggressive tumor behavior.** Ben Yi Tew, Los Angeles, CA

NCI/NIH-SPONSORED SESSION • 3:15 p.m.–4:45 p.m.

Room W192, McCormick Place West (Level 1)

NIH-Supported Infrastructure and Resources to Support Metabolomics Research

(not eligible for CME credit)

Moderator: Krista Anne Zanetti, Rockville, MD

- 3:20 p.m.** Barbara A. Spalholz, Bethesda, MD
- 3:45 p.m.** Victoria L. Stevens, Atlanta, GA
- 4:10 p.m.** Krista Anne Zanetti, Rockville, MD
- 4:35 p.m.** Discussion

**Program as of March 20, 2018

AWARDS AND LECTURES • 3:30 p.m.-4:15 p.m.

Room W196, McCormick Place West (Level 1)

Distinguished Lecture

Revolutions and innovations from DNA and biotechnology to convergence.

Phillip A. Sharp, Cambridge, MA

MEET AND GREET • 3:30 p.m.-4:15 p.m.

AACRcentral Amphitheater, Exhibit Hall A, McCormick Place South (Level 3)

Meet the Mentor: Undergraduate Focus

(not eligible for CME credit)

Chair: Kathleen W. Scotto, New Brunswick, NJ

Mentor to be announced.

PROFESSIONAL ADVANCEMENT SESSION • 3:30 p.m.-5:00 p.m.

Great Lakes E-G, Marriott Marquis Chicago Hotel

Getting Hired! Organized by the Associate Member Council (AMC)

(not eligible for CME credit)

- 3:35 p.m.** **How to format your CV/resume to the position for which you apply.**
Speaker to be announced
- 3:55 p.m.** **How to ace a job interview.** Edith A. Perez, South San Francisco, CA
- 4:15 p.m.** **How to negotiate a job offer.** Anees Chagpar, New Haven, CT
- 4:35 p.m.** **Panel discussion and Q&A.**

SUNDAY, APRIL 15**

SUNDAY

AWARDS AND LECTURES • 4:00 p.m.–4:45 p.m.

Room S100 (Grand Ballroom), McCormick Place South (Level 1)

Fourteenth Annual AACR-Irving Weinstein Foundation Distinguished Lecture

Gene editing and diagnostics using CRISPR tools. Jennifer A. Doudna, Berkeley, CA

Dr. Doudna is recognized for her groundbreaking scientific contributions to the fields of cell biology, chemistry, and genetics, specifically with regards to work related to CRISPR-Cas9 systems, including the characterization of these systems in conferring bacterial immunity and the development of CRISPR-Cas9 as a mechanism for eukaryotic gene editing.

MEET AND GREET • 4:00 p.m.–5:00 p.m.

Booth 1431, Exhibit Hall A, McCormick Place South (Level 3)

Meet the Editor-in-Chief of *Cancer Research*: Chi Van Dang, MD, PhD
(not eligible for CME credit)

Chi Van Dang, New York, NY

POSTER DISCUSSION SESSION • 4:00 p.m.–5:00 p.m.

Room S402, McCormick Place South (Level 4)

Targeting the Cell Cycle: Mechanism and Therapy
(not eligible for CME credit)

Chair: Selina Chen-Kiang, New York, NY

The abstracts presented in this Poster Discussion Session will also be presented in the following Poster Session:

Targeting the Cell Cycle: Mechanism and Therapy

Monday, April 16, 2018, 8:00 a.m.–12:00 p.m.

Section 23, Hall A, McCormick Place South (Level 3)

4:00 p.m. Introduction

4:10 p.m. 1522 The CDK4/6 inhibitor G1T38 enhances response to targeted therapies in preclinical models of non-small cell lung cancer. Jessica A. Sorrentino, Research Triangle Park, NC

**Program as of March 20, 2018

- 4:15 p.m.** **1523 Repression of IRF4 and CYTIP unleashes antitumor interferon response in CDK4 inhibitor therapy in mantle cell lymphoma.** Maurizio Di Liberto, New York, NY
- 4:20 p.m.** **1524 A first-in-class CDK4 inhibitor shows excellent in vitro and in vivo efficacy against ovarian cancer.** Laychiluh B. Mekonnen, Adelaide, SA, Australia
- 4:25 p.m.** **1525 SY-1365, a selective CDK7 inhibitor, exhibits potent antitumor activity against ovarian cancer models in vitro and in vivo.** Panagiotis A. Konstantinopoulos, Boston, MA
- 4:30 p.m.** **1526 WEE1 inhibition suppresses esophageal adenocarcinoma tumor growth both in vitro and in vivo.** Timothy G. Whitsett, Phoenix, AZ
- 4:35 p.m.** **1527 Splicing factors determine breast cancer cell mitosis through control of sister chromatid cohesion.** Esmee Koedoot, Leiden, Netherlands

AWARDS AND LECTURES • 4:15 p.m.–4:30 p.m.

Room S404, McCormick Place South (Level 4)

Special MICR Presentation Honoring Dr. Jane Cooke Wright
(not eligible for CME credit)

Chair: John M. Carethers, Ann Arbor, MI

AWARDS AND LECTURES • 4:30 p.m.–5:15 p.m.

Room S404, McCormick Place South (Level 4)

Thirteenth Annual AACR-Minorities in Cancer Research
Jane Cooke Wright Memorial Lectureship

Towards understanding the impact of diversity in cancer genome science. John D. Carpten, Los Angeles, CA

Dr. Carpten is being honored for pioneering contributions to cancer health disparities and for his outstanding leadership in cancer genomic science. He is among a small group of cancer geneticists with expertise in both germline genetics and somatic tumor biology.

SUNDAY, APRIL 15**

NCI/NIH-SPONSORED SESSION • 4:45 p.m.–5:45 p.m.

Room W192, McCormick Place West (Level 1)

**NCI as Your Technology Development and Commercialization Partner
(not eligible for CME credit)**

Moderator: Michael L. Salgaller, Rockville, MD

Jarrold Borkat, Gaithersburg, MD

Joseph Conrad, Bethesda, MD

Jim Pannucci, Frederick, MD

SCIENCE POLICY SESSION • 5:00 p.m.–6:15 p.m.

Room W190, McCormick Place West (Level 1)

**The Cancer Survivorship Landscape: Potential Focus Areas for the Future
A Special Session in the Memory of Jimmie C. Holland, MD
(not eligible for CME credit)**

Moderator: Anna D. Barker, Scottsdale, AZ

Panelists: Julia H. Rowland, Bethesda, MD

Gregory J. Aune, San Antonio, TX

Shelley Fuld Nasso, Silver Spring, MD

Brenda Nevidjon, Pittsburgh, PA

Julie K. Silver, Charlestown, MA

Patty Spears, Raleigh, NC

Doug Ulman, Columbus, OH

AWARDS AND LECTURES • 5:30 p.m.–6:15 p.m.

Room S406, Vista Ballroom, McCormick Place South (Level 4)

Presidential Address

Human natural killer cells: From biology to CARs in the clinic. Michael A. Caligiuri, Duarte, CA

**Program as of March 20, 2018

TOWN MEETING • 5:30 p.m.–7:00 p.m.

Room S104, McCormick Place South (Level 1)

Chemistry in Cancer Research Working Group (CICR) Town Hall Meeting and Networking Reception

(not eligible for CME credit)

- 5:30 p.m.** **Opening remarks: CICR Chair.** Melissa M. Vasbinder, Lexington, MA
- 5:40 p.m.** **CICR Editor: Update on CICR Quarterly Newsletter.** Zoe Cournia, Athens, Greece
- 5:45 p.m.** **Remarks: CICR Chair-Elect.** Julian Blagg, Sutton, Surrey, United Kingdom
- 5:55 p.m.** **Discussion of member issues; closing remarks.** Julian Blagg, Sutton, Surrey, United Kingdom

TOWN MEETING • 6:00 p.m.–8:00 p.m.

Room S106, McCormick Place South (Level 1)

Tumor Microenvironment Working Group (TME) Town Hall Meeting and Networking Reception

(not eligible for CME credit)

- 6:00 p.m.** **TME Chair: Opening remarks.** Valerie M. Weaver, San Francisco, CA
- 6:15 p.m.** **TME Chair-Elect: Remarks.** Yibin Kang, Princeton, NJ
- 6:30 p.m.** **Tissue mechanics, EMT, and genomic instability.** Celeste M. Nelson, Princeton, NJ
- 6:50 p.m.** **Confronting the unique mechanobiology of pancreas cancer.** Sunil R. Hingorani, Seattle, WA
- 7:10 p.m.** **Lymphatic vessels: Sensors and regulators of antitumor immunity.** Amanda Waite Lund, Portland, OR
- 7:30 p.m.** **Closing remarks.** Yibin Kang, Princeton, NJ

SUNDAY, APRIL 15**

SPECIAL SESSION • 6:30 p.m.-8:00 p.m.

Grand Concourse Lobby, McCormick Place North (Level 3)

Networking Hubs

(not eligible for CME credit)

Topics: Liquid Biopsies and Genomics

The Microbiome

Obesity and Prevention

Technology and Convergence

SUNDAY

TOWN MEETING • 6:30 p.m.-8:30 p.m.

Room S404, McCormick Place South (Level 4)

Pediatric Cancer Working Group

Town Hall Meeting and Networking Reception

(not eligible for CME credit)

Chair: Crystal L. Mackall, Stanford, CA

Chair-Elect. Kimberly Stegmaier, Boston, MA

The R2 platform as ITCC-P4 solution for data analysis and data sharing. Jan Koster, Amsterdam, Netherlands

The Terry Fox PROFYLE project. Adam Shlien, Toronto, ON, Canada

The Pediatric Cancer Research Data Commons project. Samuel Volchenbom, Chicago, IL

NCI-COG Pediatric MATCH Program. D. William Parsons, Houston, TX

**Program as of March 20, 2018

MONDAY, APRIL 16**

MEET-THE-EXPERT SESSION • 7:00 a.m.–8:00 a.m.

Room S103, McCormick Place South (Level 1)

3D Histology with Advanced Microscopy: Purpose and Practice

Richard Torres, New Haven, CT

Room S106, McCormick Place South (Level 1)

Cryo-EM in Cancer Research

Sriram Subramaniam, Bethesda, MD

Room S101, McCormick Place South (Level 1)

Disparities in Access to Genomic Testing in Lung Cancer

David R. Spigel, Nashville, TN

Room S405, McCormick Place South (Level 4)

Dissecting the Role of p53 in Mediating Normal Tissue Injury from Radiation

David G. Kirsch, Durham, NC

Room S404, McCormick Place South (Level 4)

Improving Patient Outcomes Through the Engine of Basic Research

Richard M. Marais, Manchester, United Kingdom

Room N427, McCormick Place North (Level 4)

The MANO Method: A High-Throughput Evaluation System for Variants of Uncertain Significance in the Cancer Genome

Hiroyuki Mano, Tokyo, Japan

Room N228, McCormick Place North (Level 2)

Metastatic Niche: Diverse Functions and Therapeutic Opportunities

Yibin Kang, Princeton, NJ

Room S402, McCormick Place South (Level 4)

New Paradigms for the Treatment of Metastatic Cancer in Humans

Bruce R. Zetter, Boston, MA

**Program as of March 20, 2018

Room S406 (Vista Ballroom), McCormick Place South (Level 4)

Next-Generation Immunotherapies: Targeting Innate Lymphocytes and Tumor Microenvironment

Eric Vivier, Marseille, France

Room S504, McCormick Place South (Level 5)

Systemic Therapy for Locally Advanced and Metastatic Bladder Cancer: A Rapidly Evolving Landscape

Elizabeth R. Plimack, Philadelphia, PA

Room S102, McCormick Place South (Level 1)

Therapy-Related Myeloid Neoplasms: When Genetics and Environment Collide

Michelle M. Le Beau, Chicago, IL

Room W190, McCormick Place West (Level 1)

TRIM24: An Epigenetic Oncogene and Breast Cancer

Michelle C. Barton, Houston, TX

Room S100 (Grand Ballroom), McCormick Place South (Level 1)

Using CRISPR-Enabled Functional Genomics to Chart the DNA Damage Response

Daniel Durocher, Toronto, ON, Canada

Room S103, McCormick Place South (Level 1)

Using Implementation Science Strategies to Reduce Cancer Disparities in Urban and Rural Settings

Graham A. Colditz, St. Louis, MO

Room N227, McCormick Place North (Level 2)

Using Precision Medicine to Address Cancer Health Disparities

Chanita Hughes-Halbert, Charleston, SC

**Program as of March 20, 2018

AWARDS AND LECTURES • 7:15 a.m.-8:00 a.m.

Room S501, McCormick Place South (Level 5)

Distinguished Lecture

Cancer biomarkers: Moving from promise to reality. Anna D. Barker, Scottsdale, AZ

AWARDS AND LECTURES • 7:15 a.m.-8:00 a.m.

Room S105, McCormick Place South (Level 1)

Distinguished Lecture

New strategies for HER2 targeted therapy in breast cancer. C. Kent Osborne, Houston, TX

POSTER SESSION • 8:00 a.m.-12:00 p.m.

Exhibit Hall A, McCormick Place South (Level 3)

(not eligible for CME credit)

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner, the Annual Meeting App (available at www.AACR.org/AACR2018), and in the print Poster Sessions and Exhibits Guide. A limited number of copies of the print guide are available in the Exhibit Hall.

Tumor Biology

- | | |
|-----------|---|
| Section 1 | Adaptation and Checkpoints in Tumorigenesis |
| Section 2 | Advances in the Generation and Analysis of Patient-Derived Xenografts |
| Section 3 | Biomarkers of Metastasis |
| Section 4 | Mechanisms Underlying Metastasis 2 |
| Section 5 | Regulation of Stemness in Cancer |
| Section 6 | Translational Therapeutics in Cancer Models 1 |
| Section 7 | Tumor Heterogeneity 2 |

Science Education

Section 8 2018 Margaret Foti Undergraduate Prizes in Cancer Research

Epidemiology

Section 9 Descriptive Epidemiology of Cancer
 Section 10 Genetic Contributions to Cancer Epidemiology 2: Next-Generation Sequencing and Familial Cancers

Prevention Research

Section 11 Molecular Mechanisms and Targets for Cancer Prevention

Bioinformatics and Systems Biology

Section 12 Application of Bioinformatics to Cancer Biology 1
 Section 13 Integrative Cancer Biology 2

Molecular and Cellular Biology / Genetics

Section 14 Autophagy
 Section 15 DNA Repair and Damage Response
 Section 16 Epigenetic Therapy
 Section 17 Genotype/Phenotype Correlations
 Section 18 High-Throughput Sequencing 2
 Section 19 Metabolic Pathways
 Section 20 Mitosis and Telomeres
 Section 21 Navigating the Cancer Chromatin Landscape
 Section 22 Novel Biomarkers and Drivers of the Cancer Transcriptome
 Section 23 Targeting the Cell Cycle: Mechanism and Therapy

Clinical Research

Section 24 Adoptive Cell Therapy 1
 Section 25 Biomarker Discovery 2
 Section 26 Liquid Biopsy 2
 Section 27 Molecular Diagnostics 2: Laboratory Correlates for Targeted Agents and Preclinical and Clinical Trials
 Section 28 Pediatric Cancer
 Section 29 Special Populations / Biostatistics in Clinical Trials

**Program as of March 20, 2018

Cancer Chemistry

- Section 30 Target Based Drug Discovery
 Section 43 Late-Breaking Research: Cancer Chemistry

Immunology

- Section 31 Immune Checkpoints 1
 Section 32 Immune Response to Therapies 2
 Section 33 Modifiers of the Tumor Microenvironment 2
 Section 34 Therapeutic Antibodies, including Engineered Antibodies 1
 Section 45 Late-Breaking Research: Immunology 1

Endocrinology

- Section 35 Growth Factors and Nuclear Receptor Signaling

Experimental and Molecular Therapeutics

- Section 36 Acquired Resistance against Molecularly Targeted Therapies
 Section 37 Cell Cycle, Drug Resistance, and Combinations
 Section 38 Experimental Agents and Combinations for Hematologic Malignancies 2
 Section 39 Identification of Molecular Drug Targets
 Section 40 New Targets 1
 Section 41 Therapeutic Resistance: New Targets and New Inhibitors
 Section 44 Late-Breaking Research: Experimental and Molecular Therapeutics 2

Clinical Trials

- Section 42 Phase I Clinical Trials 2

PROFESSIONAL ADVANCEMENT SESSION • 8:15 a.m.-10:00 a.m.

Regency A-B, Hyatt Regency McCormick Place

Women in Cancer Research Career Mentoring Session

(not eligible for CME credit)

Chair: Lucile L. Adams-Campbell, Washington, DC

Keynote Address: Passion, Perseverance, and People: My guiding principles. Marcia R. Cruz-Correa, San Juan, PR

MONDAY, APRIL 16**

PLENARY SESSION • 8:15 a.m.–10:15 a.m.

N Hall B (Plenary Hall), McCormick Place North (Level 3)

Elucidating the Complexities of Cancer

Chair: John D. Carpten, Los Angeles, CA

- 8:15 a.m.** **Introduction.** John D. Carpten, Los Angeles, CA
- 8:20 a.m.** **Advancing cancer diagnostics with artificial intelligence.** Jason D. Hipp and Martin Stumpe, Mountain View, CA [PL02-01*]
- 8:45 a.m.** **Making the invisible visible in real time.** Samuel Achilefu, St. Louis, MO
- 9:10 a.m.** **Role of lymphatic vessels in shaping the tumor immune microenvironment.** Melody A. Swartz, Chicago, IL
- 9:35 a.m.** **Decoding patient genomes through the hierarchical pathway architecture of the cancer cell.** Trey Ideker, La Jolla, CA [PL02-04*]
- 10:00 a.m.** **Opportunities/challenges for the future.** John D. Carpten, Los Angeles, CA

FORUM • 9:30 a.m.–11:30 a.m.

Room S504, McCormick Place South (Level 5)

Minorities in Cancer Research Forum: The Sandwich Generation—Advice on How to Succeed as a Cancer Researcher while Maintaining Life-Work Blend

Cochairs: Sanya A. Springfield, Bethesda, MD; Gerardo Colón-Otero, Jacksonville, FL

Moderator: Sanya A. Springfield, Bethesda, MD

- 9:40 a.m.** **Career burnout in medicine and cancer research: What is the evidence?** Liselotte (Lotte) N. Dyrbye, Rochester, MN
- 10:00 a.m.** **Personal life case presentation.** Dineo Khabele, Kansas City, KS
- 10:20 a.m.** **Effective burnout prevention: Mayo Clinic School of Medicine experience with the THRIVE program.** Alexandra P. Wolanskyj-Spinner, Rochester, MN
- 10:40 a.m.** **Personal life case presentation.** Luis G. Carvajal-Carmona, Davis, CA

**Program as of March 20, 2018

MEET AND GREET • 10:00 a.m.–11:00 a.m.

Booth 1431, Exhibit Hall A, McCormick Place South (Level 3)

**Meet the Editor-in-Chief of *Cancer Epidemiology, Biomarkers & Prevention*:
Timothy R. Rebbeck, PhD**

(not eligible for CME credit)

Timothy R. Rebbeck, Boston, MA

SPECIAL SESSION • 10:30 a.m.–11:30 a.m.

Membership Hub, Grand Concourse Lobby

Member Appreciation Hour: Celebrating AACR Long-Term Members
(not eligible for CME credit)

PROFESSIONAL ADVANCEMENT SESSION • 10:30 a.m.–12:00 p.m.

Great Lakes E-G, Marriott Marquis Chicago Hotel

**Logistics of Starting a Laboratory, Organized by the
Associate Member Council (AMC)**

(not eligible for CME credit)

- 10:35 a.m.** **Finances and budgeting.** Jeffrey P. MacKeigan, Grand Rapids, MI
- 11:05 a.m.** **Recruitment and management of personnel.** Cory Abate-Shen,
New York, NY
- 11:25 a.m.** **Time management.** Aime T. Franco, Little Rock, AR
- 11:45 a.m.** **Panel discussion and Q&A**

MONDAY, APRIL 16**

MAJOR SYMPOSIA • 10:30 a.m.–12:15 p.m.

Room N227, McCormick Place North (Level 2)

CDK Inhibitors: From Bench to Bedside

Chair: Charles J. Sherr, Memphis, TN

10:30 a.m. Introduction

10:35 a.m. CDK4/6 inhibitors: A paradigm shift in cancer treatment. Charles J. Sherr, Memphis, TN

11:05 a.m. Novel mechanisms of acquired resistance to selective CDK4/6 inhibition. Geoffrey I. Shapiro, Boston, MA [SY19-02*]

11:35 a.m. Transcriptional addiction and CDK7 inhibition in cancer. Richard A. Young, Cambridge, MA

Room S406 (Vista Ballroom), McCormick Place South (Level 4)

Convergence of Immunity and Cancer Metabolism

Chair: Chi Van Dang, New York, NY

10:30 a.m. Introduction

10:35 a.m. Cancer and immune cell food fight. Craig B. Thompson, New York, NY

11:05 a.m. Metabolic checkpoints of antitumor T-cell responses. Susan M. Kaech, New Haven, CT

11:35 a.m. MYC, metabolism, and immunity. Chi Van Dang, New York, NY

Room N427, McCormick Place North (Level 4)

Novel Radiosensitizers

Chair: Julie K. Schwarz, St. Louis, MO

10:30 a.m. Introduction

10:35 a.m. Genomic biomarkers for radiation resistance and targeted radiosensitizers. Henning Willers, Boston, MA [SY24-01*]

11:05 a.m. Improving radiosensitivity in cervical cancer by targeting tumor metabolism. Julie K. Schwarz, St. Louis, MO [SY24-02*]

11:35 a.m. Translation of radiation sensitizers from the laboratory to clinical trials. Geoffrey Higgins, Oxford, United Kingdom

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings* (the abstract number is listed in brackets above).

**Program as of March 20, 2018

Room S103, McCormick Place South (Level 1)

Preclinical Studies of Pediatric Cancer: Beyond Mammalian Models

Chair: Anna Philpott, Cambridge, United Kingdom

10:30 a.m. Introduction

10:35 a.m. Management of MAP kinase and apoptosis signaling thresholds by microRNAs. W. Brent Derry, Toronto, ON, Canada [SY28-01*]

11:05 a.m. A phosphorylation switch regulating proliferation and differentiation in *Xenopus* development and neuroblastoma. Anna Philpott, Cambridge, United Kingdom [SY28-02*]

11:35 p.m. Visualizing cancer cell processes and therapy responses at single cell resolution using zebrafish. David M. Langenau, Charlestown, MA

Room W196, McCormick Place West (Level 1)

Use of Next-Generation Sequencing for Multidisciplinary Molecular Tumor Boards and Treatment Decisions

Chair: David B. Solit, New York, NY

10:30 a.m. Introduction

10:35 a.m. The application of integrative sequencing for precision oncology. Arul M. Chinnaiyan, Ann Arbor, MI

11:05 a.m. Reshaping cancer care delivery through multidisciplinary molecular tumor boards. W. Michael Korn, San Francisco, CA [SY08-02*]

11:35 a.m. Defining the actionable genome. David B. Solit, New York, NY

MONDAY

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings* (the abstract number is listed in brackets above).

MONDAY, APRIL 16**

NCI/NIH-SPONSORED SESSION • 10:30 a.m.–12:15 p.m.

Room W192, McCormick Place West (Level 1)

**NCI Initiatives Generating, Translating, and Sharing “Omics”
Data to Advance Precision Oncology**

(not eligible for CME credit)

Cochairs: Jaime G. Auvil, Bethesda, MD; Jean C. Zenklusen, Bethesda, MD

Jaime Guidry Auvil, Bethesda, MD

Jean C. Zenklusen, Bethesda, MD

Caitlyn Barrett, Bethesda, MD

Ina Felau, Bethesda, MD

Nicholas B. Griner, Rockville, MD

Subhashini Jagu, Bethesda, MD

Christopher Kinsinger, Bethesda, MD

Roy Tarnuzzer, Bethesda, MD

Zhining Wang, Bethesda, MD

MONDAY

**RECENT ADVANCES IN DIAGNOSTICS
AND THERAPEUTICS RESEARCH • 10:30 a.m.–12:15 p.m.**

Room W190, McCormick Place West (Level 1)

Extracellular Vesicles: Current State of the Art and Perspectives

Chair: Hector Peinado, Madrid, Spain

10:30 a.m. Biologic and functional heterogeneity of extracellular vesicles: What is an exosome? Clotilde Thery, Paris, France

11:00 a.m. Tracking tumor extracellular vesicles in vivo at high spatiotemporal resolution. Jacky G. Goetz, Strasbourg Cedex, United Kingdom

11:30 a.m. Extracellular vesicles in metastatic dissemination: Tiny messengers hit the road. Hector Peinado, Madrid, Spain

**Program as of March 20, 2018

N Hall C, McCormick Place North (Level 1)

In Vivo Monitoring of Immunotherapy Responses

Chair: Hiroyoshi Nishikawa, Kashiwa, Chiba, Japan

- 10:30 a.m.** **Targeting regulatory T cells for therapeutic gain: Means and mechanisms.** Sergio A. Quezada, London, United Kingdom
- 11:00 a.m.** **Immune-suppressive network in tumor microenvironment.** Hiroyoshi Nishikawa, Kashiwa, Chiba, Japan
- 11:30 a.m.** **ImmunoPET for in vivo monitoring of immunotherapy responses.** Anna M. Wu, Los Angeles, CA

Room S100 (Grand Ballroom), McCormick Place South (Level 1)

Microbiome Interplay with Therapy Response

Chair: Laurence Zitvogel, Villejuif, France

- 10:30 a.m.** **The impact of the intestinal microbiome in influencing the efficacy and toxicity of immune checkpoint inhibitors.** Laurence Zitvogel, Villejuif, France
- 11:00 a.m.** **The role of the gut and tumor microbiome in therapeutic response.** Jennifer A. Wargo, Houston, TX
- 11:30 a.m.** **The microbiome at the intersection of host genetics and environmental cues in cancer.** Giorgio Trinchieri, Bethesda, MD

Room S105, McCormick Place South (Level 1)

Targeting the Drug-Tolerant State

Chair: Jeffrey A. Engelman, Cambridge, MA

- 10:30 a.m.** **Identifying and targeting vulnerabilities in chemotherapy-resistant triple-negative breast cancer.** Helen M. Piwnica-Worms, Houston, TX
- 10:55 a.m.** **Towards rational combinatorial cancer treatment—a functional genomic approach.** Daniel S. Peeper, Amsterdam, Netherlands
- 11:20 a.m.** **Targeting the drug-tolerant state in lung cancer: Can we prevent acquired resistance?** Aaron N. Hata, Charlestown, MA
- 11:45 a.m.** **The tumor microenvironment in therapy response and resistance: Challenges and opportunities.** Anna C. Obenauf, New York, NY

MONDAY, APRIL 16**

*Recent Advances in Diagnostics
and Therapeutics Research (cont'd)*

Room 106, McCormick Place South (Level 1)

Translational Research to Address Cardiac Toxicity and Cancer Survivorship

Chair: Jennifer R. Klemm, Westwood, KS

- 10:30 a.m.** **Exploring cancer survivorship and the growing demands on health care delivery.** Jennifer R. Klemm, Westwood, KS
- 11:00 a.m.** **Cardio-oncology and models of translational research from the cardiologist perspective.** Daniel J. Lenihan, St. Louis, MO
- 11:30 a.m.** **Cardiology and cancer biomarkers: Overlapping risk factors and underlying pathophysiology.** Anne H. Blaes, Minneapolis, MN

RECENT ADVANCES IN ORGAN SITE RESEARCH • 10:30 a.m.–12:15 p.m.

Room S404, McCormick Place South (Level 4)

Brain Metastasis

Chair: Josh Neman, Los Angeles, CA

- 10:30 a.m.** **Genetic heterogeneity in brain metastases: Therapeutic implications.** Priscilla K. Brastianos, Brookline, MA
- 11:00 a.m.** **The role of the blood-tumor barrier in brain metastases.** Patricia S. Steeg, Bethesda, MD
- 11:30 a.m.** **Breast to brain metastasis: Wolf in sheep's clothing.** Josh Neman, Los Angeles, CA

RECENT ADVANCES IN PREVENTION AND INTERCEPTION RESEARCH • 10:30 a.m.–12:15 p.m.

Room N228, McCormick Place North (Level 2)

Translational Research in Liver Cancer Prevention

Chair: Kenneth Kenji Tanabe, Boston, MA

- 10:30 a.m.** **Rising rates and changing landscape and etiology of HCC: Opportunities and challenges for prevention.** Ann W. Hsing, Palo Alto, CA

**Program as of March 20, 2018

- 11:00 a.m.** **Drug discovery for liver cancer chemoprevention.** Thomas Baumert, Strasbourg, France
- 11:30 a.m.** **Opportunities for secondary prevention of HCC.** Kenneth Kenji Tanabe, Boston, MA

Room S102, McCormick Place South (Level 1)

Translational Research in Melanoma Prevention

Chair: David E. Fisher, Boston, MA

- 10:30 a.m.** **From control of pigmentation to pathways controlling sun-seeking behaviors.** David E. Fisher, Boston, MA
- 11:00 a.m.** **Genetically engineered models: A gateway to next-generation melanoma preventatives.** Christin E. Burd, Columbus, OH
- 11:30 a.m.** **Preventing DNA photoproducts: Nanoparticles before the beach and quantum chemistry after.** Douglas E. Brash, New Haven, CT

REGULATORY SCIENCE AND POLICY SESSION • 10:30 a.m.–12:15 p.m.

Room S401bcd, McCormick Place South (Level 4)

Scientific and Regulatory Challenges in Development of CAR-T Therapy for Solid Tumors

Chair: Ke Liu, Silver Spring, MD

Gary E. Archer, Durham, NC

Behnam Badie, Duarte, CA

Peter F. Bross, Silver Spring, MD

Stephen Gottschalk, Memphis, TN

Carl H. June, Philadelphia, PA

MONDAY, APRIL 16**

CLINICAL TRIALS PLENARY SESSION 3 • 10:30 a.m.-12:30 p.m.

N Hall B (Plenary Hall), McCormick Place North (Level 3)

Immunotherapy Combinations: The New Frontier in Lung Cancer

Chair: Alice T. Shaw, Boston, MA

- 10:30 a.m. CT075 KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC.** Leena Gandhi, New York, NY
- 10:50 a.m. Discussant.** Roy S. Herbst, New Haven, CT
- 11:00 a.m. CT076 IMpower150: PFS results for atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (chemo) across PD-L1 expression subgroups defined by the SP142 and SP263 IHC assays confirm all-comer benefit in 1L metastatic NSCLC (mNSCLC).** Marcin Kowanetz, South San Francisco, CA
- 11:20 a.m. Discussant.** Justin F. Gainor, Boston, MA
- 11:30 a.m. CT077 Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): Initial results from CheckMate 227.** Matthew D. Hellmann, New York, NY
- 11:50 a.m. Discussant.** Naiyer Rizvi, New York, NY
- 12:00 p.m. CT078 Tumor mutation burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): Identification of TMB cutoff from CheckMate 568.** Suresh S. Ramalingam, Atlanta, GA
- 12:20 p.m. Discussant to be announced**

MEET AND GREET • 11:00 a.m.-12:00 p.m.

Booth 1431, Exhibit Hall A, McCormick Place South (Level 3)

**Meet the Editors-in-Chief of *Cancer Discovery*:
Lewis C. Cantley, PhD and José Baselga, MD, PhD
(not eligible for CME credit)**

Lewis C. Cantley, New York, NY

José Baselga, New York, NY

**Program as of March 20, 2018

SPECIAL SESSION • 11:45 a.m.–12:30 p.m.

AACRcentral Amphitheater, Hall A, McCormick Place South (Level 3)

Tumor Microenvironment Working Group (TME) Networking Session with Early-Career Researchers

(not eligible for CME credit)

- 11:45 a.m.** **Moderator:** Daniela F. Quail, Montreal, QC, Canada
- 11:45 a.m.** **TME Career Perspective: Clinical/industry.** Alexandra Snyder, New York, NY
- 11:45 a.m.** **TME Career Perspective: Basic science/academia.** Mikala Egeblad, Cold Spring Harbor, NY
- 11:45 a.m.** **TME Career Perspective: Journal editing/publishing.** Alexia-Ileana Zaromytidou, London, United Kingdom

MEET-THE-EXPERT SESSION • 12:15 p.m.–1:00 p.m.

Room S405, McCormick Place South (Level 4)

Repair of Endogenous DNA Damage

Tomas Lindahl, London, United Kingdom

NCI/NIH-SPONSORED SESSION • 12:15 p.m.–1:45 p.m.

Room W192, McCormick Place West (Level 1)

The NCI Cancer Research Data Commons

(not eligible for CME credit)

Chair: Anthony Kerlavage, Rockville, MD

Allen Dearry, Durham, NC

Tanja M. Davidsen, Bethesda, MD

Izumi Hinkson, Rockville, MD

Stephen Jett, Rockville, MD

Ian M. Fore, Rockville, MD

Juli Klemm, Rockville, MD

MONDAY, APRIL 16**

SPECIAL SESSION • 12:30 p.m.–1:30 p.m.

Room N226, McCormick Place North (Level 2)

Annual Business Meeting of Members

(not eligible for CME credit)

Participants in speaking order:

AACR Chief Executive Officer: Margaret Foti, Philadelphia, PA

AACR President: Michael A. Caligiuri, Duarte, CA

AACR President-Elect: Elizabeth M. Jaffee, Baltimore, MD

AACR Past President: Nancy E. Davidson, Seattle, WA

AACR Treasurer: William N. Hait, Raritan, NJ

SPECIAL SESSION • 12:30 p.m.–2:30 p.m.

Room S103, McCormick Place South (Level 1)

**Stand Up To Cancer Open Scientific Session:
Bridging the Gap between the Bench and Bedside**

(not eligible for CME credit)

SU2C-Ovarian Cancer Research Fund Alliance–National Ovarian Cancer Coalition Ovarian Cancer Dream Team: Predicting PARP inhibitor resistance. Elizabeth M. Swisher, Seattle, WA

**SU2C-Dutch Cancer Society Colorectal Cancer Early Detection Dream Team:
Novel detection methodologies.** Victor E. Velculescu, Baltimore, MD

SU2C Innovative Research Grant Class of 2016: Dynamic measurement of the evolving cancer genome to guide personalized therapeutic optimization. Daniel A. Landau, New York, NY

SU2C Colorectal Cancer Dream Team: Targeted genomic, metabolic, and immunologic vulnerabilities of colorectal cancer. Luis A. Diaz, Jr., New York, NY

SU2C-Lustgarten Foundation Pancreatic Cancer Dream Team: CXCR4 inhibition promotes immune reactions in CRC and PDAC tumors. Douglas T. Fearon, Cold Spring Harbor, NY

MONDAY

**Program as of March 20, 2018

MAJOR SYMPOSIA • 1:00 p.m.–2:45 p.m.

N Hall C, McCormick Place North (Level 1)

AACR-Bayard D. Clarkson Symposium: Stem Cell Dynamics in Cancer

Chair: Elaine Fuchs, New York, NY

- 1:00 p.m. Introduction**
- 1:05 p.m. Stem cells in squamous cell carcinomas: Their biology, heterogeneity, and resistance to therapy.** Elaine Fuchs, New York, NY [SY39-01*]
- 1:35 p.m. Imaging stem cell dynamics in living mice.** Jacco Van Rheenen, Utrecht, Netherlands
- 2:05 p.m. Stem cell competition is central to leukemogenesis.** Irving L. Weissman, Stanford, CA [SY39-03*]

Room S105, McCormick Place South (Level 1)

Digital Pathology: Advances in Cancer Diagnostics

Chair: Anil Parwani, Columbus, OH

- 1:00 p.m. Introduction**
- 1:05 p.m. Advancing cancer diagnostics: Applications of digital pathology and artificial intelligence.** Anil Parwani, Columbus, OH
- 1:35 p.m. Telepathology: The value of internal and international teleconsultation for cancer diagnostics.** Liron Pantanowitz, Pittsburgh, PA
- 2:05 p.m. Pixels to diagnosis: How to develop and validate clinically meaningful image analysis algorithms.** Metin Gurcan, Winston-Salem, NC

Room N427, McCormick Place North (Level 4)

Exploiting Senescence for Cancer Therapy

Chair: René Bernards, Amsterdam, Netherlands

- 1:00 p.m. Introduction**
- 1:05 p.m. A one-two punch approach to the treatment of cancer.** René Bernards, Amsterdam, Netherlands
- 1:35 p.m. A versatile senolytic vehicle and its application to cancer.** Manuel Serrano, Madrid, Spain
- 2:05 p.m. Dual targeting of senescence and tumor immunity for cancer therapy.** Andrea Alimonti, Bellinzona, Switzerland [SY26-03*]

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings* (the abstract number is listed in brackets above).

Room S406 (Vista Ballroom), McCormick Place South (Level 4)

Genomic Approaches in Cancer Immunology

Chair: Ash A. Alizadeh, Stanford, CA

- 1:00 p.m. Introduction**
- 1:05 p.m. Epigenetic programs defining tumor-specific T-cell dysfunction and therapeutic reprogrammability.** Andrea Schietinger, New York, NY
- 1:35 p.m. Targets, drivers and resistors of the human antitumor immune response.** Nir Hacohen, Charlestown, MA
- 2:05 p.m. Title to be announced.** Ash A. Alizadeh, Stanford, CA

Room S102, McCormick Place South (Level 1)

Histone and Chromatin Modifier Mutations in Cancer Pathogenesis and Therapeutic Response

Chair: Suzanne J. Baker, Memphis, TN

- 1:00 p.m. Introduction**
- 1:05 p.m. Driver mutations in chromatin modifiers in medulloblastoma and their potential therapeutic implications.** Stefan M. Pfister, Heidelberg, Germany
- 1:35 p.m. Polycomb dysregulation by oncohistones.** Peter W. Lewis, Madison, WI
- 2:05 p.m. Transforming chromatin: Oncogenic histone H3 in diffuse intrinsic pontine gliomas.** Suzanne J. Baker, Memphis, TN

Room W196, McCormick Place West (Level 1)

Resistance to Immunotherapy: Intrinsic and Extrinsic Mechanisms

Chair: Thomas F. Gajewski, Chicago, IL

- 1:00 p.m. Introduction**
- 1:05 p.m. Understanding tumor escape on a whole-genome level.** Nicholas P. Restifo, Bethesda, MD
- 1:35 p.m. Intrinsic tumor genomic and metabolic factors leading to immunoresistance.** Patrick Hwu, Houston, TX
- 2:05 p.m. Integrating tumor and host mechanisms of immunotherapy resistance.** Thomas F. Gajewski, Chicago, IL

**Program as of March 20, 2018

RECENT ADVANCES IN CANCER HEALTH DISPARITIES RESEARCH • 1:00 p.m.–2:45 p.m.

Room S402, McCormick Place South (Level 4)

Prostate Cancer Disparities: Focus on African American Men

Chair: Judd W. Moul, Durham, NC

- 1:00 p.m.** **Prostate cancer in African American men: Disparities in screening.**
Judd W. Moul, Durham, NC
- 1:30 p.m.** **Distinct biologic features of prostate cancer in African American men.**
Shiv K. Srivastava, Rockville, MD
- 2:00 p.m.** **Prostate cancer in African American men: Disparities in advanced disease—Management and clinical trial outcomes and opportunities.**
Celestia S. Higano, Seattle, WA

RECENT ADVANCES IN DIAGNOSTICS AND THERAPEUTICS RESEARCH • 1:00 p.m.–2:45 p.m.

Room S100 (Grand Ballroom), McCormick Place South (Level 1)

Metabolic Vulnerabilities and Cancer Therapy

Chair: Susan E. Critchlow, Macclesfield, United Kingdom

- 1:00 p.m.** **Targeting methionine adenosyltransferase 2 alpha (MAT2A) in *MTAP*-deleted cancer.** Katya Marjon, Cambridge, MA
(not eligible for CME credit)
- 1:25 p.m.** **NFS1 undergoes positive selection in lung tumors and protects cells from ferroptosis.** Richard L. Possemato, New York, NY [NG02*]
- 1:45 p.m.** **Targeting metabolism in pancreatic cancer.** Angela T. Alistar, Morristown, NJ
- 2:10 p.m.** **New developments in targeting lactate transporters.** Susan E. Critchlow, Macclesfield, United Kingdom

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings* (the abstract number is listed in brackets above).

Room N227, McCormick Place North (Level 2)

Spatial Interactions in Cancer

Chair: Sylvia K. Plevritis, Stanford, CA

- 1:00 p.m.** **Omic and multiscale image analyses to reveal mechanisms of resistance in breast cancer.** Joe W. Gray, Portland, OR
- 1:30 p.m.** **The role of local and systemic microenvironments in breast tumor progression.** Kornelia Polyak, Boston, MA
- 2:00 p.m.** **Characterizing the spatial microenvironment of primary tumors and paired metastatic lymph nodes.** Sylvia K. Plevritis, Stanford, CA

**RECENT ADVANCES IN
ORGAN SITE RESEARCH • 1:00 p.m.–2:45 p.m.**

Room S504, McCormick Place South (Level 5)

Cutting-Edge Head and Neck Cancer Therapy

Chair: Cherie-Ann O. Nathan, Shreveport, LA

- 1:00 p.m.** **Molecular risk stratification in HPV-positive oropharyngeal squamous cell carcinoma.** Jose P. Zavallos, St. Louis, MO
- 1:30 p.m.** **Multimodality precision immunotherapy.** Umamaheswar Duvvuri, Pittsburgh, PA; J. Silvio Gutkind, La Jolla, CA
- 2:00 p.m.** **Therapeutic targeting of tumor-stroma crosstalk.** Sufi M. Thomas, Kansas City, KS

Room W190, McCormick Place West (Level 1)

The Epigenetic Basis of Pediatric and Young Adult Brain Tumors

Chair: Michael D. Taylor, Toronto, ON, Canada

- 1:00 p.m.** **Mechanisms in metastasis for medulloblastoma.** Michael D. Taylor, Toronto, ON, Canada
- 1:30 p.m.** **Novel functions of PTEN in the nucleus: What's a nice lipid phosphatase doing in a place like this?** Frank B. Furnari, La Jolla, CA
- 2:00 p.m.** **Rhabdoid tumor biology: Answers and more questions.** Annie A. Huang, Toronto, ON, Canada

**Program as of March 20, 2018

Room N228, McCormick Place North (Level 2)

Merkel Cell Carcinoma

Chair: James A. DeCaprio, Boston, MA

- 1:00 p.m.** **The genomics and epigenomics of merkel cell carcinoma.** Paul W. Harms, Ann Arbor, MI
- 1:30 p.m.** **UV-induced mutations and polyomavirus target similar pathways in Merkel cell carcinoma.** James A. DeCaprio, Boston, MA
- 2:00 p.m.** **Immune therapy for Merkel cell carcinoma: Progress and challenges.** Paul Nghiem, Seattle, WA

RECENT ADVANCES IN PREVENTION AND INTERCEPTION RESEARCH • 1:00 p.m.–2:45 p.m.

Room S404, McCormick Place South (Level 4)

RANK Ligand and Molecularly Guided Breast Cancer Prevention

Chair: Geoffrey J. Lindeman, Parkville, Australia

- 1:00 p.m.** **Tissue mechanics modulates risk to malignancy.** Valerie M. Weaver, San Francisco, CA
- 1:30 p.m.** **Identifying adult stem/progenitor cell vulnerabilities for chemoprevention.** Rama Khokha, Toronto, ON, Canada
- 2:00 p.m.** **RANK ligand and breast cancer prevention in *BRCA1* mutation carriers.** Geoffrey J. Lindeman, Melbourne, VIC, Australia

SCIENCE POLICY SESSION • 1:00 p.m.–2:45 p.m.

Room S401bcd, McCormick Place South (Level 4)

A Town Hall Discussion of AACR's Priorities in Tobacco Policy

Chair: Roy S. Herbst, New Haven, CT

Panelists: Brian A. King, Atlanta, GA
Cathy Backinger, Silver Spring, MD
Michele Bloch, Rockville, MD
Dorothy K. Hatsukami, Minneapolis, MN
Christopher S. Lathan, Boston, MA

MONDAY, APRIL 16**

POSTER SESSION • 1:00 p.m.-5:00 p.m.

Exhibit Hall A, McCormick Place South (Level 3)

(not eligible for CME credit)

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner, the Annual Meeting App (available at AACR.org/AACR2018), and in the print Poster Sessions and Exhibits Guide. A limited number of copies of the print guide are available in the Exhibit Hall.

Tumor Biology

- Section 1 Epithelial Cancer Stem Cell Biology
- Section 2 Epithelial-to-Mesenchymal Transition and EMT and TGF- β in Metastasis
- Section 3 Novel Mechanisms Regulating Angiogenesis
- Section 4 Pediatrics 1: Genomics, Epigenetics, and Biomarkers
- Section 5 Surveying the Tumorigenic Microenvironment
- Section 6 The Metastatic Microenvironment
- Section 7 Translational Therapeutics in Cancer Models 2
- Section 8 Tumor Heterogeneity 3

Advocates Poster Session (Scientist \leftrightarrow Survivor Program)

- Section 9 Advocates Poster Session 1 (1:00 p.m.-3:00 p.m.)

Epidemiology

- Section 10 Screening, Early Detection, and Risk Prediction
- Section 44 Late-Breaking Research: Epidemiology and Prevention

Prevention Research

- Section 11 Biomarkers, Intervention, and Early Detection for Cancer Prevention

Bioinformatics and Systems Biology

- Section 12 Application of Bioinformatics to Cancer Biology 2
- Section 13 New Software for Data Analysis

Molecular and Cellular Biology / Genetics

- Section 14 CDK and CDK Inhibitors: Mechanism and Therapy
- Section 15 Ferroptosis, Metabolism, and Cancer Cell Death
- Section 16 Gene Discovery
- Section 17 Kinases and Phosphatases

**Program as of March 20, 2018

Section 18	Metabolic Regulation
Section 19	Metabolism and Cellular Functions 2
Section 20	Noncoding RNAs and Cancer
Section 21	Nuclear Oncoproteins and Tumor Suppressor Genes
Section 22	Receptors and Growth Factors
Section 23	Transcription Factor Crosstalk and Aberrant Transcriptional Control
Section 45	Late-Breaking Research: Molecular and Cellular Biology / Genetics 1

Clinical Research

Section 24	Adoptive Cell Therapy 2
Section 25	Biomarker Discovery 3
Section 26	Biomarkers of Therapeutic Response in Clinical Trials
Section 27	Novel Immunotherapies and Laboratory Models in Pediatric Cancer
Section 28	Prognostic Biomarkers
Section 43	Late-Breaking Research: Clinical Research 1

Cancer Chemistry

Section 30	Antitumor Agents
Section 31	Cancer Biology Insights Emerging from Proteomic Investigations

Immunology

Section 32	Immune Checkpoints 2
Section 33	Immune Mechanisms Invoked by Therapies 1
Section 34	Therapeutic Antibodies, Including Engineered Antibodies 2

Experimental and Molecular Therapeutics

Section 36	Design, Structure/Activity, and Modeling
Section 37	Modulation of DNA Damage and Repair
Section 38	Monitoring the Evolution of Therapeutic Resistance
Section 39	New Agents and New Targets
Section 40	New Targets 2
Section 41	Novel Experimental Combinations

Clinical Trials

Section 42	Phase II-III Clinical Trials
------------	------------------------------

MONDAY, APRIL 16**

CAREER DISCUSSION • 1:30 p.m.–2:15 p.m.

AACRcentral Amphitheater, Hall A, McCormick Place South (Level 3)

Careers in Industry, Organized by the Associate Member Council (AMC)

(not eligible for CME credit)

NCI/NIH-SPONSORED SESSION • 1:45 p.m.–2:45 p.m.

Room W192, McCormick Place West (Level 1)

NCI Cancer Diagnosis Program Initiatives and Resources

(not eligible for CME credit)

Aniruddha Ganguly, Bethesda, MD

Lyndsay N. Harris, Rockville, MD

Mickey Williams, Frederick, MD

MEET THE RESEARCH ICON • 2:30 p.m.–3:00 p.m.

AACRcentral Amphitheater, Hall A, McCormick Place South (Level 3)

Meet the Research Icon, Organized by the Associate Member Council (AMC)

(not eligible for CME credit)

SPECIAL SESSION • 2:45 p.m.- 4:45 p.m.

Room S103, McCormick Place South (Level 1)

Stand Up To Cancer Open Scientific Session: Harnessing the Whole Immunotherapy Arsenal

(not eligible for CME credit)

SU2C-St. Baldrick's Foundation Pediatric Cancer Dream Team: Novel CAR T. Crystal L. Mackall, Stanford, CA

MONDAY

**Program as of March 20, 2018

SU2C-American Cancer Society Lung Cancer Dream Team: Novel biomarker candidates for response. Roy S. Herbst, New Haven, CT

SU2C Catalyst® Pediatrics Team Supported by Bristol-Myers Squibb: Response of hypermutated cancers to immunotherapy. Uri Y. Tabori, Toronto, ON, Canada

SU2C Innovative Research Grant Class of 2017: Gut microbiome and response to immunotherapy. Jennifer A. Wargo, Houston, TX

Van Andel Research Institute-SU2C Cancer Epigenetics Dream Team and SU2C Catalyst® Lung Epigenetics Team Supported by Merck: Using epigenetic therapies to increase response to immunotherapy. Stephen B. Baylin, Baltimore, MD

AWARDS AND LECTURES • 3:00 p.m.-4:00 p.m.

Room W190, McCormick Place West (Level 1)

NCI Director's Address and Fireside Chat with AACR Leaders

Moderators: Michael A. Caligiuri, Duarte, CA; Elizabeth M. Jaffee, Baltimore, MD
Norman E. Sharpless, Bethesda, MD

MEET AND GREET • 3:00 p.m.-4:00 p.m.

Booth 1431, Exhibit Hall A, McCormick Place South (Level 3)

Meet the Editor-in-Chief of *Molecular Cancer Research*:

Karen E. Knudsen, PhD

(not eligible for CME credit)

Karen E. Knudsen, Philadelphia, PA

MONDAY, APRIL 16**

POSTER DISCUSSION SESSION • 3:00 p.m.–4:00 p.m.

Room S402, McCormick Place South (Level 4)

Systems and Computational Biology

(not eligible for CME credit)

The abstracts presented in this Poster Discussion Session will also be presented in the following Poster Session:

Systems and Computational Biology

Tuesday, April 17, 2018, 8:00 a.m.-12:00 p.m.

Section 13, Hall A, McCormick Place South (Level 3)

- 3:00 p.m. Introduction**
- 3:10 p.m. 3296 SMART: Serial measurements of molecular and architectural responses to therapy.** Brett Johnson, Portland, OR
- 3:15 p.m. 3297 A tyrosine kinase interactome reveals network states that guide the use of targeted therapies in cancer.** Swati Kaushik, San Francisco, CA
- 3:20 p.m. 3298 High-content phenotyping of somatic cancer mutations by functional variomics.** Nidhi Sahni, Houston, TX
- 3:25 p.m. 3299 High-throughput combinatorial CRISPR-Cas9 gene knockout reveals most genetic interactions are context dependent.** John Paul Shen, San Diego, CA
- 3:30 p.m. 3300 Network analysis of the human protein-protein interactome: Tumorigenic signaling mechanisms.** Kamrun N. Begum, New York, NY
- 3:35 p.m. 3301 Using a novel single-cell lineage-tracing technique to uncover the mechanisms driving nongenetic cancer relapse.** Yaara Oren, Boston, MA
- 3:40 p.m. 3302 The molecular landscape of oncogenic signaling pathways in The Cancer Genome Atlas.** Francisco Sanchez-Vega, New York, NY
- 3:45 p.m. 3303 A comprehensive TCGA Pan-Cancer molecular study of gynecologic and breast cancers.** Rehan Akbani, Houston, TX

MEET AND GREET • 3:00 p.m.–4:30 p.m.

AACRcentral-Associate Member Resource and Career Center,
Hall A, McCormick Place South (Level 3)

Associate Member Council (AMC) Meet and Greet

(not eligible for CME credit)

AMC Chair: Ken Dutton-Regester, Brisbane, QLD, Australia

**Program as of March 20, 2018

CLINICAL TRIALS MINISYMPOSIUM 2 • 3:00 p.m.-5:00 p.m.

N Hall C, McCormick Place North (Level 1)

Updates in Immuno-oncology Trials

Chair: Michael B. Atkins, Washington, DC

3:00 p.m. **Introduction**

3:05 p.m. **CT110 Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).**
Rakesh Awasthi, East Hanover, NJ

3:20 p.m. **CT111 Avelumab (anti-PD-L1) as first-line maintenance (1L mn) or second-line (2L) therapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): updated phase Ib results from the JAVELIN Solid Tumor trial.** Hyun Cheol Chung, Seoul, Republic of Korea

3:35 p.m. **CT112 Durvalumab + tremelimumab in patients with metastatic urothelial cancer.** Arjun V. Balar, New York, NY

3:50 p.m. **CT113 Safety and activity of second-line durvalumab + tremelimumab in non-squamous advanced NSCLC.** Jamie Chaft, New York, NY

4:05 p.m. **CT114 Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (NSCLC): Results of the phase 3 CheckMate 078 study.** Yi-Long Wu, Guangzhou, China

4:20 p.m. **CT115 Updated survival results of the KEYNOTE-040 study of pembrolizumab vs standard-of-care chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma.** Denis Soulières, Montreal, QC, Canada

4:35 p.m. **CT116 Nivolumab (Nivo) vs investigator's choice (IC) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): 2-yr outcomes in the overall population and PD-L1 subgroups of CheckMate 141.** Robert L. Ferris, Pittsburgh, PA

4:50 p.m. **Discussion**

MONDAY, APRIL 16**

MAJOR SYMPOSIUM • 3:00 p.m.-5:00 p.m.

Room S102, McCormick Place South (Level 1)

AACR-JCA Joint Symposium: Cancer Cell Plasticity

Cochairs: Mary J.C. Hendrix, Shepherdstown, WV; Yutaka Kondo, Nagoya, Japan

- 3:00 p.m. Tumorigenic roles of lncRNAs in human gliomas.** Yutaka Kondo, Nagoya, Japan
- 3:30 p.m. Targeting the plasticity of aggressive tumor cells.** Mary J.C. Hendrix, Shepherdstown, WV
- 4:00 p.m. Dissecting cancer biology with iPS cell technology.** Yasuhiro Yamada, Tokyo, Japan
- 4:30 p.m. Suppression of EMT in relation to immune cytotoxicity.** Steven M. Frisch, Morgantown, WV

MINISYMPOSIA • 3:00 p.m.-5:00 p.m.

Room W196, McCormick Place West (Level 1)

Clinical Research

Molecular Predictors of Response, Mediators of Resistance, Mechanisms of Action, Pharmacodynamic Markers, and Novel Disease Subsets

Cochairs: Catherine C. Smith, San Francisco, CA; Roger S. Lo, Los Angeles, CA

- 3:00 p.m. Introduction**
- 3:05 p.m. 2951 Gene expression profiling identifies new adult “triple-negative” acute lymphoblastic leukemia (ALL) subgroups.** Anna Ferrari, Bologna, Italy
- 3:20 p.m. 2952 Targeting CDK9 reactivates epigenetically silenced genes in cancer.** Hanghang Zhang, Philadelphia, PA
- 3:35 p.m. 2953 Overall survival results of the single-institution molecular screening MOSCATO trial in hard-to-treat advanced cancers.** Yolla El Dakdouki, Paris, France
- 3:50 p.m. 2954 Immunomodulator maintenance post autologous stem cell transplant predicts better outcome in multiple myeloma patients with clonal hematopoiesis of indeterminate potential.** Tarek H. Mouhieddine, Boston, MA

**Program as of March 20, 2018

- 4:05 p.m. **2955 A radiomic-based MRI phenotype is uniquely associated with hypermutated genotype in gliomas.** Islam Hassan, Houston, TX
- 4:20 p.m. **2956 Mechanisms of resistance for osimertinib for patients with *EGFR*-mutant lung cancer: MD Anderson Cancer Center single-institution experience with osimertinib resistance.** Xiuning Le, Houston, TX
- 4:35 p.m. **2957 Sequential transcriptomic and phosphorylation landscape of acute myelogenous leukemia (AML) on the single-cell level.** Victoria E. Wang, San Francisco, CA

Room S406 (Vista Ballroom), McCormick Place South (Level 4)

Clinical Research

Use of Liquid Biopsies in Clinical Trials

Cochairs: Costanza Paoletti, Ann Arbor, MI; Dario Marchetti, Houston, TX

- 3:00 p.m. **Introduction**
- 3:05 p.m. **2958 Development of a superenhancer element-associated transcription factor signature in primary tumors for the identification of liver metastasis in colorectal cancer patients.** Roshni Roy, Dallas, TX
- 3:20 p.m. **2959 Analysis of circulating tumor DNA reveals genomic alterations in metastatic prostate cancer patients treated with abiraterone acetate plus prednisone or enzalutamide.** Jelena Belic, Graz, Austria
- 3:35 p.m. **2960 Concordance of genomic single-nucleotide variations (SNV) by next-generation sequencing (NGS) in paired tumor tissue and plasma in colorectal cancer (CRC).** Preeti Lal, Graz, Austria
- 3:50 p.m. **2961 First metastasis NGS analysis reveals new targets for personalized treatment in advanced breast cancer.** Celine Callens, Paris, France
- 4:05 p.m. **2962 Clinical relevance of circulating cell-free DNA using amplicon-based next-generation sequencing panel in colorectal cancer patients with liver metastasis.** Hiroki Osumi, Tokyo, Japan
- 4:20 p.m. **2963 Characterization of disease evolution in sequential sampled metastatic breast cancer using liquid biopsy.** Lisa Welter, Los Angeles, CA
- 4:35 p.m. **2964 On-treatment changes in circulating tumor DNA (ctDNA) level as an early predictor of clinical outcome in the LOTUS randomized phase 2 trial of 1st-line ipatasertib (IPAT) + paclitaxel (PAC) for metastatic triple-negative breast cancer (mTNBC).** Matthew J. Wongchenko, South San Francisco, CA
(not eligible for CME credit)

Room S505, McCormick Place South (Level 5)

Epidemiology

Genetic and Molecular Epidemiology of Cancer Risk and Prognosis

Cochairs: Michael B. Cook, Rockville, MD; Michael E. Scheurer, Houston, TX

- 3:00 p.m. Introduction**
- 3:05 p.m. 2965 Functionally informed genome-wide interaction analysis of nonsteroidal anti-inflammatory drugs on colorectal cancer risk.** Xiaoliang Wang, Seattle, WA
- 3:20 p.m. 2966 A genome-wide scan identifies a new locus associated with pediatric rhabdomyosarcoma.** Philip J. Lupo, Houston, TX
- 3:35 p.m. 2967 Ethnic-specific risk of neurotoxicity and its impact on treatment outcomes among pediatric patients receiving acute lymphoblastic leukemia therapy.** Michael E. Scheurer, Houston, TX
- 3:50 p.m. 2968 Imputation of the prostate cancer transcriptome in over 230,000 men reveals novel germline-somatic interaction mechanism of cancer risk.** Nima C. Emami, San Francisco, CA
- 4:05 p.m. 2969 Genetically predicted blood protein biomarkers and prostate cancer risk: An analysis in over 140,000 European descendants.** Lang Wu, Nashville, TN
- 4:20 p.m. 2970 Multiple new susceptibility loci identified in genome-wide association study of Ewing sarcoma.** Mitchell J. Machiela, Bethesda, MD
- 4:35 p.m. 2971 Digital image analysis based IHC4+C assay and prognosis in hormone receptor-positive breast cancer.** Mustapha Abubakar, Rockville, MD

Room N427, McCormick Place North (Level 4)

Experimental and Molecular Therapeutics

Identification of Biomarkers and Molecular Drug Targets

Cochairs: Harriet Wikman, Hamburg, Germany; Steven A. Johnsen, Goettingen, Germany

- 3:00 p.m. Introduction**
- 3:05 p.m. 2972 Co-clinical trial of olaparib and temozolomide in SCLC PDX models uncovers new biomarkers of sensitivity.** Benjamin J. Drapkin, Boston, MA
- 3:20 p.m. 2973 A comprehensive panel of patient-derived xenografts representing the molecular heterogeneity and diversity of triple-negative breast cancer.** Elisabetta Marangoni, Paris, France

**Program as of March 20, 2018

- 3:35 p.m.** **2974 Primary tumor data mining identifies a novel synthetic lethal partner of the BRCA1 mutation in breast cancer.** Subarna Sinha, Menlo Park, CA
- 3:50 p.m.** **2975 Synthetic lethality in synovial sarcoma: SS18-SSX fusions and DNA damage response (DDR) inhibitors.** Emmy DG Fleuren, London, United Kingdom
- 4:05 p.m.** **2976 Confirmation of in-cell target engagement using the proteolysis targeting chimeras (PROTACs) against pirin.** Swee Y. Sharp, London, United Kingdom
- 4:20 p.m.** **2977 PI3K/mTOR pathway inhibition induces Aurora B-mediated cell death in *NOTCH1* mutant head and neck squamous (HNSCC) cells.** Vaishnavi Sambandam, Houston, TX
- 4:35 p.m.** **2978 The utilization of a human MCL1 knockin mouse suggests that reductions in B-cells and monocytes may serve as clinically relevant pharmacodynamic markers of MCL1 inhibition.** Brian Belmontes, Thousand Oaks, CA
(not eligible for CME credit)

Room S100 (Grand Ballroom), McCormick Place South (Level 1)

Immunology

Defining New Immunotherapeutic Targets through Deep Molecular Characterization

Cochairs: Matthew Spitzer, San Francisco, CA; Katerina A. Politi, New Haven, CT

- 3:00 p.m.** **Introduction**
- 3:05 p.m.** **2979 A balance of genomic instability, tumor-immune contexture and TGF- β signaling contributing to exclusion of T cells governs response to PD-L1 checkpoint blockade.** Sanjeev Mariathasan, South San Francisco, CA
- 3:20 p.m.** **2980 Single-cell RNA sequencing reveals AML immunoediting under pressure from engineered T-cell therapy.** Kelly G. Paulson, Seattle, WA
- 3:35 p.m.** **2981 Clonal deletion of tumor-specific T cells by combination checkpoint blockade compromises antitumor efficacy in low tumor burden states.** Chien-Chun Steven Pai, San Francisco, CA
- 3:50 p.m.** **2982 Somatic TP53 mutations alter the immune microenvironment after chemotherapy in breast cancer.** Mellissa J. Nixon, Nashville, TN
- 4:05 p.m.** **2983 CD25 enables oncogenic BCR and TCR signaling and represents a therapeutic target in lymphoblastic malignancies.** Jaewoong Lee, Monrovia, CA

- 4:20 p.m.** **2984 Effects of anti-CTLA-4 and anti-PD-1 on memory T-cell differentiation and resistance to tumor relapse.** Stephen Mok, Houston, TX
- 4:35 p.m.** **2985 Radiotherapy and α CD40 nonredundantly augment immunity to checkpoint blockade in refractory pancreatic ductal adenocarcinoma.** Hannah Dada, Philadelphia, PA

Room S403, McCormick Place South (Level 4)

Molecular and Cellular Biology / Genetics

Drugging the Undruggable: Using Synthetic Lethality and Other Approaches to Develop New Treatment Strategies

Cochairs: Tomoo Iwakuma, Kansas City, KS; Scott J. Weir, Kansas City, KS

- 3:00 p.m.** **Introduction**
- 3:05 p.m.** **2986 E-cadherin/ROS1 inhibitor synthetic lethality in breast cancer.** Ilirjana Bajrami, London, United Kingdom
- 3:20 p.m.** **2987 Identification of new combination therapies for lung tumors harboring KRAS mutations.** Miriam Molina-Arcas, London, United Kingdom
- 3:35 p.m.** **2988 Loss of Rbm38 cooperates with mutant p53 to promote lymphomagenesis through downregulation of Pten.** Jin Zhang, Davis, CA
- 3:50 p.m.** **2989 BET inhibitors induce Rac1-dependent MNK and eIF4E phosphorylation in cancer cells.** Thao Pham, Chicago, IL
- 4:05 p.m.** **2990 Attenuation of RNA polymerase II pausing mitigates BRCA1-associated R-loop accumulation and tumorigenesis.** Xiaowen Zhang, San Antonio, TX
- 4:20 p.m.** **2991 Cytoplasmic mislocalization of CTCF by NPM1c in acute myeloid leukemia resulting in inhibited CTCF regulatory functions generating aberrant genetic and epigenetic profiles.** Atom Wang, Toronto, ON, Canada

Room N227, McCormick Place North (Level 2)

Molecular and Cellular Biology / Genetics

Cancer Epigenetics and Epigenetic Therapy

Cochairs: Daniel Diniz De Carvalho, Toronto, ON, Canada; Cheryl Arrowsmith, Toronto, ON, Canada

- 3:00 p.m.** **Introduction**
- 3:05 p.m.** **2993 A switch in epigenetic silencing mechanisms of endogenous retroviruses during human genome evolution.** Hitoshi Ohtani, Grand Rapids, MI

**Program as of March 20, 2018

- 3:20 p.m.** **2994 Discovery of selective, noncovalent small-molecule inhibitors of DNMT1 as an alternative to traditional DNA hypomethylating agents.** Melissa B. Pappalardi, Collegeville, PA
(not eligible for CME credit)
- 3:35 p.m.** **2995 CDK9 phosphorylates BRG1 chromatin remodeler.** Somnath Pandey, Philadelphia, PA
- 3:50 p.m.** **2996 Insulator dysfunction and epigenetic oncogene activation in SDH-deficient gastrointestinal stromal tumor.** William A. Flavahan, Boston, MA
- 4:05 p.m.** **2997 Epigenomic signatures of acquired platinum resistance in high-grade serous ovarian cancer.** Fang Fang, Bloomington, IN
- 4:20 p.m.** **2998 Dynamic 3D chromosomal landscapes in acute leukemia.** Palaniraja Thandapani, New York, NY
- 4:35 p.m.** **2999 Low-dose demethylation therapy for the treatment of cisplatin-resistant testicular cancer.** Michael J. Spinella, Urbana, IL

Room S504, McCormick Place South (Level 5)

Molecular and Cellular Biology / Genetics

Sampling the Cancer Genome and the Epigenome: Opportunities and Exquisite Vulnerabilities

Cochairs: Nada Jabado, Montreal, QC, Canada; Matthew L. Meyerson, Boston, MA

- 3:00 p.m.** **Introduction**
- 3:05 p.m.** **3000 Pervasive intratumor heterogeneity and subclonal selection across cancer types.** Stefan Dentro, Cambridge, United Kingdom
- 3:20 p.m.** **3001 Broad/IBM Project: Discovery of treatment resistance mechanisms through use of liquid biopsy genomics services.** Gad Getz, Charlestown, MA
- 3:35 p.m.** **3002 Genome engineering approaches to generate models of chromosome arm-level cancer aneuploidy.** Alison Marie Taylor, Boston, MA
- 3:50 p.m.** **3003 Loss of heterozygosity of essential genes represents a novel class of cancer vulnerabilities.** Caitlin A. Nichols, Boston, MA
- 4:05 p.m.** **3004 Single-cell mutational profiling of clonal evolution in myelodysplastic syndromes (MDS) during therapy and disease progression.** Alexey Aleshin, Stanford, CA
- 4:20 p.m.** **3005 International Cancer Genome Consortium.** Andrew Biankin, Stanford, CA
- 4:35 p.m.** **3006 Molecular characterization of baseline and serial multiple myeloma patients from the MMRF CoMMpass study.** Jonathan J. Keats, Phoenix, AZ

Room S101, McCormick Place South (Level 1)

Clinical Research

Cancer Survivorship and Disparities

Cochairs: Anna D. Barker, Scottsdale, AZ; Jeri Francoeur, Ormond Beach, FL

- 3:00 p.m. Introduction**
- 3:05 p.m. 3007 Monogenic and polygenic associations with subsequent breast cancer risk in survivors of childhood cancer: The St. Jude Lifetime Cohort Study (SJLIFE).** Zhaoming Wang, Memphis, TN
- 3:20 p.m. 3008 Effect of exercise on acute and late-onset doxorubicin-induced cardiotoxicity.** Fei Wang, Houston, TX
- 3:35 p.m. 3009 Changes in recreational physical activity and prognosis in breast cancer survivors.** Audrey Y. Jung, Heidelberg, Germany
- 3:50 p.m. 3010 Biobanking and genomic research: Understanding and acceptance of safety-net patients, primary care providers, and minority groups.** Terry Davis, Shreveport, LA
- 4:05 p.m. 3011 Determinants and prognostic value of quality of life in patients with pancreatic ductal adenocarcinoma.** Yang Deng, Houston, TX
- 4:20 p.m. 3012 Urban neighborhood and residential factors associated with breast cancer in African American women: A systematic review.** Brandi P. Smith, Champaign, IL

Room S405, McCormick Place South (Level 4)

Tumor Biology

Deciphering Cancer Mechanisms in Animal Models

Cochairs: Kathryn A. O'Donnell, Dallas, TX; Fotis Asimakopoulos, Madison, WI

- 3:00 p.m. Introduction**
- 3:05 p.m. 3014 Location specificity in fusion-negative rhabdomyosarcoma driven by cell of origin.** Catherine J. Drummond, Memphis, TN
- 3:20 p.m. 3015 Precise investigation of cancer stem cells in mouse glioblastoma.** Xuanhua P. Xie, New York, NY
- 3:35 p.m. 3016 Ezh2 is a dose-dependent mediator of prostate cancer aggressiveness and lineage transformation.** Kristine M. Wadosky, Buffalo, NY
- 3:50 p.m. 3017 Identifying drivers for advanced prostate cancer by a transposon-based genetic screen.** Min Zou, New York, NY

**Program as of March 20, 2018

- 4:05 p.m.** **3018 Expression of oncogenic Nras and a MYC transgene in germinal center B cells induces a highly malignant multiple myeloma.** Adhithi Rajagopalan, Madison, WI
- 4:20 p.m.** **3019 PRL3 contributes to the onset and progression of T-cell acute lymphoblastic leukemia in a zebrafish model.** Rachel E. Sieg, Lexington, KY
- 4:35 p.m.** **3020 An essential role for *Argonaute 2* in EGFR-KRAS signaling in pancreatic cancer development.** Sunita Shankar, Ann Arbor, MI

Room S501, McCormick Place South (Level 5)

Tumor Biology

Organ-Specific Metastasis

Cochairs: Ruth J. Muschel, Oxford, United Kingdom; Danny R. Welch, Kansas City, KS

- 3:00 p.m.** **Introduction**
- 3:05 p.m.** **3021 Plexin-B3 regulates cellular motility, invasiveness, and metastasis in pancreatic cancer.** Sugandha Saxena, Omaha, NE
- 3:20 p.m.** **3022 Lymph node metastasis in solid tumors: A marker or driver of disease progression?** Ethel R. Pereira, Boston, MA
- 3:35 p.m.** **3023 Dissecting mechanisms of breast cancer metastasis through patient-derived circulating tumor cells.** Remi Klotz, Los Angeles, CA
- 3:50 p.m.** **3024 Genomic characterization of organ-specific metastasis from prospective clinical sequencing of 20,000 cancer patients.** Francisco Sanchez-Vega, New York, NY
- 4:05 p.m.** **3025 Ligand-independent EphA2 signaling drives an amoeboid phenotype that promotes melanoma brain metastasis development.** Chao Zhang, Tampa, FL
- 4:20 p.m.** **3026 Role of AnnexinA2, Sema3D, and PlexinD1 in mediating perineural invasion as a mechanism of metastasis in pancreatic ductal adenocarcinoma.** Noelle R. Jurcak, Baltimore, MD
- 4:35 p.m.** **3027 Single-cell RNA sequencing defines regulatory networks in ER+ breast cancer organ-specific metastases.** Nuria Padilla Just, Aurora, CO

MONDAY, APRIL 16**

**REGULATORY SCIENCE
AND POLICY SESSION • 3:00 p.m.–5:00 p.m.**

Room S401bcd, McCormick Place South (Level 4)

Real World Evidence in Oncology and Its Implications

Chair: Amy P. Abernethy, New York, NY

Sean Khozin, Silver Spring, MD

Jeff D. Allen, Washington, DC

William Capra, San Francisco, CA

Cynthia Huang, New York, NY

Elad Sharon, Bethesda, MD

MONDAY

AWARDS AND LECTURES • 4:15 p.m.-5:00 p.m.

Room S106, McCormick Place South (Level 1)

**Second Annual AACR-Waun Ki Hong Award for Outstanding
Achievement in Translational and Clinical Cancer Research**

Developing combination precision therapies for lung cancer. Pasi A. Jänne, Boston, MA

Dr. Jänne is honored for his seminal therapeutic discoveries, including being one of the codiscoverers of EGFR mutations. Findings from his work have led to the development of several clinical trials.

**Program as of March 20, 2018

NCI/NIH-SPONSORED SESSION • 4:00 p.m.–5:30 p.m.

Room W192, McCormick Place West (Level 1)

**Multidisciplinary Approaches for Single-Cell Analysis
(not eligible for CME credit)**

Anthony Dickherber, Marietta, GA

Juli Klemm, Rockville, MD

Shannon Hughes, Bethesda, MD

Nastaran Zahir, Bethesda, MD

Gabor Marth, Salt Lake City, UT

Raul Rabadan, New York, NY

Tania Konry, Boston, MA

Alexander K. Shalek, Cambridge, MA

AWARDS AND LECTURES • 4:15 p.m.–4:30 p.m.

Room S404, McCormick Place South (Level 4)

**Special WICR Presentation Honoring Dr. Charlotte Friend
(not eligible for CME credit)**

Chair: Judith S. Sebolt-Leopold, Ann Arbor, MI

MONDAY, APRIL 16**

AWARDS AND LECTURES • 4:30 p.m.–5:15 p.m.

Room S105, McCormick Place South (Level 1)

Fifty-Eighth Annual AACR G.H.A. Clowes Memorial Award

Cancer drivers and dependencies. Scott W. Lowe, New York, NY

Dr. Lowe is recognized for outstanding research on the mechanisms of tumor suppression, including discovering the process of oncogene-induced senescence and how that senescence contributes to therapeutic suppression of tumors in vivo.

AWARDS AND LECTURES • 4:30 p.m.–5:15 p.m.

Room S404, McCormick Place South (Level 4)

**Twenty-First Annual AACR-Women in Cancer Research
Charlotte Friend Memorial Lectureship**

Unraveling mechanisms of oncogenic Ras-mediated tumorigenesis. Dafna Bar-Sagi,
New York, NY

Dr. Bar-Sagi, a world-renowned cancer biologist, is recognized for her work in Ras oncogene and its role in the regulation of cell proliferation and survival, tumor immunity, cellular metabolism, and cell-to-cell signaling.

MONDAY

FORUM • 5:00 p.m.–6:30 p.m.

Room S100 (Grand Ballroom), McCormick Place South (Level 1)

Biomarkers of Checkpoint Blockade Inhibitor Response: What Are They?

Moderator: Elaine R. Mardis, Columbus, OH

Panel: Alexandra Snyder, New York, NY
David L. Rimm, New Haven, CT

**Program as of March 20, 2018

Room W196, McCormick Place West (Level 1)

The BMI Paradox in Cancer: Does One Size Fit All and What Does It Mean for Cancer Patients?

Moderator: Jeffrey A. Meyerhardt, Boston, MA

Panel: Bette J. Caan, Oakland, CA
Pamela J. Goodwin, Toronto, ON, Canada

N Hall C, McCormick Place North (Level 1)

CTCs and ctDNA: Complementary Biomarkers for Precision Medicine

Moderator: Sarah-Jane Dawson, East Melbourne, VIC, Australia

Panel: Daniel F. Hayes, Ann Arbor, MI
Ash A. Alizadeh, Stanford, CA

Room S102, McCormick Place South (Level 1)

Origins of Metastasis: Monoclonal or Polyclonal?

Moderator: Jonathan P. Sleeman, Mannheim, Germany

Panel: G. Steven Bova, Tampere, Finland
Andrew J. Ewald, Baltimore, MD

Room S406 (Vista Ballroom), McCormick Place South (Level 4)

Precision Therapy: When Is Better—Up Front or at Relapse?

Moderator: Gideon Blumenthal, Silver Spring, MD

Panel: Alice T. Shaw, Boston, MA
Scott Kopetz, Houston, TX

Room N227, McCormick Place North (Level 2)

To Monitor or Not to Monitor: Surveillance in Hereditary Cancer

Moderator: David Malkin, Toronto, ON, Canada

Panel: Kim E. Nichols, Memphis, TN
Thierry Frebourg, Rouen, France

MONDAY, APRIL 16**

SPECIAL SESSION • 5:00 p.m.–6:30 p.m.

Room N427, McCormick Place North (Level 4)

AACR/ASCO Joint Session

Speakers to be announced.

SPECIAL SESSION • 5:00 p.m.–6:30 p.m.

Room W190, McCormick Place West (Level 1)

Unsolved Mysteries: Failure to Translate: The IGF-1R and PI3K Inhibitors

Chair: Douglas Yee, Minneapolis, MN

Failure to translate: The IGF-1R and PI3K inhibitors. Douglas Yee, Minneapolis, MN

Why aren't PI3K inhibitors working in clinical trials? Carlos L. Arteaga, Dallas, TX

IGF-1R: A challenging target. Valentine Moya Macaulay, Oxford, United Kingdom

TOWN MEETING • 5:00 p.m.–7:00 p.m.

Jackson Park A-D, Hyatt Regency McCormick Place

Minorities in Cancer Research Town Meeting

(not eligible for CME credit)

Chair: John M. Carethers, Ann Arbor, MI

Great Lakes E-G, Marriott Marquis Chicago

Radiation Science and Medicine Working Group Town Hall Meeting and Networking Reception: Is Dose per Fraction the New Method to Personalize Radiation Therapy Treatments?

(not eligible for CME credit)

Chair: David R. Gius, Chicago, IL

Chair-Elect: Mary Helen Barcellos-Hoff, San Francisco, CA

Panelists: Sandra Demaria, New York, NY
Navita Somaiah, London, United Kingdom
Samuel Strober, Stanford, CA
Julia R. White, Columbus, OH

**Program as of March 20, 2018

AWARDS AND LECTURES • 5:15 p.m.–6:00 p.m.

Room S105, McCormick Place South (Level 1)

Twelfth Annual AACR Princess Takamatsu Memorial Lectureship

Modulating immune response: Lessons learned from mouse models of cancer development. Lisa M. Coussens, Portland, OR

Dr. Coussens is honored for her work that has increased our understanding of immune cells in fostering tumor development and metastasis. Her paradigm-shifting studies have demonstrated that tumor-infiltrating immune cells can be both pro- and antitumorigenic as well as influence response to therapy.

NCI/NIH-SPONSORED SESSION • 5:30 p.m.–6:30 p.m.

Room W192, McCormick Place West (Level 1)

The NCI PREVENT Program: Translating Innovative Ideas in Cancer Prevention to the Clinic (not eligible for CME credit)

Moderator: Shizuko Sei, North Potomac, MD

Mark S. Miller, Rockville, MD

Elizabeth R. Glaze, Bethesda, MD

PROFESSIONAL ADVANCEMENT SESSION • 6:00 p.m.–8:00 p.m.

Regency A-B, Hyatt Regency McCormick Place

Minorities in Cancer Research Professional Advancement Session: Navigating the Road to a Successful Career in Cancer Research (not eligible for CME credit)

Cochairs: Brian M. Rivers, Atlanta, GA; Kimlin T. Ashing, Duarte, CA

MONDAY, APRIL 16**

SPECIAL SESSION • 6:00 p.m.–8:00 p.m.

Room S103, McCormick Place South (Level 1)

Joint Cancer Immunology (CIMM) / Tumor Microenvironment (TME) Working Groups Evening Scientific Session

(not eligible for CME credit)

- 6:00 p.m.** **Opening remarks: CIMM Chair.** Jedd D. Wolchok, New York, NY
- 6:15 p.m.** **Microenvironmental regulation of cancer metastasis and therapeutic efficacy.** Johanna A. Joyce, Lausanne, Switzerland
- 6:45 p.m.** **Combinatorial approaches to checkpoint blockade.** F. Stephen Hodi, Boston, MA
- 7:15 p.m.** **Results from a phase 1 clinical trial of CXCR4 inhibition in cancers resistant to T-cell checkpoint antagonists.** Douglas T. Fearon, Cold Spring Harbor, NY
- 7:45 p.m.** **Closing remarks: TME Chair.** Valerie M. Weaver, San Francisco, CA

TOWN MEETING • 6:30 p.m.–8:00 p.m.

Room S106, McCormick Place South (Level 1)

Molecular Epidemiology Working Group (MEG) Town Hall Meeting and Networking Reception

(not eligible for CME credit)

- 6:30 p.m.** **MEG Chair: Opening remarks.** Melissa L. Bondy, Houston, TX
- 6:45 p.m.** **MEG Chair-Elect: Remarks.** Ellen L. Goode, Rochester, MN
- 6:50 p.m.** **Diet, nutrition, physical activity and cancer: A global perspective. The WCRF/AICR Third Expert Report—10 years of progress.** Nigel T. Brockton, Arlington, VA
- 6:55 p.m.** **Peer review process overview.** Angela Y. Ng, Bethesda, MD
- 7:10 p.m.** **Etiquette and practices of peer review.** Julie R. Palmer, Boston, MA
- 7:15 p.m.** **Explaining the process of peer review.** Leah E. Mechanic, Bethesda, MD
- 7:25 p.m.** **Panel discussion**
- 7:35 p.m.** **Closing remarks.** Ellen L. Goode, Rochester, MN

**Program as of March 20, 2018

TUESDAY, APRIL 17**

MEET-THE-EXPERT SESSION • 7:00 a.m.–8:00 a.m.

Room W190, McCormick Place West (Level 1)

Cancer Stem Cells: A Queen Bee to Target

Shrikant Anant, Kansas City, KS

Room S102, McCormick Place South (Level 1)

Epigenetic Therapy: Bench to Bedside

Jean-Pierre J. Issa, Philadelphia, PA

Room S103, McCormick Place South (Level 1)

Epigenetics: A Gatekeeper to DNA Amplification

Johnathan R. Whetstine, Winchester, MA

Room S404, McCormick Place South (Level 4)

***Helicobacter pylori*: Paradigm of a Cancer-Inducing Bacterium**

Thomas Meyer, Berlin, Germany

Room S406 (Vista Ballroom), McCormick Place South (Level 4)

Multiscale Imaging

Joe W. Gray, Portland, OR

Room N227, McCormick Place North (Level 2)

Mutant p53 Activities in Somatic and Germline Mouse Tumor Models

Guillermina Lozano, Houston, TX

Room S504, McCormick Place South (Level 5)

Population Perspectives on Ovarian Cancer: What Is New in Etiology, Screening, and Prevention?

Nicolas A. Wentzensen, Bethesda, MD

Room W196, McCormick Place West (Level 1)

Precision Medicine for Lung Cancer

Christine M. Lovly, Nashville, TN

**Program as of March 20, 2018

TUESDAY, APRIL 17**

Room S105, McCormick Place South (Level 1)

Present and Future Mouse Models for Preclinical Testing of Targeted and Immune Therapeutics

Kwok-Kin Wong, New York, NY

Room S100 (Grand Ballroom), McCormick Place South (Level 1)

Principles of Response and Resistance to Cancer Therapies

(not eligible for CME credit)

Levi A. Garraway, Indianapolis, IN

Room S501, McCormick Place South (Level 5)

Statistics Helps! Avoid Common Pitfalls and Build a Solid Foundation on Quantitative Reasoning in the Big Data Era

J. Jack Lee, Houston, TX

Room S106, McCormick Place South (Level 1)

Title to Be Announced

Otis W. Brawley, Atlanta, GA

Room N228, McCormick Place North (Level 2)

Uniform, Accurate, and Cost-Effective WGS Variant Calling: The PCAWG Experience

Lincoln D. Stein, Toronto, ON, Canada

Room N427, McCormick Place North (Level 4)

Update on Androgen Receptors as a Potential Therapeutic Target in Breast Cancer

Jennifer K. Richer, Aurora, CO

TUESDAY

**Program as of March 20, 2018

POSTER SESSION • 8:00 a.m.-12:00 p.m.

Exhibit Hall A, McCormick Place South (Level 3)

(not eligible for CME credit)

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner, the Annual Meeting App (available at www.AACR.org/AACR2018), and in the print Poster Sessions and Exhibits Guide. A limited number of copies of the print guide are available in the Exhibit Hall.

Tumor Biology

- Section 1 Cancer Imaging: Immunology and Systems Analysis in Vivo
- Section 2 Cancer Stem Cell Characterization
- Section 3 Carcinogenesis 1
- Section 4 Harnessing the Power of Cell Lines for Cancer Research
- Section 5 Immune Cells in the Microenvironment
- Section 6 Metastasis, Invasion, and Migration 1
- Section 7 Pediatrics 2: Preclinical Therapies, Resistance, and Stem Cells
- Section 8 Radiation Studies Using in Vitro and Computational Models

Epidemiology

- Section 9 Biomarkers of Exogenous and Endogenous Risk Factors in Cancer Epidemiology

Advocates Poster Session (Scientist↔Survivor Program)

- Section 10 Advocates Poster Session 2 (8:00 a.m.-10:00 a.m.)

Prevention Research

- Section 11 Prevention, Interception, and Early Detection Research

Bioinformatics and Systems Biology

- Section 12 Sequence Analysis and Unique Database Resources
- Section 13 Systems and Computational Biology

Molecular and Cellular Biology / Genetics

- Section 14 Epigenetic Changes as Molecular Markers of Cancer
- Section 15 Exploring Oncogenic Transcription Factors
- Section 16 Genomic Instability
- Section 17 Genomic Profiling of Tumors 1

TUESDAY, APRIL 17**

Section 18	Genomic Profiling of Tumors 2
Section 19	Kinases 2
Section 20	Metabolomics
Section 21	Oncogene Growth Factors and Their Receptors
Section 22	Therapeutic Approaches
Section 23	Ubiquitylation, Vesicles, and Membranes
Section 45	Late-Breaking Research: Molecular and Cellular Biology / Genetics 2

Clinical Research

Section 24	Adoptive Cell Therapy 3
Section 25	Biomarker Discovery 4
Section 26	Immune Checkpoints 3
Section 27	Liquid Biopsy 3
Section 28	Molecular Classification of Tumors 1: Epigenetic Therapy, Functional and Molecular Imaging, and Tumor Heterogeneity
Section 43	Late-Breaking Research: Clinical Research 2

Cancer Chemistry

Section 30	Drug Delivery
------------	---------------

Endocrinology

Section 31	Steroid Receptors and Preclinical Studies of Endocrine-Related Cancers
------------	--

Immunology

Section 32	Immunomodulatory Agents and Interventions 1
Section 33	Innate Immune Responses in Cancer
Section 34	Therapeutic Antibodies, including Engineered Antibodies 3

Experimental and Molecular Therapeutics

Section 35	Novel and Canonical Targets
Section 36	Novel Assay Technology and Delivery Systems
Section 37	Pharmacogenetics and Pharmacogenomics
Section 38	Receptor Targeting and the Tumor Microenvironment
Section 39	Resistance and Biology
Section 40	Targeting Oncogenes, Tumor Suppressors, or Gene Products
Section 41	Therapeutic Targeting

Clinical Trials

Section 42	Phase I Trials in Progress
------------	----------------------------

**Program as of March 20, 2018

PLENARY SESSION • 8:15 a.m.–10:15 a.m.

N Hall B (Plenary Hall), McCormick Place North (Level 3)

Fundamental and Applied Cancer Immunology

Chair: Crystal L. Mackall, Stanford, CA

- 8:15 a.m.** **Introduction.** Crystal L. Mackall, Stanford, CA
- 8:20 a.m.** **Tools for T cells: New approaches to analyzing T-cell responsiveness and repertoire in cancer.** Mark M. Davis, Stanford, CA
- 8:45 a.m.** **Exploring and therapeutically exploiting the tumor microenvironment.** Johanna A. Joyce, Epalinges, Switzerland
- 9:10 a.m.** **Mining and integrating large-scale tumor molecular profiles to inform cancer immunology and immunotherapy.** X. Shirley Liu, Boston, MA
- 9:35 a.m.** **Overcoming resistance to PD-1 blockade.** Antoni Ribas, Los Angeles, CA
- 10:00 a.m.** **Opportunities/challenges for the future.** Crystal L. Mackall, Stanford, CA

PROFESSIONAL ADVANCEMENT SESSION • 9:00 a.m.–2:00 p.m.

Regency Ballroom A-E, Hyatt Regency McCormick Place

AACR Special Program for High School Students: The Conquest of Cancer and the Next Generation of Cancer Researchers

(not eligible for CME credit)

Chair: Kathleen W. Scotto, New Brunswick, NJ

- 8:30 a.m.** **Registration and breakfast**
- 9:00 a.m.** **Opening remarks**
- 9:10 a.m.** **Understanding cancer.** Speaker to be announced.
- 9:40 a.m.** **Keys to cancer prevention.** Speaker to be announced.
- 10:10 a.m.** **Message from a cancer survivor.** Speaker to be announced.
- 10:30 a.m.** **Why cancer research needs you.** Speaker to be announced.
- 11:15 a.m.** **Tour of Exhibit Hall and poster sessions**
- 12:15 p.m.** **Networking lunch**
- 1:00 p.m.** **Student poster presentations**
- 1:30 p.m.** **Prizes, awards, and closing remarks**

TUESDAY, APRIL 17**

MEET AND GREET • 10:00 a.m.–11:00 a.m.

Booth 1431, Exhibit Hall A, McCormick Place South (Level 3)

**Meet the Editor-in-Chief of *Molecular Cancer Therapeutics*:
Napoleone Ferrara, MD**
(not eligible for CME credit)

Napoleone Ferrara, La Jolla, CA

MAJOR SYMPOSIA • 10:30 a.m.–12:15 p.m.

Room W190, McCormick Place West (Level 1)

**Breaking Down Silos by Promoting Data Sharing, Standards, and
Reproducibility for Cancer Genome Analysis**

Chair: Subha Madhavan, Washington, DC

10:30 a.m. Introduction

**10:35 a.m. Standardizing and democratizing access to cancer MoDx data to drive
treatment decisions.** Subha Madhavan, Washington, DC

11:05 a.m. A data biosphere for biomedical research. Benedict Paten, Santa Cruz, CA

11:35 a.m. Reuse of genomics data and lessons for cancer research. Alvis Brazma,
Cambridge, United Kingdom [SY31-03*]

Room S504, McCormick Place South (Level 5)

**Controlled Proteostasis: Controlling Protein Function by
Controlling Protein Levels**

Chair: Craig M. Crews, New Haven, CT

10:30 a.m. Introduction

10:35 a.m. PROTAC-mediated protein degradation as a new therapeutic modality.
Craig M. Crews, New Haven, CT

11:05 a.m. Small molecules that catalyze the degradation of a splicing factor. Deepak
Nijhawan, Dallas, TX

**11:35 a.m. Development and mechanistic characterization of USP7 deubiquitinase
inhibitors.** Ingrid Wertz, South San Francisco, CA [SY23-03*]

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*
(the abstract number is listed in brackets above)

**Program as of March 20, 2018

Room S406 (Vista Ballroom), McCormick Place South (Level 4)

Dharma Master Jiantai Symposium in Biomarkers: Insights into Tumor Cell Fates and Drug Resistance from Single-Cell Analyses

Chair: Caroline Dive, Manchester, United Kingdom

- 10:30 a.m. Introduction**
- 10:35 a.m. Deciphering intratumoral heterogeneity by single cell RNA sequencing.** Itay Tirosh, Rehovot, Israel
- 11:05 a.m. Single-cell analysis of therapy resistance in cancer.** Arjun Raj, Philadelphia, PA
- 11:35 a.m. Molecular analysis of circulating tumor cells: A single cell-based liquid biopsy biomarker of chemo response.** Caroline Dive, Manchester, United Kingdom

Room S102, McCormick Place South (Level 1)

Energy Balance at the Nexus of the Host-Tumor Microenvironment Interaction

Chair: Lee W. Jones, New York, NY

- 10:30 a.m. Introduction**
- 10:35 a.m. Role of nitrogen metabolism in obesity-associated pancreatic cancer.** Nada Y. Kalaany, Boston, MA [SY29-01*]
- 11:05 a.m. Obesity-associated inflammation during cancer metastasis.** Daniela F. Quail, Montreal, QC, Canada
- 11:35 a.m. The impact of aerobic exercise on breast cancer progression.** Erik R. Nelson, Urbana, IL [SY29-03*]

Room S103, McCormick Place South (Level 1)

Identifying Molecular Targets in the “Quiet” Pediatric Genome

Chair: D. William Parsons, Houston, TX

- 10:30 a.m. Introduction**
- 10:35 a.m. Pediatric cancer genomics: From pilot studies to precision oncology trials.** D. William Parsons, Houston, TX
- 11:05 a.m. The burden and timing of mutations in childhood cancer genomes.** Adam Shlien, Toronto, ON, Canada
- 11:35 a.m. Targeting the cancer single cell transcriptome.** Sam Behjati, Cambridgeshire, United Kingdom

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings* (the abstract number is listed in brackets above)

Room S404, McCormick Place South (Level 4)

Intercepting Metastasis in Gastrointestinal Malignancies

Chair: Eduard Batlle, Barcelona, Spain

- 10:30 a.m. Introduction**
- 10:35 a.m. Precision medicine strategies for the control of pancreatic cancer.** Raghu Kalluri, Houston, TX
- 11:05 a.m. Targeting DNA repair to improve immune-surveillance and restrict cancer growth.** Alberto Bardelli, Candiolo, Italy
- 11:35 a.m. TGF-beta signaling, immune evasion, and metastasis in colorectal cancer.** Eduard Batlle, Barcelona, Spain

N Hall B (Plenary Hall), McCormick Place North (Level 3)

Rational Combination Therapies in Immune-oncology

Chair: Elizabeth M. Jaffee, Baltimore, MD

- 10:30 a.m. Introduction**
- 10:35 a.m. Raising the tail in cancer immunotherapy: The tissue is the issue; but the scoop is in the poop.** Jennifer A. Wargo, Houston, TX
- 11:05 a.m. A tale of two complexities: Epigenetics and immunology.** Nilofer S. Azad, Baltimore, MD
- 11:35 a.m. MEKKing tumors more responsive to immunotherapy: Implications of the MAPK pathway in tumor immune evasion.** Justin M. Balko, Nashville, TN

Room N427, McCormick Place North (Level 4)

Tumor Myeloid Microenvironment

Chair: Miriam Merad, New York, NY

- 10:30 a.m. Introduction**
- 10:35 a.m. Targeting the tumor microenvironment to reawaken tumor immunity.** David G. DeNardo, St. Louis, MO
- 11:05 a.m. The relationship between Batf3-DC and antitumor T-cell responses.** Stefani Spranger, Cambridge, MA [SY18-02*]
- 11:35 a.m. Cross-presenting DC in the TME.** Matthew F. Krummel, San Francisco, CA [SY18-03*]

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings* (the abstract number is listed in brackets above).

**Program as of March 20, 2018

RECENT ADVANCES IN DIAGNOSTICS AND THERAPEUTICS RESEARCH • 10:30 a.m.–12:15 p.m.

Room S105, McCormick Place South (Level 1)

Recent Advances in Epigenetic Therapy

Chair: Cheryl Arrowsmith, Toronto, ON, Canada

- 10:30 a.m.** **Enhancing antitumor immune response by DNA-demethylating agents.** Daniel DeCarvalho, Toronto, ON, Canada
- 11:00 a.m.** **Epigenetic regulation of cancer cell drug tolerance.** Marie Classon, South San Francisco, CA
(not eligible for CME credit)
- 11:30 a.m.** **Probing the epigenome for therapeutic opportunities.** Cheryl Arrowsmith, Toronto, ON, Canada

Room S501, McCormick Place South (Level 5)

Recent Advances in Modeling Autochthonous Cancer in Mice

Chair: Lukas E. Dow, New York, NY

- 10:30 a.m.** **Exploring mammary tumorigenesis through somatic CRISPR-based genome editing.** Jos Jonkers, Amsterdam, Netherlands
- 11:00 a.m.** **Deciphering obesity-mediated immune evasion mechanisms in colorectal tumorigenesis.** Omer H. Yilmaz, Cambridge, MA
- 11:30 a.m.** **Defining oncogenic drivers in colorectal cancer using in vivo gene editing.** Lukas E. Dow, New York, NY

RECENT ADVANCES IN ORGAN SITE RESEARCH • 10:30 a.m.–12:15 p.m.

Room N227, McCormick Place North (Level 2)

Epigenetic Opportunities in Hematologic Cancers

Chair: Ari M. Melnick, New York, NY

- 10:30 a.m.** **Myeloma: Epigenetic mechanisms and therapy.** Jonathan D. Licht, Gainesville, FL
- 11:00 a.m.** **The novel epitranscriptome dimension in leukemia.** Michael G. Kharas, Gainesville, FL
- 11:30 a.m.** **Harnessing the epigenome for immunotherapy of heme malignancies.** Ari M. Melnick, New York, NY

TUESDAY, APRIL 17**

**RECENT ADVANCES IN PREVENTION
AND INTERCEPTION RESEARCH • 10:30 a.m.–12:15 p.m.**

Room W196, McCormick Place West (Level 1)

Cancer Vaccines and Prevention

Chair: Olivera J. Finn, Pittsburgh, PA

- 10:30 a.m.** **Next-generation HPV vaccines.** Richard B. Roden, Baltimore, MD
- 11:00 a.m.** **DCIS as a model for developing breast cancer immunoprevention.** Brian J. Czerniecki, Tampa, FL
- 11:30 a.m.** **Targeting premalignant lesions with a MUC1 peptide vaccine.** Olivera J. Finn, Pittsburgh, PA

**REGULATORY SCIENCE
AND POLICY SESSION • 10:30 a.m.–12:15 p.m.**

Room S401bcd, McCormick Place South (Level 4)

Recently Approved Breakthrough Therapies and New Approval Endpoints

Chair: Ashley F. Ward, Silver Spring, MD

Najat Bouchkouj, Silver Spring, MD

Dow-Chung Chi, Silver Spring, MD

Noelle Frey, Philadelphia, PA

Mark J. Levis, Baltimore MD

Matthew R. Smith, Boston, MA

Additional speakers to be announced.

TUESDAY

**Program as of March 20, 2018

CLINICAL TRIALS PLENARY SESSION 4 • 10:30 a.m.-12:30 p.m.

N Hall C, McCormick Place North (Level 1)

Novel Immuno-oncology Strategies

Chair: To be announced

- 10:30 a.m.** **CT144 Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma.**
Mohammed Milhem, Iowa City, IA
- 10:50 a.m.** **Discussant to be announced**
- 11:00 a.m.** **CT145 A Cancer Research UK phase I trial of anti-GD2 chimeric antigen receptor (CAR) transduced T cells (1RG-CART) in patients with relapsed or refractory neuroblastoma.** Karin Straathof, London, United Kingdom
- 11:20 a.m.** **Discussant to be announced**
- 11:30 a.m.** **CT146 First-in-human phase I combination of the IL-15 receptor super agonist complex ALT-803 with a therapeutic (anti-CD20) monoclonal antibody (mAb) for patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL).** Todd A. Fehniger, St. Louis, MO
- 11:50 a.m.** **Discussant.** Thomas S. Waldmann, Bethesda, MD
- 12:00 p.m.** **CT147 Safety and efficacy of high purity and activity NK cells therapy in combination with IgG1 antibody in patients with gastric or colorectal cancer: A phase I clinical trial.** Takeshi Ishikawa, Kyoto, Japan
- 12:20 p.m.** **Discussant to be announced**

TUESDAY, APRIL 17**

MAJOR SYMPOSIUM • 10:30 a.m.–12:30 p.m.

Room S106, McCormick Place South (Level 1)

Minorities in Cancer Research Scientific Symposium: Population-Specific Research on Cancer Targeted Treatments and Drug Response—Contributing to the Elimination of Cancer Health Disparities

Cochairs: Laura Fejerman, San Francisco, CA; Rick A. Kittles, Duarte, CA

Moderator: Rick A. Kittles, Duarte, CA

10:30 a.m. Introduction

10:40 a.m. Exploring the TNBC landscape through the AR lens: Our multi-institutional experience. Ritu Aneja, Atlanta, GA

11:00 a.m. Development of a novel therapeutic splice-switching oligonucleotide targeting race-related androgen receptor signaling and aggressive prostate cancer. Jennifer A. Freedman, Durham, NC

11:20 a.m. Tumoral expression of drug and xenobiotic metabolizing enzymes in breast cancer patients of different ethnicities with implications to personalized medicine. Albert J. Steppi, Tallahassee, FL

NCI/NIH-SPONSORED SESSION • 10:30 a.m.–12:30 p.m.

Room W192, McCormick Place West (Level 1)

Funding Opportunities for Cancer Research at Multiple NIH Institutes and Centers

(not eligible for CME credit)

Julia T. Arnold, Bethesda, MD

Sundar Venkatachalam, Rockville, MD

Gary J. Murray, Bethesda, MD

Abee Boyles, Research Triangle Park, NC

Solita Chiayeng Wang, Bethesda, MD

Mukesh Verma, Bethesda, MD

Phuong Kim Pham, Bethesda, MD

Pamela Anne Marino, Bethesda, MD

Syed Musaddaq Quadri, Bethesda, MD

TUESDAY

**Program as of March 20, 2018

SPECIAL SESSION • 10:30 a.m.–12:30 p.m.

Room N228, McCormick Place North (Level 2)

Radiation Science and Medicine Working Group Scientific Session: Utilizing Molecular Signatures to Inform Clinical Outcome Predictions in Radiation Response

Chair: David S. Yu, Atlanta, GA

Multi'omic strategies for stratified medicine. Francesca M. Buffa, Oxford, United Kingdom

Preoperative breast radiotherapy: A platform for understanding radiation response. Janet K. Horton, Durham, NC

Physical biomarkers for prognostic stratification of pancreatic cancer and identification of its therapeutic resistance. Eugene J. Koay, Houston, TX

A genomic basis for precision radiation therapy. Javier F. Torres-Roca, Tampa, FL

SPECIAL SESSION • 10:45 a.m.–11:30 a.m.

AACRcentral Amphitheater, Hall A, McCormick Place South (Level 3)

Cancer Immunology Working Group (CIMM) Networking Session with Early-Career Researchers

(not eligible for CME credit)

CIMM Chair and Moderator: Jedd D. Wolchok, New York, NY

Transitioning to a career in academia. Weiping Zou, Ann Arbor, MI

Transitioning to a career in industry. Olivier De Henau, New York, NY

Transitioning to a career in industry. David Schaer, New York, NY

Transitioning to a career in clinical research. Vinod Balachandran, New York, NY

CAREER DISCUSSION • 11:45 a.m.–12:30 p.m.

AACRcentral Amphitheater, Hall A, McCormick Place South (Level 3)

The Role of Social Media in Your Cancer Research Career: Developing an Online Presence, Organized by the Associate Member Council (AMC)

(not eligible for CME credit)

TUESDAY, APRIL 17**

AWARDS AND LECTURES • 12:30 p.m.–1:00 p.m.

Room S402, McCormick Place South (Level 4)

Gertrude B. Elion Cancer Research Award Lecture

The role of mitochondrial fatty acid beta-oxidation in ovarian cancer chemoresistance.

Dong-Joo Cheon, Albany, NY

Dr. Cheon is recognized for her seminal work on the role of mitochondrial fatty acid beta-oxidation in ovarian cancer chemoresistance. She has unveiled a novel mechanism underlying chemoresistance and has paved the pathway for improved treatment strategies for ovarian cancer.

NCI/NIH-SPONSORED SESSION • 12:30 p.m.–2:30 p.m.

Room W192, McCormick Place West (Level 1)

**Technology Transfer and Intellectual Property:
Career Opportunities for Scientists**

(not eligible for CME credit)

Cochairs: Randy Micheletti, Glen Ellyn, IL; Phuong Kim Pham, Bethesda, MD

Jason V. Cristofaro, Bethesda, MD

John Hewes, Rockville, MD

Melissa Maderia, Frederick, MD

**REGULATORY SCIENCE
AND POLICY SESSION • 1:00 p.m.–1:45 p.m.**

Room S401bdc, McCormick Place South (Level 4)

FDA Priorities: A Conversation with Deputy Commissioner Anna Abram

Anna Abram, Silver Spring, MD

TUESDAY

**Program as of March 20, 2018

MEET AND GREET • 1:00 p.m.–2:00 p.m.

AACRcentral Amphitheater, Hall A, McCormick Place South (Level 3)

Meet the 2018-2019 AACR President, Elizabeth M. Jaffee, MD

Elizabeth M. Jaffee, Baltimore, MD

Booth 1431, Exhibit Hall A, McCormick Place South (Level 3)

Meet the Editors-in-Chief of *Cancer Immunology Research*:

Robert D. Schreiber, PhD, and Philip D. Greenberg, MD

(not eligible for CME credit)

Robert D. Schreiber, St. Louis, MO

Philip D. Greenberg, Seattle, WA

MAJOR SYMPOSIA • 1:00 p.m.–2:45 p.m.

Room N227, McCormick Place North (Level 2)

Dharma Master Jiantai Symposium in Targeted Therapy: KRAS Revisited: Isoform and Mutation-Specific Functions in Cancer

Chair: Adrienne D. Cox, Chapel Hill, NC

1:00 p.m. Introduction

1:05 p.m. The contextual clues that modulate the oncogenic output of K-Ras.

Kevin M. Haigis, Boston, MA

1:35 p.m. Inhibitor combinations targeting KRAS effector signaling in KRAS-mutant pancreatic cancer. Adrienne D. Cox, Chapel Hill, NC [SY20-02*]

2:05 p.m. State-specific small-molecule ligands for K-Ras. Kevan M. Shokat, San Francisco, CA

Room S103, McCormick Place South (Level 1)

Distinguishing Aggressive from Nonaggressive Lesions: Foundations for Cancer Prevention

Chair: John S. Witte, San Francisco, CA

- 1:00 p.m. Introduction**
- 1:05 p.m. Identification of women susceptible to aggressive vs. nonaggressive breast cancer subtypes, and implications for screening/prevention.** Montserrat Garcia-Closas, Rockville, MD
- 1:35 p.m. Genetic and genomic approaches for distinguishing latent from potentially aggressive prostate cancers.** John S. Witte, San Francisco, CA
- 2:05 p.m. Use of genomics and liquid biopsies to define clonal evolution from precursor conditions such as MGUS/smoldering myeloma to overt myeloma.** Irene M. Ghobrial, Boston, MA

Room W196, McCormick Place West (Level 1)

Genetics and Epigenetics in Tumor and TME: Origins, Evolution, and Drug Resistance

Chair: Joseph F. Costello, San Francisco, CA

- 1:00 p.m. Introduction**
- 1:05 p.m. Why do lung adenocarcinomas respond to kinase inhibitors while glioblastomas don't? Contrasting patterns of tumor evolution.** Matthew L. Meyerson, Boston, MA
- 1:30 p.m. Epigenetics in tumor and tumor microenvironment: Heterogeneity and drug resistance.** Christoph Plass, Heidelberg, Germany
- 1:55 p.m. Functional interrogation of cell plasticity in cancer.** Yejing Ge, New York, NY [NG08*]
- 2:15 p.m. Driver lessons from studies of brain tumor evolution.** Joseph F. Costello, San Francisco, CA

N Hall B (Plenary Hall), McCormick Place North (Level 3)

Genomic/Functional Screens to Predict Response/Resistance to Immunotherapy

Chair: W. Nicholas Haining, Boston, MA

- 1:05 p.m. Beyond mutational load: Integrated molecular analyses in checkpoint blockade.** Alexandra Snyder, New York, NY
- 1:30 p.m. Bridging clinical and functional genomics to guide discovery of response mechanisms to immune checkpoint blockade.** Eliezer M. Van Allen, Brookline, MA

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings* (the abstract number is listed in brackets above).

**Program as of March 20, 2018

- 1:55 p.m.** **Immune evasion mechanisms in melanoma resistant to targeted and/or immunotherapy.** Willy Hugo, Los Angeles, CA [NG04*]
- 2:15 p.m.** **In vivo genetic screens for genes that modulate tumor immunity.**
W. Nicholas Haining, Boston, MA

Room S102, McCormick Place South (Level 1)

Improvement in the Understanding of Global Health Disparities: Ongoing and Recommended Solutions

Chair: Julie R. Galow, Seattle, WA

- 1:00 p.m.** **Introduction**
- 1:05 p.m.** **Government and civil society efforts in global cancer control.** Ophira Ginsburg, New York, NY [SY03-01*]
- 1:35 p.m.** **Innovative strategies for overcoming global disparities in cancer risk assessment and prevention.** Olufunmilayo I. Olopade, Chicago, IL
- 2:05 p.m.** **Opportunities for international partnering in cancer diagnosis and treatment.** Julie R. Galow, Seattle, WA

Room S406 (Vista Ballroom), McCormick Place South (Level 4)

Integrative Data Science for the Precision Medicine Era

Chair: Yu Shyr, Nashville, TN

- 1:00 p.m.** **Introduction**
- 1:05 p.m.** **Knowledge management and decision support for commonly tested susceptibility mutations.** Giovanni Parmigiani, Boston, MA [SY32-01*]
- 1:35 p.m.** **An evolution in integrative cancer research: From big data to insights.**
Philip Payne, St. Louis, MO
- 2:05 p.m.** **Towards a pathology imaging data commons for discovery and precision oncology.** Michael J. Becich, Pittsburgh, PA

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings* (the abstract number is listed in brackets above).

Room S105, McCormick Place South (Level 1)

Liquid Biopsies in Cancer: Facts, Challenges, and Perspectives

Chair: Catherine Alix-Panabières, Montpellier, France

- 1:00 p.m. Introduction**
- 1:05 p.m. Molecular and functional characterization of circulating tumor cells in carcinoma patients.** Catherine Alix-Panabières, Montpellier, France [SY21-01*]
- 1:35 p.m. Towards cancer screening using circulating DNA.** Y. M. Dennis Lo, Shatin, Hong Kong
- 2:05 p.m. Cancer-derived extracellular vesicles and liquid biopsy: What have we learned?** Dolores Di Vizio, Los Angeles, CA

N Hall C, McCormick Place North (Level 1)

Metabolic Strategies and Vulnerabilities in Cancer

Chair: Karen H. Vousden, London, United Kingdom

- 1:00 p.m. Introduction**
- 1:05 p.m. Targeting liabilities of altered metabolism in cancer.** Matthew G. Vander Heiden, Cambridge, MA
- 1:35 p.m. Metabolic vulnerability of PTEN mutant cancer.** Ramon E. Parsons, New York, NY [SY22-02*]
- 2:05 p.m. Mutant GNAS drives pancreatic tumorigenesis via PKA-SIK signaling and reprogramming lipid metabolism.** Nabeel M. Bardeesy, Boston, MA

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings* (the abstract number is listed in brackets above).

**Program as of March 20, 2018

Room N427, McCormick Place North (Level 4)

Optimizing Response to Endocrine Therapy

Chair: Rachel Schiff, Houston, TX

- 1:00 p.m.** **Introduction**
- 1:05 p.m.** **Endocrine resistance in metastatic breast cancer: Mechanisms and new therapeutic strategies.** Rachel Schiff, Houston, TX [SY01-01*]
- 1:30 p.m.** **Not all “SERDs” are equal: Context-independent ER degradation and full ER antagonism define the next generation of ER therapeutics.**
Ciara Metcalfe, South San Francisco, CA [NG05*]
- 1:50 p.m.** **Blockade of estrogen signaling boosts antitumor immunity by dwindling cancer-promoting myelopoiesis.** Jose R. Conejo-Garcia, Tampa, FL [SY01-02*]
- 2:10 p.m.** **Novel strategies for targeting advanced prostate cancer.** Karen E. Knudsen, Philadelphia, PA

Room S106, McCormick Place South (Level 1)

Radiomics and Quantitative Imaging

Chair: Michael V. Knopp, Columbus, OH

- 1:00 p.m.** **Introduction**
- 1:05 p.m.** **Imaging-based readouts in oncology: The pathway to upcoming breakthroughs.** Michael V. Knopp, Columbus, OH
- 1:35 p.m.** **Radiomics and deep learning in breast cancer diagnosis.** Maryellen Giger, Chicago, IL
- 2:05 p.m.** **Clinical perspective of radiomics in therapy response monitoring.**
Lawrence H. Schwartz, New York, NY

Room W190, McCormick Place West (Level 1)

Tumor-Host Interactions Regulating Cancer Metastasis

Chair: Danny R. Welch, Kansas City, KS

- 1:00 p.m.** **Introduction**
- 1:05 p.m.** **Metastatic progression enabled by stromal and immune cell plasticity.**
Rosandra Natasha Kaplan, Potomac, MD
- 1:30 p.m.** **Metabolic feedback loops in cancer progression.** Brunhilde H. Felding, La Jolla, CA

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings* (the abstract number is listed in brackets above).

- 1:55 p.m. Chromosomal instability promotes metastasis through a cytosolic DNA response.** Samuel F. Bakhoun, New York, NY [NG-03*]
- 2:15 p.m. Mitochondrial genetic contributions to metastatic efficiency.** Danny R. Welch, Kansas City, KS [SY37-03*]

SPECIAL SESSION • 1:00 p.m.–3:00 p.m.

Room S404, McCormick Place South (Level 4)

Pediatric Cancer Working Group Scientific Session: Presentations from the NCI Pediatric Preclinical Testing Consortium and the ITCC Pediatric Preclinical Proof-of-Concept Program

- 1:00 p.m. PPTC overview.** Malcolm A. Smith, Bethesda, MD
- 1:10 p.m. ITCC-P4 overview and current status.** Stefan M. Pfister, Heidelberg, Germany
- 1:30 p.m. Genomic landscape of the Pediatric Preclinical Testing Consortium patient-derived xenograft tumor models.** John M. Maris, Philadelphia, PA
- 1:55 p.m. Systematic target actionability reviews for pediatric solid tumors.** Hubert N. Caron, Basel, Switzerland
- 2:10 p.m. Lessons from the PPTP.** Peter J. Houghton, San Antonio, TX
- 2:23 p.m. Biomarker discovery and development.** Richard B. Lock, Sydney, NSW, Australia
- 2:35 p.m. The single-mouse trial: A preclinical platform feasible for drug screening, model characterization, and translational biomarker development.** Julia B. Schueler, Wilmington, MA

POSTER SESSION • 1:00 p.m.–5:00 p.m.

Exhibit Hall A, McCormick Place South (Level 3)

(not eligible for CME credit)

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner, the Annual Meeting App (available at www.AACR.org/AACR2018), and in the print Poster Sessions and Exhibits Guide. A limited number of copies of the print guide are available in the Exhibit Hall.

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings* (the abstract number is listed in brackets above).

**Program as of March 20, 2018

Tumor Biology

- Section 1 Carcinogenesis 2
- Section 2 Cell Adhesion and Extracellular Matrix
- Section 3 Determining How the Immune System Drives Tumor Progression
- Section 4 Mechanisms and Models of Gastrointestinal Malignancies
- Section 5 Molecular Imaging: Novel Probes and Preclinical Studies
- Section 6 Pediatrics 3: Signaling, Transcription, and Metastasis
- Section 7 Radiation Studies Using in Vivo and Clinical Models
- Section 8 Therapeutic Approaches to Metastasis
- Section 45 Late-Breaking Research: Tumor Biology 2

Epidemiology

- Section 10 Biomarkers of Prognosis and Pharmacoepidemiology
- Section 11 Cancer in Minority Populations, Health Disparities, and Survivorship Research

Bioinformatics and Systems Biology

- Section 13 Statistical Methods, Mathematical Modeling, and Molecular Modeling

Molecular and Cellular Biology / Genetics

- Section 14 Checkpoints and Cell Cycle Progression
- Section 15 Epigenomics
- Section 16 Genomic Profiling of Tumors 3
- Section 17 GTPases and Their Regulators and Effectors
- Section 18 Immunologic and Other Cancer Cell Death
- Section 19 MicroRNA Therapeutics
- Section 20 Noncoding RNAs: From Biology to Therapy
- Section 21 Post-transcriptional and Translational Control of Cell Fate
- Section 22 Tumor Suppressor Genes 1
- Section 23 Tumor-Stroma and Cell-Cell Interactions

Clinical Research

- Section 24 Diagnostic Biomarkers
- Section 25 Immune Checkpoints 4
- Section 26 Immune Mechanisms Invoked by Therapies 2
- Section 27 Liquid Biopsy 4
- Section 28 Molecular Classification of Tumors 2: Molecular Predictors of Response, Tumor Staging, and Correlation of Clinical and Molecular Markers
- Section 29 Novel Preclinical Therapies in Pediatric Solid Tumors
- Section 31 Drug Discovery Tools

Immunology

- Section 32 Adaptive Immunity in Tumors
- Section 33 Immunomodulatory Agents and Interventions 2
- Section 34 New Immunosuppressive Mechanisms in Cancer
- Section 44 Late-Breaking Research: Immunology 2

Regulatory Science and Science Health Policy

- Section 35 Regulatory Science and Science Health Policy

Experimental and Molecular Therapeutics

- Section 36 Canonical Targets 1
- Section 37 Combination Chemotherapy 1
- Section 38 DNA Damage and Cell Cycle Regulation Experimental Therapeutics
- Section 39 Novel Targets and Inhibitors
- Section 40 Microenvironmental and Cell Nonautonomous Factors in Mediating Therapeutic Resistance
- Section 41 Pharmacokinetics and Pharmacodynamics
- Section 43 Late-Breaking Research: Experimental and Molecular Therapeutics 3

Clinical Trials

- Section 42 Phase I / II, II, and III Trials in Progress

NCI/NIH-SPONSORED SESSION • 2:45 p.m.-4:15 p.m.

Room W192, McCormick Place West (Level 1)

NCI Funding Opportunities for Diversity Training and Disparities Research in Cancer (not eligible for CME credit)

Moderator: Peter Ogunbiyi, Rockville, MD

Alison Lin, Bethesda, MD

Nicole E. McNeil Ford, Bethesda, MD

Abigail Soyombo, Bethesda, MD

Tiffany A. Wallace, Rockville, MD

**Program as of March 20, 2018

CLINICAL TRIALS MINISYMPOSIUM 3 • 2:45 p.m.-5:00 p.m.

N Hall C, McCormick Place North (Level 1)

Biomarkers in Immuno-oncology

Chair: Kurt A.Schallper, New Haven, CT

2:45 p.m. **Introduction**

2:50 p.m. **CT175 Biomarker analyses from a phase I study of WNT974, a first-in-class Porcupine inhibitor, in patients (pts) with advanced solid tumors.** Jordi Rodon, Barcelona, Spain

3:05 p.m. **CT176 Effect of JAK/STAT or PI3K δ plus PD-1 inhibition on the tumor microenvironment: Biomarker results from a phase Ib study in patients with advanced solid tumors.** John M. Kirkwood, Pittsburgh, PA

3:20 p.m. **CT177 Epacadostat plus durvalumab in patients with advanced solid tumors: Preliminary results of the ongoing, open-label, phase I/II ECHO-203 study.** Aung Naing, Houston, TX

3:35 p.m. **CT178 Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update and association between biomarkers and overall survival in CheckMate 275.** Padmanee Sharma, Houston, TX

3:50 p.m. **CT179 Safety, efficacy, and immune correlates of alternative doses and schedules of entinostat combined with pembrolizumab in patients with advanced solid tumors— Results from SNDX-275-0141 phase I trial.** Anthony W. Tolcher, San Antonio, TX

4:05 p.m. **CT180 Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors.** Lillian L. Siu, Toronto, ON, Canada

4:20 p.m. **CT181 Safety, activity, and biomarkers for neoadjuvant anti-PD-1 therapy in melanoma.** Alexander C. Huang, Philadelphia, PA

4:35 p.m. **CT182 The anti-PD-1 antibody spartalizumab (PDR001) in combination with dabrafenib and trametinib in previously untreated patients with advanced BRAF V600-mutant melanoma: First efficacy, safety, and biomarker findings from the part 2 biomarker cohort of COMBi-i.** Reinhard Dummer, Zürich, Switzerland

4:50 p.m. **Discussion**

TUESDAY

AWARDS AND LECTURES • 3:00 p.m.-3:45 p.m.

Room S404, McCormick Place South (Level 4)

Twelfth Annual AACR Award for Outstanding Achievement in Chemistry in Cancer Research

Nuclear receptors, PET imaging, and advances in understanding therapy resistance in breast and prostate cancers. John A. Katzenellenbogen, Urbana, IL

Dr. Katzenellenbogen is recognized for his seminal work on the development of chemical tools to study the estrogen receptor, which is an important biomarker in breast cancer research. He has also created PET imaging agents that are used in the clinic to diagnose prostate and breast cancer.

MEET THE RESEARCH ICON • 3:00 p.m.-3:30 p.m.

AACRcentral Amphitheater, Hall A, McCormick Place South (Level 3)

Meet the Research Icon, Organized by the Associate Member Council (AMC)
(not eligible for CME credit)

MEET AND GREET • 3:00 p.m.-4:00 p.m.

Booth 1431, Exhibit Hall A, McCormick Place South (Level 3)

**Meet the Editor-in-Chief of *Cancer Prevention Research*:
Scott M. Lippman, MD**
(not eligible for CME credit)

Scott M. Lippman, La Jolla, CA

POSTER DISCUSSION SESSION • 3:00 p.m.–4:00 p.m.

Room S402, McCormick Place South (Level 4)

Liquid Biopsy

(not eligible for CME credit)

The abstracts presented in this Poster Discussion Session will also be presented in the following Poster Session:

Liquid Biopsy 6

Wednesday, April 18, 2018, 8:00 a.m.-12:00 p.m.

Section 27, Hall A, McCormick Place South (Level 3)

- 3:00 p.m. Introduction**
- 3:10 p.m. 5598 Development and optimization of a comprehensive high-sensitivity NGS cancer assay and bioinformatics pipeline for plasma cfDNA profiling.** Juber Patel, New York, NY
- 3:15 p.m. 5599 Noninvasive genomic profiling of cerebral spinal fluid in breast cancer patient with leptomeningeal disease.** Masahiro Oikawa, Houston, TX
- 3:20 p.m. 5600 Establishment and characterization of a unique circulating tumor cells-derived xenograft (CDX) in prostate cancer.** Vincent Faugeroux, Villejuif, France
- 3:25 p.m. 5601 Single-cell molecular profiling of circulating tumor cells (CTCs) within the TRACERx study reveals heterogeneous patterns in early non-small cell lung cancer (NSCLC).** Francesca Chemi, Manchester, United Kingdom
- 3:30 p.m. 5602 Detection of circulating cell-free tumor DNA (ctDNA) in patients with small cell lung cancer (SCLC).** Sumitra Mohan, Manchester, United Kingdom
- 3:35 p.m. 5603 Analytical validation of a comprehensive 500-gene ctDNA panel designed for immuno-oncology and DNA damage research.** Elena Helman, Redwood City, CA
- 3:40 p.m. 5604 Novel DNA methylation biomarkers show high sensitivity and specificity for blood-based detection of colorectal cancer—A clinical biomarker discovery and validation study.** Sarah Østrup Jensen, Aarhus, Denmark

TUESDAY, APRIL 17**

LATE-BREAKING MINISYMPOSIUM • 3:00 p.m.-5:00 p.m.

Room S101, McCormick Place South (Level 1)

Minisymposium: Late-Breaking Research

Chair: Lisa A. Newman, Detroit, MI

- 3:05 p.m. LB-337 Adipose inflammation and the risk of benign and malignant breast disease in African American women.** Asra N. Shaik, Detroit, MI
- 3:20 p.m. LB-338 SHP2 inhibition enhances sensitivity to MEK inhibitors in multiple resistant cancer models.** Carmine Fedele, New York, NY
- 3:35 p.m. LB-339 Biomarkers predictive of response to pembrolizumab in head and neck cancer (HNSCC).** Tanguy Y. Seiwert, Chicago, IL
- 3:50 p.m. LB-340 Combinatorial platform for CART cell therapy for glioblastoma.** Donald M. O'Rourke, Philadelphia, PA
- 4:05 p.m. LB-341 The Polycomb Repressor Complex 1 promotes recruitment of myeloid-derived suppressor cells and immune evasion during bone colonization in castration-resistant prostate cancer.** Filippo G. Giancotti, Houston, TX
- 4:20 p.m. LB-342 Targeted gene control with bifunctional molecules to harness endogenous chromatin-modifying activity.** Anna M. Chiarella, Chapel Hill, NC
- 4:35 p.m. LB-343 Development of plasma cell-free DNA (cfDNA) assays for early cancer detection: First insights from the Circulating Cell-Free Genome Atlas Study (CCGA).** Alexander A. Aravanis, Menlo Park, CA

MAJOR SYMPOSIA • 3:00 p.m.-5:00 p.m.

Room S103, McCormick Place South (Level 1)

AACR/CSCO Joint Symposium: Precision Therapeutics

Cochairs: Marcus E. Peter, Chicago, IL; Gong Chen, Guangzhou, China

- 3:00 p.m. Using toxic siRNAs to treat cancer.** Marcus E. Peter, Chicago, IL
- 3:30 p.m. Progress of precision medicine for lung cancer in China.** Zhi-Jie Wang, Beijing, China
- 4:00 p.m. Overcoming drug resistance and tumor heterogeneity in gastrointestinal cancers.** Ryan B. Corcoran, Boston, MA
- 4:30 p.m. Progress in precision medicine for gastrointestinal cancer in China.** Zhi-Hao Lu, Beijing, China

**Program as of March 20, 2018

TUESDAY

Room N228, McCormick Place North (Level 2)

MICR-MEG Joint Symposium: Aggressive Cancer Phenotypes in Racial/Ethnic Minority Populations: Opportunities and Challenges

Cochairs: Laura Fejerman, San Francisco, CA; Melissa L. Bondy, Houston, TX

Moderator: Laura Fejerman, San Francisco, CA

- 3:10 p.m.** **Title to be announced.** John M. Carethers, Ann Arbor, MI
3:30 p.m. **Title to be announced.** Kathleen A. Cooney, Salt Lake City, UT
3:50 p.m. **Title to be announced.** Hashem B. El-Serag, Houston, TX

MINISYMPOSIA • 3:00 p.m.–5:00 p.m.

Room S406 (Vista Ballroom), McCormick Place South (Level 4)

Clinical Research

Emerging Immunotherapy Targets and Combination Strategies to Overcome Treatment Resistance

Cochairs: Aude G. Chapuis, Seattle, WA; Patrick A. Ott, Boston, MA

- 3:00 p.m.** **Introduction**
- 3:05 p.m.** **4934 Immunostimulatory and oncolytic properties of rotavirus can overcome resistance to immune checkpoint blockade therapy.** Sandrine Valsesia-Wittmann, Lyon, France
- 3:20 p.m.** **4935 High-throughput immune-oncology screen identifies EGFR inhibitors as potent enhancers of CTL antigen-specific tumor cell killing.** Patrick H. Lizotte, Boston, MA
- 3:35 p.m.** **4936 Combination CD40 agonist and PD-1 antagonist antibody therapy enhances vaccine-induced T-cell responses in nonimmunogenic cancers.** Hayley S. Ma, Baltimore, MD
- 3:50 p.m.** **4937 Targeting epithelial membrane protein 2 on breast tumor cells with a fusion construct containing the serine protease granzyme B.** Madhuri Wadehra, Los Angeles, CA
- 4:05 p.m.** **4938 OX40 agonist antibody-based combination therapy with PI3K β selective inhibitor enhances T-cell immunity.** Weiyi Peng, Houston, TX
- 4:20 p.m.** **4939 Driving natural killer cell antigen-specific targeting of cancer via next-generation trivalent molecules.** Martin Felices, Minneapolis, MN
- 4:35 p.m.** **4940 Nonredundant roles for immune checkpoint blockade and agonistic CD40 in mediating T-cell responses in pancreatic ductal adenocarcinoma.** Alexander H. Morrison, Philadelphia, PA

Room S504, McCormick Place South (Level 5)

Epidemiology

Endogenous and Exogenous Factors in Cancer Risk and Mortality

Cochairs: Corinne E. Joshu, Baltimore, MD; Siobhan Sutcliffe, St. Louis, MO

- 3:00 p.m. Introduction**
- 3:05 p.m. 4941 Sexually transmitted infections and risk of epithelial ovarian cancer: Results from the Nurses' Health Studies.** Renée Turzanski Fortner, Heidelberg, Germany
- 3:20 p.m. 4942 Serologic markers of infectious agents and ovarian cancer: Markers of prior *Chlamydia trachomatis* infection associated with increased ovarian cancer risk in two independent populations.** Britton Trabert, Bethesda, MD
- 3:35 p.m. 4943 Circulating immunologic markers and risk of multiple myeloma and its precursor disease: A nested case-control study.** Jonathan N. Hofmann, Bethesda, MD
- 3:50 p.m. 4944 Insulin resistance and long-term cancer-specific and all-cause mortality: The Women's Health Initiative (WHI).** Kathy Pan, Torrance, CA
- 4:05 p.m. 4945 Absolute risk prediction models for pancreatic cancer.** Jihye Kim, Boston, MA
- 4:20 p.m. 4946 The association between antihypertensive medication, sRAGE, and risk of pancreatic cancer: Results from the Women's Health Initiative Study.** Zhensheng Wang, Houston, TX
- 4:35 p.m. 4947 Aspirin use and risk of lethal prostate cancer in the Atherosclerosis Risk in Communities cohort.** Lauren M. Hurwitz, Baltimore, MD

Room W190, McCormick Place West (Level 1)

Experimental and Molecular Therapeutics

A Therapeutic "About Face": Reversing Drug Resistance

Cochairs: Christine M. Lovly, Nashville, TN; Alexander E. Drilon, New York, NY

- 3:00 p.m. Introduction**
- 3:05 p.m. 4948 MDM2 antagonism overcomes resistance to CDK4/6 inhibition in melanoma.** Anna E. Vilgelm, Nashville, TN
- 3:20 p.m. 4949 The role of symmetric cell division in post-therapy glioma-initiating cell expansion.** Atique U. Ahmed, Chicago, IL
- 3:35 p.m. 4950 MPS1 as a novel target in endocrine- and palbociclib-resistant estrogen receptor-positive breast cancer.** Joanna Nikitorowicz-Buniak, London, United Kingdom
- 3:50 p.m. 4951 Inhibiting guanylate binding protein 1 (GBP1) impedes ovarian cancer progression.** Dhanir Tailor, Palo Alto, CA

**Program as of March 20, 2018

- 4:05 p.m. 4952 Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to ER-directed therapies.** Utthara Nayar, Boston, MA
- 4:20 p.m. 4953 Metabolic targeting of chemoresistance perturbs clonal complexity in pancreatic cancer.** Andrea Viale, Houston, TX
- 4:35 p.m. 4954 Decoding tumor microenvironment to enhance NSCLC targeted therapy.** Haichuan Hu, Charlestown, MA

Room S102, McCormick Place South (Level 1)

Experimental and Molecular Therapeutics

Early Novel Drug Development

Cochairs: Ricky W. Johnstone, Melbourne, Australia; Scott A. Armstrong, Boston, MA

- 3:00 p.m. Introduction**
- 3:05 p.m. 4955 Heterogeneous nuclear ribonucleoprotein C as a novel therapeutic target for acute myeloid leukemia.** Vindhya Vijay, Gainesville, FL
- 3:20 p.m. 4956 Functional characterization of the ivosidenib (AG-120) and azacitidine combination in a mutant IDH1 AML cell model.** Katharine Yen, Cambridge, MA
(not eligible for CMA credit)
- 3:35 p.m. 4957 The novel imipridone ONC212 highly synergizes with the BCL-2 inhibitor ABT-199 in AML and activates orphan receptor GPR132.** Takenobu Nii, Houston, TX
- 3:50 p.m. 4958 VTP50469 is a novel, orally available menin-MLL1 inhibitor effective against MLL-rearranged and NPM1-mutant leukemia.** Andrei V. Krivtsov, Boston, MA
- 4:05 p.m. 4959 CP-506, a next-generation hypoxia-activated prodrug, as promising novel anticancer therapeutic.** Sophie Thiolloy, Liège, Belgium
(not eligible for CME credit)
- 4:20 p.m. 4960 First-in-class, highly BDII-selective BET family inhibitor ABBV-744 displays potent antitumor activity in androgen receptor-positive prostate cancer models and an improved tolerability profile.** Emily J. Faivre, North Chicago, IL
(not eligible for CME credit)
- 4:35 p.m. 4961 A highly potent novel class of SRC-3 inhibitors for the treatment of uveal melanoma.** Salma Kaochar, Houston, TX

Room W196, McCormick Place West (Level 1)

Immunology

Epigenetic and Metabolic Regulation of Cancer Immunity

Cochairs: Juan R. Cubillos-Ruiz, New York, NY; Steven Josefowicz, New York, NY

- 3:00 p.m. Introduction**
- 3:05 p.m. 4962 Metabolic rewiring of macrophages by CpG stimulates antitumor activity that overrides CD47 resistance in pancreatic cancer.** Mingen Liu, Philadelphia, PA
- 3:20 p.m. 4963 Targeting glutamine metabolism as a means of enhancing antitumor T-cell responses.** Robert Leone, Baltimore, MD
- 3:35 p.m. 4964 Metabolically activated macrophages mediate obesity-driven TNBC progression.** Payal Tiwari, Chicago, IL
- 3:50 p.m. 4965 Entinostat transforms the suppressive tumor microenvironment of breast cancer and promotes survival and anti-responses when combined with checkpoint inhibition.** Evanthia T. Roussos Torres, Baltimore, MD
- 4:05 p.m. 4966 The SUV39H1-H3K9me3 axis mediates colon carcinoma cell intrinsic apoptosis and immune evasion.** Chunwan Lu, Augusta, GA
- 4:20 p.m. 4967 HDAC11 function as a transcriptional regulator in immature myeloid cells to myeloid-derived suppressor cells transition.** Jie Chen, Washington, DC
- 4:35 p.m. 4968 Tumor innate immunity primed by specific interferon stimulated endogenous retroviruses.** David A. Barbie, Boston, MA

Room S105, McCormick Place South (Level 1)

Molecular and Cellular Biology / Genetics

Metabolism: Emerging Concepts and Therapy

Cochairs: Sufi M. Thomas, Kansas City, KS; Mark W. Dewhirst, Durham, NC

- 3:00 p.m. Introduction**
- 3:05 p.m. 4969 Autophagy modulates lipid metabolism to support liver kinase B1 (LKB1)-deficient lung tumor growth.** Vrushank D. Bhatt, New Brunswick, NJ
- 3:20 p.m. 4970 Mitochondrial trafficking in the bone marrow microenvironment promotes bioenergetic flexibility in multiple myeloma.** Christopher R. Marlein, Norwich, United Kingdom
- 3:35 p.m. 4971 Identification of new modulators of nucleotide metabolism and replication stress in PDAC.** Evan R. Abt, Los Angeles, CA
- 3:50 p.m. 4972 PDK inhibition sensitizes bladder tumors to cisplatin.** Benjamin L. Woolbright, Kansas City, KS

**Program as of March 20, 2018

- 4:05 p.m.** **4973 MYCN mediates cysteine addiction and sensitizes to ferroptosis in cancer cells.** Frank Westermann, Heidelberg, Germany
- 4:20 p.m.** **4974 Prospective study of untargeted urinary metabolomics and risk of lung cancer among female never-smokers in Shanghai, China.** Wei Jie Seow, Singapore, Singapore
- 4:35 p.m.** **4975 Tumor metabolism and cognitive dysfunction in CNS lymphoma.** James L. Rubenstein, San Francisco, CA

Room S405, McCormick Place South (Level 4)

Molecular and Cellular Biology / Genetics

Understanding the Genomic Dark Matter

Cochairs: Aurora Esquela Kerscher, Norfolk, VA; Carlo M. Croce, Columbus, OH

- 3:00 p.m.** **Introduction**
- 3:05 p.m.** **4976 Small RNA sequencing of preoperative blood plasma identifies microRNA signature enabling to find pancreatic cancer patients who will not benefit from surgical resection.** Ondrej Slaby, Brno, Czech Republic
- 3:20 p.m.** **4977 MIR1307 mediates pancreatic cancer resistance to FOLFIRINOX chemotherapy by affecting response to DNA damage.** Chiara Braconi, London, United Kingdom
- 3:35 p.m.** **4978 On circular RNAs in breast cancer.** Marcel Smid, Rotterdam, Netherlands
- 3:50 p.m.** **4979 Novel miRNA regulation in an early progression model of pancreatic ductal adenocarcinoma.** Nina J. Chu, Baltimore, MD
- 4:05 p.m.** **4980 Regulating the regulator: Long noncoding RNAs in the p53 network in colorectal cancer.** Ashish Lal, Bethesda, MD
- 4:20 p.m.** **4981 Circulating mir-320 promotes immunosuppressive macrophages M2 phenotype associated with lung cancer progression.** Orazio Fortunato, Milan, Italy
- 4:35 p.m.** **4982 Oncogenic role of THOR, a conserved cancer/testis long noncoding RNA.** Yashar Niknafs, Ann Arbor, MI

Room S505, McCormick Place South (Level 5)

Prevention Research

Preclinical Studies of Cancer Prevention

Cochairs: Zigang Dong, Austin, MN; Shivendra V. Singh, Pittsburgh, PA

- 3:00 p.m.** **Introduction**
- 3:05 p.m.** **4983 Intermittent dosing regimens of naproxen and aspirin inhibit azoxymethane-induced rat colon adenoma progression to adenocarcinoma and carcinoma invasion.** Chinthalapally V. Rao, Oklahoma City, OK

- 3:20 p.m.** **4984 Celastrol inhibits high fat diet-induced obesity and intestinal tumorigenesis in APC^{Min/+} mice by modulating gut microbes and inflammation.** Naveena B. Janakiram, Oklahoma City, OK
- 3:35 p.m.** **4985 M4OC-Prevent: Clinical evaluation of metformin for oral cancer precision prevention.** J. Silvio Gutkind, La Jolla, CA
- 3:50 p.m.** **4986 Association of sirtuins and diet in cancer development: Studying the roles of SIRT2/3.** Mohamed A. Ahmed, Chicago, IL
- 4:05 p.m.** **4987 Biofilm-producing sulfate-reducing bacteria suppress tumor burden in a rat model of colon cancer.** Susheel Bhanu Busi, Columbia, MO
- 4:20 p.m.** **4988 PI3K γ -deficiency protects against pancreatic tumorigenesis at the expense of diet-Induced hyperlipidemia and hepatotoxicity.** Carolina Torres, Chicago, IL
- 4:35 p.m.** **4989 Efficacy of erlotinib and/or naproxen when administered by intermittent dosing schedules in the prevention of chemically induced urinary bladder cancers.** Altaf Mohammed, Bethesda, MD

Room N227, McCormick Place North (Level 2)

Tumor Biology

Stemness and Cancer

Cochairs: Peter B. Dirks, Toronto, ON, Canada; Adrienne Boire, New York, NY

- 3:00 p.m.** **Introduction**
- 3:05 p.m.** **4990 Regenerative origin of colorectal metastasis stem cells.** Karuna Ganesh, New York, NY
- 3:35 p.m.** **4992 Sirt6 loss increases stemness and defense against oxidative stress in tumor-propagating cells, promoting tumor growth and maintenance in squamous cell carcinoma.** Jee-Eun Choi, Boston, MA
- 3:50 p.m.** **4993 Breast epithelial cell lines from normal breast with luminal and intrinsic subtypes-enriched gene expression document interindividual differences in differentiation cascade.** Brijesh Kumar, Indianapolis, IN
- 4:05 p.m.** **4994 p53 and RB regulate Hedgehog responsiveness via autophagy-mediated ciliogenesis.** Jason E. Cain, Clayton, Australia
- 4:20 p.m.** **4995 Identity fraud: Lineage plasticity as a mechanism of anti-androgen resistance and target for therapy.** Alastair H. Davies, Vancouver, BC, Canada
- 4:35 p.m.** **4996 MLL3 haploinsufficiency preserves self-renewal capacity in HSCs with extensive cumulative division histories.** Jeffrey Magee, St. Louis, MO

**Program as of March 20, 2018

Room S106, McCormick Place South (Level 1)

Tumor Biology

Molecular Mechanisms Driving Metastasis

Cochairs: Conor C. Lynch, Tampa, FL; Binzhi Qian, Edinburgh, United Kingdom

- 3:00 p.m. Introduction**
- 3:05 p.m. 4997 Identifying dynamic EMT states and constructing a proteomic EMT landscape of lung cancer using single-cell multidimensional analysis.** Loukia G. Karacosta, Stanford, CA
- 3:20 p.m. 4998 Targeting DHPS to abrogate TGF β -induced metastasis in breast cancer.** Robert G \ddot{u} th, Northridge, CA
- 3:35 p.m. 4999 Identifying intercellular phenotypic stability factors for a hybrid epithelial-mesenchymal phenotype.** Mohit Kumar Jolly, Houston, TX
- 3:50 p.m. 5000 Biomaterial scaffolds that capture metastatic tumor cells in vivo to detect, treat, and study mechanisms of the premetastatic niche and metastasis.** Grace G. Bushnell, Ann Arbor, MI
- 4:05 p.m. 5001 Identification of a Six2/Sox2/Nanog stem cell axis that promotes breast cancer metastatic colonization.** Michael U. Oliphant, Aurora, CO
- 4:20 p.m. 5002 KRT13 promotes stemness and drives metastasis in breast cancer through direct interaction with plakoglobin-desmoplakin complexes regulating c-Myc signaling pathway.** Lijuan Yin, Los Angeles, CA
- 4:35 p.m. 5003 RNase activity of MCP1P1 regulates key elements of mesenchymal phenotype of clear cell renal cell carcinoma cells.** Katarzyna Miekus, Krakow, Poland

Room S501, McCormick Place South (Level 5)

Tumor Biology

Expanding the Definition of the Tumor Microenvironment

Cochairs: Derek C. Radisky, Jacksonville, FL; David G. DeNardo, St. Louis, MO

- 3:00 p.m. Introduction**
- 3:05 p.m. 5004 Profiling the extracellular matrix landscape of tumor microenvironments using proteomics.** Alexandra Naba, Chicago, IL
- 3:20 p.m. 5005 Aging promotes changes to peritoneal and omental collagen structure that contribute to increased ovarian cancer metastatic success.** Elizabeth Harper, Notre Dame, IN
- 3:35 p.m. 5006 Kit-dependent tissue resident macrophage progenitors drive cancer progression.** Paulina Pathria, La Jolla, CA

- 3:50 p.m. 5007 Absence of mammary tissue-resident macrophages is associated with reduced breast cancer susceptibility mediated by the cancer-associated 8q24 gene desert.** Adam C. Soloff, Charleston, SC
- 4:05 p.m. 5008 Crosstalk between epithelial- $IKK\alpha$ -deletion and symbiotic bacterial-fungal infection in skin carcinogenesis.** Na-Young Song, Frederick, MD
- 4:20 p.m. 5009 Defined factors overcome T-cell exhaustion via abscopal effect.** Danny Khalil, New York, NY
- 4:35 p.m. 5010 Advantages in using orthotopic syngeneic tumor models to evaluate immune-based approaches for cancer treatment.** Jean-François Mirjole, Dijon Cedex, France

**REGULATORY SCIENCE
AND POLICY SESSION • 3:00 p.m.–5:00 p.m.**

Room S401bcd, McCormick Place South (Level 4)

Implications of the 2017 FDA Reauthorization Act (FDARA) on Pediatric Cancer Drug Development

Chair: Gregory H. Reaman, Silver Spring, MD

Speakers: Nancy F. Goodman, Washington, DC
D. William Parsons, Houston, TX
Gilles Vassal, Villejuif, France
Brenda Weigel, Minneapolis, MN

TUESDAY

AWARDS AND LECTURES • 3:30 p.m.–4:15 p.m.

Room S100 (Grand Ballroom), McCormick Place South (Level 1)

Sixth Annual AACR-CRI Lloyd J. Old Award in Cancer Immunology

Genetic engineering of anticancer immune responses. Antoni Ribas, Los Angeles, CA

Dr. Ribas is recognized for his groundbreaking contributions to the successful development of checkpoint inhibitor immunotherapy for patients with metastatic melanoma. This has dramatically changed the treatment options for patients with melanoma and many other cancers.

**Program as of March 20, 2018

AWARDS AND LECTURES • 3:45 p.m.-4:30 p.m.

Room S404, McCormick Place South (Level 4)

Twenty-Seventh Annual AACR-American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention

Evolving approaches in cancer epidemiology: Time, serendipity, and risk. Leslie Bernstein, Duarte, CA

Dr. Bernstein is recognized as a world leader in cancer epidemiology and prevention. She has made multiple, sustained contributions to understanding the impact of lifestyle and reproductive factors on breast cancer risk and survival.

AWARDS AND LECTURES • 4:00 p.m.-4:45 p.m.

Room N427, McCormick Place North (Level 4)

Twenty-Third Annual AACR-Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research

Re-envisioning clinical cancer research. Johann S. de Bono, Sutton, United Kingdom

Dr. de Bono is honored for seminal contributions to the field of clinical cancer research. His pioneering work has led to numerous drug approvals, including abiraterone, carbazitaxel, olaparib, and afatinib.

NCI/NIH-SPONSORED SESSION • 4:15 p.m.-5:45 p.m.

Room W192, McCormick Place West (Level 1)

Translating Cancer Technologies from Lab to Market: Success Stories from the NCI SBIR Program (not eligible for CME credit)

Michael Weingarten, Bethesda, MD

TUESDAY, APRIL 17**

SPECIAL SESSION • 4:45 p.m.–6:00 p.m.

Jackson Park A-D, Hyatt Regency McCormick Place

Novel Immunotherapeutics Interactome: Small Molecules and Antibody-Drug Conjugates

(not eligible for CME credit)

Cochairs: Justin Guinney, Seattle, WA; Rodrigo Dienstmann, Barcelona, Spain

FORUM • 5:00 p.m.–6:30 p.m.

Room S100 (Grand Ballroom), McCormick Place South (Level 1)

Cell Autonomous Therapies versus Immunotherapy

Moderator: Jeffrey A. Engelman, Cambridge, MA

Panel: Neal Rosen, New York, NY
Thomas F. Gajewski, Chicago, IL

Room S105, McCormick Place South (Level 1)

Controversies and Challenges to Targeting Progesterone Receptors in ER+ Breast Cancer

Moderator: C. Kent Osborne, Houston, TX

Panel: Carol A. Lange, Minneapolis, MN
Jason Carroll, Cambridge, United Kingdom

N Hall B (Plenary Hall), McCormick Place North (Level 3)

Current Status of Cellular Therapy (CAR T Cells and BiTes)

Moderator: David M. Barrett, Philadelphia, PA

Panel: Nabil Ahmed, Houston, TX
Ralf Bargou, Würzburg, Germany

N Hall C, McCormick Place North (Level 1)

Is Genome-Informed Cancer Medicine Generating Patient Benefit or Just Hype?

Moderator: José Baselga, New York, NY

Panel: David Hyman, New York, NY
Vinay K. Prasad, Portland, OR

TUESDAY

**Program as of March 20, 2018

Room N427, McCormick Place North (Level 4)

Prostate Cancer Screening and the Genetics/Biology Contribution to Racial Disparity Outcomes

Moderator: Isaac J. Powell, Detroit, MI

Panel: Ruth D. Etzioni, Seattle, WA
Aliccia B. Bollig-Fischer, Detroit, MI

Room W196, McCormick Place West (Level 1)

Translational Value of Preclinical Cancer Models: From PDXs to GEMMs and Organoids

Moderator: Frederic J. De Sauvage, South San Francisco, CA

Panel: Karen M. Cichowski, Boston, MA
Mark A. Rubin, Bern, Switzerland

SCIENCE POLICY SESSION • 5:00 p.m.–6:30 p.m.

Room S401bcd, McCormick Place South (Level 4)

Biden Cancer Foundation Colloquia

Elizabeth M. Jaffee, Baltimore, MD

SPECIAL SESSION • 5:00 p.m.–6:30 p.m.

Room S406 (Vista Ballroom), McCormick Place South (Level 4)

Unsolved Mysteries: Advances in Basic Science and Clinical Care of Cancer Cachexia

Chair: Daniel Marks, Portland, OR

5:00 p.m. Cancer cachexia: A definition and neuroscience perspective. Daniel Marks, Portland, OR

5:10 p.m. Molecular mechanisms of muscle wasting in cancer. Denis C. Guttridge, Columbus, OH

5:30 p.m. Recent clinical trial findings and identification of new therapeutic targets. Marion E. Couch, Indianapolis, IN

Room S102, McCormick Place South (Level 1)

Unsolved Mysteries: The Molecular Definition of Cancer: Does Age at Diagnosis Matter?

Chair: Katherine A. Janeway, Boston, MA

- 5:00 p.m.** **Breaking down age barriers traditionally present in oncology.** Katherine A. Janeway, Boston, MA
- 5:10 p.m.** **The challenge of drug development when molecular mechanisms span age of diagnosis.** Barrett J. Rollins, Boston, MA
- 5:30 p.m.** **The order and pattern of mutations across the age of diagnosis.** Adam Shlien, Toronto, ON, Canada

TOWN MEETING • 6:00 p.m.–8:00 p.m.

Room S106, McCormick Place South (Level 1)

Cancer Immunology Working Group (CIMM) Town Hall Meeting and Networking Reception

Co-sponsored by the Association for Cancer Immunotherapy (CIMT) (not eligible for CME credit)

- 6:00 p.m.** **Opening remarks: CIMM Chair.** Jedd D. Wolchok, New York, NY
- 6:15 p.m.** **Remarks: CIMM Chair-Elect.** Dmitry I. Gabrilovich, Philadelphia, PA
- 6:30 p.m.** **Cancer Immunology Research: Update from the Editors-in-Chief.** Robert D. Schreiber, St. Louis, MO; Philip D. Greenberg, Seattle, WA
- 6:35 p.m.** **Introduction, CIMT Leadership.** Cornelis J. M. Melief, Leiden, Netherlands
- 6:40 p.m.** **Individualized cancer vaccination: Current status and perspectives.** Sebastian Kreiter, Mainz, Germany
- 7:00 p.m.** **How to define a good tumor neoepitope.** Pramod K. Srivastava, Farmington, CT
- 7:20 p.m.** **Closing remarks.** Dmitry I. Gabrilovich, Philadelphia, PA

**Program as of March 20, 2018

WEDNESDAY, APRIL 18**

MEET-THE-EXPERT SESSION • 7:00 a.m.–8:00 a.m.

Room S404, McCormick Place South (Level 4)

Biospecimen Core Resources for Comprehensive Consortium Projects in Cancer

Scott D. Jewell, Grand Rapids, MI

Room N427, McCormick Place North (Level 4)

Detection and Therapeutic Targeting of Malignant Stem Cell Reprogramming

Catriona H. M. Jamieson, La Jolla, CA

Room N228, McCormick Place North (Level 2)

Dissecting lncRNA Regulatory Mechanisms in Cancer

Christopher A. Maher, St. Louis, MO

Room S105, McCormick Place South (Level 1)

How Obesity and Energy Balance Influence Cancer: Epidemiology, Pathophysiology, and Clinical Significance

Michael N. Pollak, Montreal, QC, Canada

Room S406 (Vista Ballroom), McCormick Place South (Level 4)

The HSF1 Stress Response Pathway in Cancer: Discovering Chemical Probes and Drugs

Paul Workman, London, United Kingdom

Room W190, McCormick Place West (Level 1)

Is There a Therapeutic Window for Wnt Signaling Inhibitors in Cancer?

Owen Sansom, Glasgow, United Kingdom

Room S102, McCormick Place South (Level 1)

Mechanism of Tandem Duplication Formation in BRCA1 Mutant Cancer

Ralph Scully, Boston, MA

Room W196, McCormick Place West (Level 1)

Molecular Imaging for Characterizing Tumor Biology and Assessing Treatment Response

Heiko Schoder, New York, NY

**Program as of March 20, 2018

Room S504, McCormick Place South (Level 5)

Precision Imaging

Martin G. Pomper, Baltimore, MD

Room S100 (Grand Ballroom), McCormick Place South (Level 1)

Reprogramming the Tumor Microenvironment to Enhance “Next-Generation” Adoptive Cellular Therapy

Kunle Odunsi, Buffalo, NY

Room S402, McCormick Place South (Level 4)

Title to Be Announced

Myles A. Brown, Boston, MA

PLENARY SESSION • 8:00 a.m.–10:00 a.m.

N Hall B (Plenary Hall), McCormick Place North (Level 3)

Impact of Cancer Genomics on Cancer Susceptibility and Therapeutic Response

Chair: Karen H. Vousden, London, United Kingdom

- 8:00 a.m. Introduction.** Karen H. Vousden, London, United Kingdom
- 8:05 a.m. Tumor genomic profiling to identify therapeutic biomarkers and guide clinical care.** Michael F. Berger, New York, NY
- 8:30 a.m. Pharmacogenomics of chemotherapeutic-induced toxicities: Challenges and opportunities.** M. Eileen Dolan, Chicago, IL [PL04-02*]
- 8:55 a.m. Chromatin remodeling machines in cancer: New mechanisms and therapeutic opportunities.** Cigall Kadoch, Boston, MA
- 9:20 a.m. Oncohistones in cancer: How to turn a cell’s symphony into non-harmonic rap?** Nada Jabado, Montreal, QC, Canada [PL04-04*]
- 9:45 a.m. Opportunities/challenges for the future.** Karen H. Vousden, London, United Kingdom

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings* (the abstract number is listed in brackets above).

**Program as of March 20, 2018

POSTER SESSION • 8:00 a.m.-12:00 p.m.

Exhibit Hall A, McCormick Place South (Level 3)

(not eligible for CME credit)

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner, the Annual Meeting App (available at www.AACR.org/AACR2018), and in the print Poster Sessions and Exhibits Guide. A limited number of copies of the print guide are available in the Exhibit Hall.

Tumor Biology

- Section 1 Applications of 3D Models for Tumor Biology and Therapeutic Studies
- Section 2 Carcinogenesis 3
- Section 3 Carcinoma-Associated Fibroblasts in Tumor Progression
- Section 4 Dissecting Tumorigenesis in Vivo Using Genetic Approaches and Spontaneous Tumor Models
- Section 5 Metabolism and the Microbiome: Defining the Greater Microenvironment
- Section 6 Metastasis, Invasion, and Migration 2
- Section 7 Molecular Profiles, Circulating Cancer Cells, and Metastasis
- Section 8 The Systemic Microenvironment in Tumorigenesis
- Section 44 Late-Breaking Research: Tumor Biology 3

Endocrinology

- Section 9 Clinical Endocrinology

Epidemiology

- Section 10 Diet, Alcohol, Tobacco, and Other Lifestyle Risk Factors

Prevention Research

- Section 11 Population and Behavioral Studies in Cancer

Bioinformatics and Systems Biology

- Section 13 New Algorithms

Molecular and Cellular Biology / Genetics

- Section 15 DNA Methylation
- Section 16 Genomic Profiling of Tumors 4
- Section 17 Genomic Profiling of Tumors 5
- Section 18 MicroRNAs as Biomarkers
- Section 19 Signaling and Hormonal Inputs to Transcription Factor Regulation
- Section 20 Signaling and Therapy
- Section 21 Targets Affecting Metabolism
- Section 22 Tumor Suppressor Genes 2
- Section 45 Late-Breaking Research: Molecular and Cellular Biology / Genetics 3

Clinical Research

- Section 24 Diagnostic and Prognostic Biomarkers in Clinical Trials
- Section 25 Immunomodulatory Agents and Interventions 3
- Section 26 Liquid Biopsy 5
- Section 27 Liquid Biopsy 6
- Section 28 Therapeutic Antibodies, Including Engineered Antibodies 4
- Section 29 Vaccines 2

Cancer Chemistry

- Section 30 Emerging Proteomic Technologies for Cancer Research

Immunology

- Section 31 Emerging Tools and Models in Immuno-oncology Research
- Section 32 Immune Monitoring / Clinical Correlates
- Section 33 Neoantigens in Cancer
- Section 34 Oncogenes, Inflammation, and Cancer

Experimental and Molecular Therapeutics

- Section 35 Antibodies, Fusion Proteins, and Related Biologics
- Section 36 Canonical Targets 2
- Section 37 Combination Chemotherapy 2
- Section 38 Epigenetic and Metabolic Pathways in Mediating Therapeutic Resistance
- Section 39 Novel Targets and Therapeutics
- Section 40 Regulation of Gene Expression in Drug Resistance
- Section 41 Therapeutic Approaches Based on Gene Delivery and Vector System

**Program as of March 20, 2018

SPECIAL SESSION • 10:00 a.m.–12:30 p.m.

Room N226, McCormick Place North (Level 2)

Pancreatic Cancer Action Network-AACR Grantee Discussion

(not eligible for CME credit)

Moderator: Giulio F. Draetta, Houston, TX

Deactivating the innate immune defense mechanism of pancreatic cancer. Kian-Huat Lim, St. Louis, MO

Targeting downstream effectors of KRAS via MEK and CDK-4 inhibition in PDAC. Nipun B. Merchant, Miami, FL

Use of PARP1 inhibitors to leverage a tumor-selective “kiss of death.” David A. Boothman, Dallas, TX

Clinical development of a tumor-penetrating peptide for enhanced pancreatic cancer therapy. Kazuki Sugahara, New York, NY

CAREER DISCUSSION • 10:15 a.m.–11:00 a.m.

AACRCentral Amphitheater, Hall A, McCormick Place South (Level 3)

Searching for the Right Postdoctoral Position, Organized by the Associate Member Council (AMC)

(not eligible for CME credit)

SCIENCE POLICY SESSION • 10:15 a.m.–12:00 p.m.

Room N427, McCormick Place North (Level 4)

Access to Health Care in the Era of Biologically Targeted Therapies

Chair: Sara A. Hurvitz, Santa Monica, CA

Introduction

Disparities in the use of targeted therapies for breast cancer. Katherine Reeder-Hayes, Chapel Hill, NC

Crossing the divide: Disparities in access to personalized medicine for lung cancer. Christopher S. Lathan, Boston, MA

Toward a more sustainable path for targeted cancer drugs. Justin Bekelman, Philadelphia, PA

WEDNESDAY, APRIL 18**

MAJOR SYMPOSIA • 10:15 a.m.–12:00 p.m.

Room S100 (Grand Ballroom), McCormick Place South (Level 1)

Combining Epigenetic and Immune Therapies

Chair: Stephen B. Baylin, Baltimore, MD

- 10:15 a.m. Introduction**
- 10:20 a.m. Exploring the biology of T-cell exhaustion.** Crystal L. Mackall, Stanford, CA
- 10:50 a.m. Epigenetic regulation of T-cell exhaustion: Implications for cancer immunotherapy.** Benjamin A. Youngblood, Memphis, TN [SY07-02*]
- 11:20 a.m. Probing basic understanding for the potential for epigenetic therapy to enhance the efficacy of immune checkpoint therapy.** Stephen B. Baylin, Baltimore, MD

N Hall B (Plenary Hall), McCormick Place North (Level 3)

High-Dimensional Analysis of Cancer Immunotherapy

Chair: Robert D. Schreiber, St. Louis, MO

- 10:15 a.m. Introduction**
- 10:20 a.m. Pathology from the molecular scale on up.** Garry P. Nolan, Stanford, CA
- 10:50 a.m. Is every tumor targetable? Antigen discovery for personalized cancer immunotherapy.** Michal Bassani-Sternberg, Epalinges, Switzerland
- 11:20 a.m. High-dimensional analysis of immune checkpoint blockade-induced antitumor responses.** Robert D. Schreiber, St. Louis, MO

Room S406 (Vista Ballroom), McCormick Place South (Level 4)

Innovations in T-cell Therapy

Chair: Michel Sadelain, New York, NY

- 10:15 a.m. Introduction**
- 10:20 a.m. Targeting T-cell malignancies with gene-edited CAR-T.** John F. DiPersio, St. Louis, MO
- 10:50 a.m. Armored CAR T cells: Overcoming the tumor microenvironment.** Renier J. Brentjens, New York, NY
- 11:20 a.m. Engineering T cells to access brain cancers.** Nabil Ahmed, Houston, TX

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings* (the abstract number is listed in brackets above).

**Program as of March 20, 2018

N Hall C, McCormick Place North (Level 1)

Overcoming the Immunosuppressive Tumor Microenvironment for Improving Cancer Immunotherapy

Chair: George Coukos, Lausanne, Switzerland

- 10:15 a.m. Introduction**
- 10:20 a.m. Metabolic impact on immune cell subsets in the tumor microenvironment and its therapeutic relevance.** Weiping Zou, Ann Arbor, MI [SY17-01*]
- 10:50 a.m. Metabolic interventions for unleashing host antitumor immunity and inflaming cold tumors.** Ping-Chih Ho, Epalinges, Switzerland
- 11:20 a.m. Orchestration of antitumor immune response: Lessons from ovarian cancer.** George Coukos, Lausanne, Switzerland

Room S103, McCormick Place South (Level 1)

RNA Modifications in Cancer

Chair: Reuven Agami, Amsterdam, Netherlands

- 10:15 a.m. Introduction**
- 10:20 a.m. Coordinated gene expression mediated by RNA modifications.** Reuven Agami, Amsterdam, Netherlands [SY43-01*]
- 10:50 a.m. RNA modifications and cell identity: The importance of forgetting the past to embrace the future.** Pedro J. Batista, Bethesda, MD [SY43-02*]
- 11:20 a.m. RNA methylation in cancer progression.** Chuan He, Chicago, IL

RECENT ADVANCES IN DIAGNOSTICS AND THERAPEUTICS RESEARCH • 10:15 a.m.–12:00 p.m.

Room S404, McCormick Place South (Level 4)

FGFR Signaling in Cancer

Chair: Steffi Oesterreich, Pittsburgh, PA

- 10:15 a.m. FGFR-mediated tumor-stromal interactions during breast cancer growth and progression.** Kathryn L. Schwertfeger, Minneapolis, MN
- 10:45 a.m. FGFR4—a new druggable target in endocrine resistant breast cancer.** Steffi Oesterreich, Pittsburgh, PA
- 11:15 a.m. Targeting FGFR in hepatobiliary cancers.** Andrew X. Zhu, Boston, MA

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings* (the abstract number is listed in brackets above).

Room N227, McCormick Place North (Level 2)

Molecular Prostate Imaging with PSMA and Targeted Agents**Chair:** Peter Choyke, Bethesda, MD

- 10:15 a.m.** **Overview of molecular imaging of prostate cancer.** Erik Mittra, Portland, OR
- 10:45 a.m.** **Molecular prostate imaging with PSMA and targeted agents.** Frederik Giesel, Arnold, Germany
- 11:15 a.m.** **Multimodality prostate cancer imaging: Integrating diagnostic information.** Peter Choyke, Bethesda, MD

Room W196, McCormick Place West (Level 1)

Recent Advances of Single-Cell Genomics in Cancer Research**Chair:** Sohrab Shah, Vancouver, BC, Canada

- 10:15 a.m.** **Single-cell epigenomics reveal the epigenetic evolution and lineage histories of chronic lymphocytic leukemia.** Daniel Landau, New York, NY
- 10:40 a.m.** **Genomic and transcriptomic analysis reveals incremental disruption of key signaling pathways during melanoma evolution.** A. Hunter Shain, San Francisco, CA [NG07*]
- 11:00 a.m.** **Exploiting single-cell approaches to define the evolving tumor microenvironment.** Jacqui Shields, Cambridge, United Kingdom
- 11:25 a.m.** **Scalable single-cell whole-genome sequencing: Towards population genetics of cancer.** Sohrab Shah, Vancouver, BC, Canada

Room N228, McCormick Place North (Level 2)

Tumor, Blood, and Germline Biomarkers of the Radiation Response**Chair:** Joanne B. Weidhaas, Los Angeles, CA

- 10:15 a.m.** **Recombination Proficiency Score (RPS) provides prognostic information and predicts sensitivity to treatment.** Philip Connell, Chicago, IL
- 10:45 a.m.** **Genomics-based biomarkers for personalizing treatment of patients receiving radiotherapy.** Maximilian Diehn, Stanford, CA
- 11:15 a.m.** **Defining the radiation “response” using germline microRNA-based biomarkers.** Joanne B. Weidhaas, Los Angeles, CA

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings* (the abstract number is listed in brackets above).

**Program as of March 20, 2018

Room S102, McCormick Place South (Level 1)

Using Mass Cytometry and MIBI to Monitor Patient Response

Chair: Jonathan M. Irish, Nashville, TN

- 10:15 a.m.** **Single cell mass cytometry reveals clinically and biologically distinct cells in human solid tumors.** Jonathan M. Irish, Nashville, TN
- 10:45 a.m.** **Understanding coordination of antitumor immune responses using quantitative single-cell models.** Matthew Spitzer, Stanford, CA
- 11:15 a.m.** **Using mass cytometry to determine cellular mechanisms of combination checkpoint blockade.** Spencer C. Wei, Houston, TX

RECENT ADVANCES IN PREVENTION AND INTERCEPTION RESEARCH • 10:15 a.m.–12:00 p.m.

Room W190, McCormick Place West (Level 1)

Precision Prevention and Early Detection of Cancer

Chair: Timothy R. Rebbeck, Boston, MA

- 10:15 a.m.** **Genomic approaches for cancer interception.** Avrum E. Spira, Boston, MA
- 10:40 a.m.** **Early-phase precision prevention clinical trials.** Eva Szabo, Potomac, MD
- 11:05 a.m.** **Vaccines targeting oncogenic proteins for cancer prevention.** Mary L. Disis, Seattle, WA
- 11:30 a.m.** **The clinico-genomics of localized, non-indolent prostate cancer: The CPC-GENE experience.** Michael E. Fraser, Toronto, ON, Canada [NG06*]

Room S105, McCormick Place South (Level 1)

Systemic Metabolism and Cancer

Chair: Navdeep S. Chandel, Chicago, IL

- 10:15 a.m.** **Dissecting the role of physiologic and metabolic factors in lung cancer.** Thales Papagiannakopoulos, New York, NY
- 10:45 a.m.** **Repurposing metformin as a metabolically targeted ovarian cancer treatment.** Iris Romero, Chicago, IL
- 11:15 a.m.** **The role of microbiome-derived metabolism in cancer prevention and therapy.** Scott Bultman, Chapel Hill, NC

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings* (the abstract number is listed in brackets above).

WEDNESDAY, APRIL 18**

PLENARY SESSION • 12:15 p.m.–1:45 p.m.

N Hall B (Plenary Hall), McCormick Place North (Level 3)

Annual Meeting 2018 Highlights: Vision for the Future

Chair: Elaine R. Mardis, Columbus, OH

Basic cancer science and the impact of technology. Elaine R. Mardis, Columbus, OH

Prevention and survivorship/precision prevention and interception. Speaker to be announced

Clinical trials and therapeutics. Michael A. Caligiuri, Duarte, CA

Wrap-up and vision for the future. Elizabeth M. Jaffee, Baltimore, MD